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Preface  
The present PhD project was performed at Department of Toxicology and Risk Assessment, 
National Food Institute, Technical University of Denmark. The two supervisors were Ulla Hass, 
National Food Institute, Technical University of Denmark, and Ole Andersen, Department of 
Science, Systems and Models, Roskilde University. 
The thesis is divided into two parts. Part one includes a general introduction to the topic and the 
theoretical background for the work, an overview of the main results, a general discussion and the 
conclusions. Part two, appendix 1, presents the behavioural results in details whereas the other 
results are presented in published or submitted papers, or a manuscript in preparation.  
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Summary 
Background: Androgens are key regulators of male sexual differentiation during the in utero and 
early postnatal development. Exposure to endocrine disrupting chemicals (EDCs) that counteract 
androgen action at some stage in these periods can permanently demasculinise male foetuses and 
lead to malformations of the reproductive tract. The incidence of hypospadias (where the opening of 
the urethra is on the underside of the penis) in young boys has increased over the last decades but it 
is still unclear whether human exposure to endocrine disrupting chemicals may be responsible for 
this increase.  
It is well-known that humans are exposed to a mixture of endocrine disrupting chemicals but risk 
assessment is currently based on the no observed adverse effect levels (NOAELs) for effects of one 
chemical at a time. The NOAEL is the highest tested dose at which no statistically or biologically 
adverse effects can be identified and is used in regulatory toxicology as a point of departure for 
establishing “acceptable” exposures for humans. 
 
Purpose and methods: The overall purpose of this thesis is to explore the need for improving the 
future risk assessments of mixtures of EDCs. This is done by examining the following questions:  
 Are there combined effects at NOAEL levels for individual anti-androgens based on the 
effects on anogenital distance, nipple retention and external malformations in male rats?  
 Can the combined effects be predicted based on the model approaches; dose addition or 
independent action? 
 Is sexually dimorphic behaviour in rats affected at lower dose levels of anti-androgens and 
thereby a more sensitive endpoint than morphological effects on the male external 
reproductive organs? 
 
The thesis is based on the results of in vivo studies where mated female Wistar rats were exposed to 
anti-androgens either alone or in mixtures during pregnancy and lactation. The endpoints examined 
for anti-androgenic effects in the offspring were: Anogenital distance (AGD), nipple retention (NR), 
and external (morphological) malformations in pups and sexually mature male rats. Furthermore, 
the effects of the anti-androgens were studied in the offspring at different age period using several 
behavioural tests. Additionally, the development and use of a new test for mating behaviour was a 
part of this project.  
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Results and discussion: Results from the single chemical dose response studies showed that the 
NOAEL values found were very close to the NOAELs used by various regulatory bodies. It was 
also clear that DEHP (di-(2-ethylhexyl) phthalate) at a relatively low dose of 10 mg/kg bw/day 
caused adverse anti-androgenic effects on male rat development. The drug, finasteride was by far 
the most potent chemical, and it exhibited dose-response relationships with very shallow gradients 
for all endpoints. 
In the mixture study with 3 similarly acting anti-androgens (vinclozolin, flutamide and 
procymidone), a combination of doses of each chemical, which on their own did not change the 
AGD statistically significantly, induced clear combination effects. Furthermore, exposure to low 
doses of the individual chemicals showed only modest effects on NR, while the mixture induced 
NR in the males that clearly approached the female values. Severe malformations of external 
genitalia (hypospadias) were observed in male rats with the mixture while the individual 
compounds did not cause any such effects. Increased frequencies (56%) of external malformations 
(hypospadias) were observed after exposure to a mixture of the three chemicals compared to 
administration of the three chemicals alone (0%). AGD was a good early biomarker, as a 25% 
reduction in mean AGD measured on postnatal day 1 was likely to result in clear malformations in 
approximately 50% and marked malformations in approximately 25% of the adult male rats. These 
combined effects could be predicted fairly accurately on the basis of information about the potency 
of the individual chemical components by using the dose addition concept.  
Behaviour was as sensitive an endpoint as the morphological parameters (AGD, NR and 
malformations) in the mixture study with 3 similarly acting anti-androgens (vinclozolin, flutamide 
and procymidone). Results showed that learning was impaired in mixture exposed males when 
tested in the Morris water maze.  
In the mixture study with 4 dissimilarly acting anti-androgens (vinclozolin, finasteride, DEHP and 
prochloraz) AGD, NR, and reproductive organ weights at PND (postnatal day) 16 were clearly 
affected in the mixture groups at dose levels where the individual chemicals caused no or only 
minor effects. The combined effects were equally well predicted by dose addition or independent 
action. The parameter ‘retained nipples’ was the most sensitive endpoint, with effects becoming 
noticeable at the lowest doses. Changes in AGD were almost as sensitive an endpoint, followed by 
reductions in prostate and LABC (levator ani/bulbocavernosus muscles) weights, and genital 
malformations. In addition, the experimentally observed responses for external malformations 
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clearly exceeded the predictions, suggesting that the combined effect of DEHP, vinclozolin, 
prochloraz and finasteride is synergistic with respect to malformations of external sex organs.  
To clarify, this thesis refers to effects which exceed expectations as synergism and those which 
meet expectations as additivity. 
Behaviour was a less sensitive endpoint than the morphological parameters (AGD, NR and 
malformations) in the mixture study with 4 dissimilarly acting anti-androgens (vinclozolin, 
finasteride, DEHP and prochloraz).  
Conclusion and perspectives: The data from the extended developmental toxicity studies with rats 
presented in this thesis suggest that dose addition models can in most cases predict the combined 
effects of anti-androgens and demonstrate that marked effects can occur at mixture doses below the 
NOAELs for the single chemicals.  
Since unhindered androgen action is essential for human male development in foetal life, these 
findings are highly relevant to human risk assessment. This must be emphasised because the results 
clearly indicate that risk assessment based on NOAELs for single anti-androgens may 
underestimate the risk for hypospadias and other disruptions of male sexual differentiation.  
Generally, behaviour was not as sensitive an endpoint as the as the development of the reproductive 
system but male behaviour may be just as sensitive an endpoint after exposure to mixtures of 3 
androgen receptor (AR) antagonists (vinclozolin, flutamide, and procymidone). The learning 
behaviour in Morris water maze was in this study impaired at the same dose levels at which effects 
on NR and weights of epididymides, ventral prostate and bulbouretral glands were observed. 
Behavioural testing could therefore provide useful complementary information and contribute to a 
broader picture of the toxicity of the EDCs alone or in mixtures than studies that only take the 
development of reproductive organs into account.  
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Resumé (summary in Danish)  
Baggrund: Androgener er væsentlige styrende hormoner i den seksuelle differentiering, der finder 
sted i fostertilstanden og i den tidlige postnatale udvikling hos hanner. Udsættelse for 
hormonforstyrrende stoffer, der modvirker androgener på et eller andet tidspunkt i disse perioder, 
kan permanent demaskulinisere hanfostre og føre til misdannelser af reproduktionsorganerne. 
Forekomsten af hypospadi (urinrøret udmunder på undersiden af penis) hos unge drenge er steget i 
de seneste årtier, men det er stadig uklart, om den humane eksponering for hormonforstyrrende 
stoffer kan være årsag til denne stigning.  
Det er velkendt, at mennesker er udsat for adskillige hormonforstyrrende stoffer, men ved 
risikovurderinger af stoffer sammenlignes menneskers eksponering for et stof ad gangen normalt 
med stoffets NOAEL-værdi (”No Observed Adverse Effect Level ”), dvs. den højeste dosis af 
stoffet, som i dyreforsøg ikke har givet nogen skadelige effekter.  
Formål og metoder: Det overordnede formål med denne afhandling er at undersøge behovet for at 
forbedre fremtidige risikovurderinger af udsættelse for blandinger af hormonforstyrrende stoffer. 
Dette gøres ved at undersøge følgende spørgsmål:  
• Vil samtidig eksponering for hormonforstyrrende stoffer medføre samspilseffekter ved de enkelte 
stoffers NOAEL-værdier baseret på vurdering af effekter på anogenital afstand, bibeholdte 
brystvorter og ydre misdannelser hos hanrotter?  
• Kan samspilseffekterne forudsiges baseret på modellerne ’dosis addition’ eller ’independent 
action’?  
• Er seksuelt dimorf adfærd hos rotter påvirket ved lavere dosisniveauer af anti-androgener, og 
dermed en mere følsom parameter end morfologiske effekter på de ydre hanlige 
reproduktionsorganer?  
Afhandlingen er baseret på resultaterne af in vivo undersøgelser, hvor parrede Wistar hunrotter blev 
doseret med anti-androgener enten som enkeltstoffer eller i blandinger i drægtigheds- og 
laktationsperioden. De effektmål, der generelt blev undersøgt for anti-androgene virkninger i 
afkommet var: Anogenital afstand (AGD), bibeholdelse af brystvorter (NR), og misdannelser af de 
ydre kønsorganer i unger og kønsmodne hanrotter. Derudover blev der undersøgt effekter på 
afkommet ved forskellige aldre i flere adfærdstests. I dette projekt indgik også udviklingen og 
brugen af en ny test for parringsadfærd.  
Resultater og diskussion: Resultater fra dosis-respons forsøg med enkeltstoffer viste, at de 
NOAEL-værdier, der blev fundet, lå meget tæt på dem, der anvendes til regulatoriske formål. Det 
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blev også vist, at eksponering for DEHP (di-(2-ethylhexyl) phthalat) ved en relativt lav dosis på 10 
mg/kg bw/dag førte til anti-androgene effekter hos hanrotter. Lægemidlet finasterid var væsentligt 
mere potent end de andre stoffer, og stoffet udviste dosis-respons-kurver med meget flad hældning 
for alle effektmål.  
I det første kombinationsforsøg undersøgtes effekten af 3 anti-androgener, der alle blokerer 
androgenreceptoren (vinclozolin, flutamid og procymidon). Med hensyn til AGD medførte den 
samtidige eksponering for de 3 anti-androgener en tydelig samspilseffekt, der var mere markant end 
effekterne af de enkelte stoffer, der ikke førte til signifikante effekter på AGD. Lave doser af de 
enkelte kemikalier viste kun små effekter på NR, mens en kombination inducerede NR i hanrotter, 
der nærmede sig hunlige værdier.  
Øget forekomst af misdannelser (hypospadi) (56%) blev observeret efter samtidig eksponering for 
de tre kemikalier i forhold til eksponering for de tre kemikalier alene (0%). AGD, målt PND 1, var 
en god tidlig biomarkør, idet en reduktion på 25% i AGD sandsynligvis vil resultere i alvorlige 
misdannelser af kønsorganerne hos ca. 50% og meget alvorlige misdannelser hos ca. 25% af de 
voksne hanrotter. Disse samspilseffekter kan forudsiges temmelig præcist på baggrund af viden om 
stoffernes potens og ved hjælp af konceptet om ’dosis addition’.  
Adfærd var en lige så følsom parameter, som de morfologiske parametre (AGD, NR, misdannelser) 
i det første kombinationsforsøg. Her viste resultaterne, at indlæringen blev nedsat hos to grupper af 
kombinationseksponerede hanner, når de blev testet i en Morris water maze.  
I det andet kombinationsforsøg undersøgtes effekten af 4 anti-androgener (vinclozolin, finasterid, 
DEHP og prochloraz) med forskellig virkningsmekanisme. AGD, bibeholdelse af brystvorter (NR), 
og vægt af reproduktionsorganer på PND (postnatal dag) 16 blev tydeligt påvirket af blandingen 
ved en dosis, hvor de enkelte kemikalier udviste ingen eller kun få effekter. De observerede effekter 
kunne forudsiges lige godt af ’dosis addition’ såvel som af ’independent action’. Parameteren 
’bibeholdelse af brystvorter’ var det mest følsomme effektmål, med effekter ved de laveste doser. 
Ændringer i AGD var næsten lige så følsom, efterfulgt af vægtreduktioner i prostata og LABC 
(levator ani/bulbocavernosus muskler) og misdannelser.  
Derudover oversteg de observerede resultater for misdannelser klart de forudsagte. Dette tyder på, 
at den samtidige eksponering af DEHP, vinclozolin, prochloraz og finasteride medførte 
synergistiske effekter med hensyn til misdannelser af ydre kønsorganer (hypospadi).  
I denne afhandling anvendes betegnelsen ’synergi’ når effekterne overstiger forventningerne, mens 
’additivitet’ anvendes når effekterne er lig de forventede. 
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Adfærd var i dette kombinationsforsøg (vinclozolin, finasterid, DEHP og prochloraz) ikke nær så 
følsom en parameter, som de morfologiske parametre (AGD, NR, misdannelser).  
Konklusion og perspektiver: De resultater, der præsenteres i denne afhandling fra store studier 
med drægtige rotter og deres afkom, tyder på, at ’dosis additionsmodellen’ i langt de fleste tilfælde 
kan forudsige samspilseffekten af anti-androgener, og viser at alvorlige effekter kan forekomme ved 
doser under NOAELs for enkeltstofferne.  
Disse resultater er meget relevante for den humane risikovurdering, idet en uhindret androgen 
virkning er afgørende for den mandlige udvikling. Resultaterne viser klart, at risikovurdering 
baseret på NOAELs for de enkelte anti-androgener kan undervurdere risikoen for hypospadi og 
andre alvorlige forstyrrelser af den seksuelle differentiering.  
Generelt var adfærden ikke nær så følsomt et parameter, som udviklingen af reproduktionssystemet 
(AGD, NR, misdannelser). Adfærd hos hanner efter eksponering for en kombination af 3 AR 
antagonister (vinclozolin, flutamid og procymidon) var dog ligeså følsomt idet indlæringsadfærd i 
Morris water maze i dette kombinationsforsøg var forringet ved samme dosisniveau, hvor 
bibeholdelse af brystvorter (NR), vægten af bitestikler, ventral prostata- og bulbouretral kirtler blev 
påvirket. Adfærdstestningen kan derfor give nyttige supplerende oplysninger og bidrage til et 
bredere billede af toksiciteten af anti-androgener alene eller i blandinger end undersøgelser, der kun 
tager udviklingen af reproduktionsorganer betragtning. 
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1. Introduction 
In the last 10-15 years, increasing incidences of reproductive and developmental anomalies have 
been reported among wildlife and humans. The reproductive changes are seen in wildlife for 
example in alligators (Guillette, Jr. et al. 1994), female polar bears (Wiig et al. 1998) and male gulls 
(Fry 1995).  
In humans it is well documented that the incidences of cryptorchidism and testicular cancer have 
increased over the last decades (Giwercman et al. 1993; Skakkebaek et al. 2001). The incidence of 
hypospadias is also rising, at least in Denmark, where studies have been performed (Boisen et al. 
2005). Furthermore, since 1983 a decline in semen quality has been reported (Carlsen et al. 1992), 
and semen quality of young men in Northern Europe is generally quite poor (Jørgensen et al. 2006). 
However, this topic is controversial and other researchers question this decline (Fisch 2008). 
Anderson and colleagues conclude that based on these adverse trends in male reproductive health 
we may have reached a crucial “tipping point” towards male subfertility (Andersson et al. 2008). 
The above-mentioned effects have been observed in several studies in experimental animal models 
showing reproductive malformations in male animals exposed to endocrine disrupters in the 
embryonic period (Gray et al. 1994; Gray et al. 1999b; Foster 2006; Welsh et al. 2008; Sharpe and 
Skakkebaek 2008). Studies have shown that the basic events of reproductive development are 
homologous in all mammalian species, and that rodent models have great utility for evaluating the 
potential of xenobiotics to alter human reproductive development (Gray 1992).  
The aetiology of the above-mentioned reproduction related changes in humans are uncertain but 
man-made compounds detected in the environment are increasingly suspected to be involved (Gore 
2007). The suspected compounds possess properties such as mimicking and/or antagonising 
(inhibiting) the action of normal hormones or affecting the synthesis or metabolism of endogenous 
hormones and their receptors (Sonnenschein and Soto 1998). They are often referred to as 
endocrine disrupting chemicals (EDCs). 
The consequences of EDCs can be adverse and irreversible because of the crucial role that 
hormones play in controlling development (Gray and Kelce 1996). The intra-uterine development is 
a very delicate process as the reproductive and endocrine systems undergo complex changes in 
foetal life. Foetuses and newborns are therefore considered to be uniquely susceptible and 
vulnerable to influences of EDCs whereas similarly exposed young adults are only transiently 
affected (Gray 1992; O'Connor and Chapin 2003). 
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The following definitions of endocrine disrupters and potential endocrine disrupters have generally 
been accepted in the EU and are used throughout this thesis:  
“An endocrine disrupter is an exogenous substance or mixture that alters function(s) of the 
endocrine system and consequently causes adverse health effects in an intact organism, or its 
progeny, or (sub) populations. A potential EDC is a substance that possesses properties that might 
be expected to lead to endocrine disruption in an intact organism.” (European Commission 1996) 
 
EDEN was a large EU-project and is an acronym for ”Exploring Novel Endpoints, Exposure, Low-
dose- and Mixture Effects in Humans, Aquatic Wildlife and Laboratory Animals”. The rationale for 
the EDEN project was to address key issues in the area of endocrine disruption. The National Food 
Institute took part in one of the themes, which focused on low-dose and combined effects of anti-
androgens in rats. 
Observations of low-dose effects of single endocrine disrupting chemicals have been debated (in the 
field of endocrine disruptors). Some have found effects at dose levels that are lower than normally 
tested in toxicology (vom Saal and Hughes 2005), while others have not been able to reproduce 
these low-dose effects (Ashby et al. 2004). In the EDEN dose response studies, low doses were 
included to find the NOAEL (No Observed Adverse Effect Level) for sensitive endpoints and to 
establish the shapes of the dose-response curves. Moreover, the established NOAEL doses for 
endocrine disrupting effects were used in the later mixture studies. 
Humans are daily exposed to a range of multicomponent mixtures of toxicants, of which we do not 
know the effect (Backhaus et al. 2004) as toxicological research normally only examines effects of 
single compounds (Yang 1994). Generally, risk assessments and regulations in EU as well as other 
parts of the world are based on NOAELs for single chemicals, i.e., risk assessments are performed 
by a chemical-by-chemical approach and, do not take the cocktail of chemicals into account 
(Kortenkamp 2007).  
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2. Background 
Chemicals are generally assessed for their risk for human health based on data from 
epidemiological studies, studies in laboratory animals and in vitro tests. Endocrine disrupting 
chemicals can show effects on the reproductive system and therefore reproductive toxicity studies 
are very relevant when it comes to these chemicals. There are several test guidelines (TG) for 
reproductive toxicity testing in the OECD program  (OECD 2009) (Organisation for Economic Co-
operation and Development). The OECD TG 440, “Uterotrophic Bioassay in Rodents: A short-term 
screening test for oestrogenic properties” specifically screens for potential endocrine disruption, and 
the test guidelines for reproductive toxicity include some endocrine disrupting sensitive endpoints. 
The Hershberger assay and the Uterotrophic Bioassay are both new test guidelines and they have so 
far not become part of a testing strategy. Moreover, the development and validation of several in 
vitro test guidelines with endocrine disrupting endpoints is ongoing in OECD. However, endocrine 
disruption is a fairly new concept in risk assessment, and there are at present no test methods 
available, which specifically detect all effects that have been linked to the endocrine disruption 
mechanism(s) and mode(s) of action. The two-generation study (OECD TG 416) is currently the 
most complete study available. Both in this study and in the developmental toxicity study, OECD 
TG 414 (OECD TG 414), additional endocrine sensitive endpoints may be examined on a case-by-
case basis when endocrine disruption is an issue of concern (Nielsen et al. 2008).  
Assessment of anogenital distance (AGD), which is a sensitive endpoint for anti-androgenic effects 
in male offspring, is a parameter in the Two-Generation Reproduction Toxicity Study (OECD 
2001), but is only measured in the second generation when triggered. Nipple retention in male 
offspring, which is another very sensitive endpoint for anti-androgenic effects in male offspring, is 
not included in any existing OECD guidelines.  
Recently, an OECD expert group has started development of an OECD TG for an extended one-
generation study based on the study design described in (Cooper et al. 2006). In the draft TG for the 
extended one-generation study, it is proposed to include assessment of AGD for each pup at PND 0, 
and retention of nipples in male pups at PND 12 or 13.  
In the OECD TG 416, only one adult male is examined for malformations in the external sex organs 
(hypospadias). This endpoint is optimally observed in sexually mature male rats. As data have 
shown that it could be an advantage to increase the sensitivity of this endpoint it is discussed 
whether 2-3 adult male rats pr. litter should be included in future OECD test guidelines. 
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In the two-generation study, some effects on mating behaviour in the offspring may be observed, 
when the animals are mated to produce the second generation. However, in the extended one-
generation, where the second generation only will be produced when triggered of findings in the 
first generation, the offspring is normally not mated, and effects on mating behaviour will therefore 
not be examined in animals that have been exposed during development.  
 
Chemicals risk assessment is generally carried out by dealing with only single chemical at a time. 
The process does not take account of the likelihood that combination effects might occur when 
humans or wildlife come into contact with several agents at the same time. Thus, chemical mixtures 
and mixtures of EDCs are not considered by default when making a risk assessment. Different parts 
of the regulatory system are presently aware of the mixture issue, and several initiatives are taken in 
e.g. EFSA (European Food Safety Authority) and US National Academy of Science (see section 
2.4).  
2.1 Sexual differentiation  
The foetus and young infant appear to be susceptible to endocrine-disrupting effects of xenobiotics. 
Exposure during critical developmental phases such as in utero and in the early postnatal period 
may lead to adverse effects on both reproductive development and neurodevelopment. The fact that 
many of the basic mechanisms underlying this developmental process are similar in all mammals 
indicates that chemicals that have adverse effects on reproductive development in rodents should be 
considered as potential human reproductive toxicants as well (Gray 1992).  
 
2.1.1 Sexual differentiation of the reproductive system 
In mammals the default sex/gender is female, as only exposure to androgens or testosterone of 
testicular origin during development will result in a male. In this manner androgens play a 
determining role during the most important periods of foetal development (Sharpe and Skakkebaek 
2008).  
Several endocrine disrupting chemicals can disturb this sexual differentiation, and thereby the 
developmental process of becoming a normal male or female. The primary step in the process of 
mammalian sexual differentiation occurs immediately after fertilisation. A sperm bearing either an 
X or a Y chromosome can fertilise an ovum. Whether the individual will develop testes or ovary is 
determined by the cellular expression of the testis determination factor (TDF), a protein encoded by 
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a gene known as SRY (sex determining region on the Y chromosome) (Berta et al. 1990; Welsh et 
al. 2008). When the SRY gene is expressed in the undifferentiated gonads, the testis determination 
factor binds to a specific hormone response element in the promotor region of the other genes that it 
regulates (Harley and Goodfellow 1994). When the protein products of these genes are produced, 
the male phenotypic traits, such as the testes, are formed (Berta et al. 1990). In the absence of 
expression of the SRY gene, the embryo develops into a female and the ovary is formed. In this 
respect, the female phenotype is considered the “default” pathway for reproductive development in 
mammals (O'Connor and Chapin 2003).  
2.1.2 Sexual differentiation of the brain 
An important part of the sexual differentiation that takes place during foetal and neonatal 
development is the sexual differentiation of the brain. This process, like the differentiation of the 
reproductive tract, is to a large extent determined by the levels of circulating sex hormones in the 
blood. In males, the testosterone secreted from the Leydig cells of the testes is secreted into the 
blood and reaches the brain. Testosterone is converted to oestradiol by aromatase in the brain and 
thereby oestradiol masculinises the male brain. In females, α-fetoprotein binds to oestradiol and 
prevents consequently oestradiol from entering the brain. This mechanism protects female brains 
from being masculinised by oestradiol (Puts DA et al. 2006). 
During the ‘critical periods’ of development, the central nervous system is very sensitive to altered 
hormone levels as well as chemical exposures leading to severe and permanent effects on 
development, changing the course of sexual differentiation. Behavioural development and sexual 
behaviour in adult mammals are both influenced by, respectively, organizational and activational 
effects of testosterone. This is described in Figure 1 where a neonatal administration of testosterone 
to the female rat induces a “defeminisation pattern” of sexual behaviour (loss of female lordosis 
reflex). This effect is mediated by the aromatisation of testosterone in the brain: both testosterone 
and oestrogen appear to have a role in development of masculine copulatory behaviour (Forest 
1983).  
Reproductive behaviour patterns are not the only forms of behaviour that are sexually dimorphic. 
Gender differences have been observed in play behaviour, sweet preference, activity levels and 
spatial learning (Valenstein et al. 1967; Beatty 1979; MacLusky and Naftolin 1981; Hotchkiss et al. 
2002; Kaya et al. 2002; Casto et al. 2003). These behaviours are not directly related to reproduction, 
but are influenced by gonadal steroids and can therefore be affected by altered levels of sex 
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hormones during development (Valenstein et al. 1967; Beatty 1979; MacLusky and Naftolin 1981; 
Hotchkiss et al. 2002; Kaya et al. 2002; Casto et al. 2003). 
Exposure to EDCs in the critical periods of development can alter the sexual differentiation of the 
brain by interfering with the normal action of gonadal hormones (Schantz and Widholm 2001; 
Weiss 2002). However, little research has been done on the developmental neurotoxicity of anti-
androgenic EDCs. The effects could go in two possible directions as it is expected that anti-
androgens that lower the testosterone levels and/or inhibits the aromatase activity will contribute to 
a decreased conversion of testosterone into oestradiol, and thereby lower the oestradiol levels 
needed for complete behavioural masculinisation of the male rat brain. The result of this would be a 
demasculinised male. 
Another expectation could be that the receptor mediated anti-androgens may block the androgen 
receptors in the brain, and thereby reduce the negative feedback that the endogenous testosterone 
exerts on the hypothalamus and pituitary, which will result in increased LH (luteinizing hormone) 
and testosterone production.  
 
Figure 1. The masculinisation and feminisation of the rat brain. In the rat, it has been held that adult sexual behaviour 
depends solely on organizational effects. An intact male pup or a female pup treated with testosterone shortly after birth 
and given an injection of testosterone in adulthood will exhibit male behaviours (shown by blue arrows). An intact 
female pup or a neonatally castrated male pup given an injection of oestrogen in adulthood will exhibit female 
behaviours (shown by pink arrows). The Figure is used with permission from Dr. Paul Kenyon 
http://www.flyfishingdevon.co.uk/salmon. 
 
 14 
2.2 DHT dependent tissue 
Under the influence of the androgen dihydrotestosterone (DHT) the external genitalia develop in the 
male direction, while in the absence of androgens they develop in female direction (Imperato-
McGinley et al. 1992). The specific development of the male external genitalia as well as the 
ventral prostate is DHT-dependent (Bowman et al. 2003). DHT is also responsible for regression of 
nipple anlagen in male rats, causing lack of nipple development (see 2.2.2). Therefore, male rats do 
not normally exhibit nipples or areolas as female offspring do. Furthermore, DHT is responsible for 
the development of external male genitalia and for growth of the perineum to produce a normal 
male AGD (Imperato-McGinley et al. 1985; Imperato-McGinley et al. 1986). The AGD is therefore 
a sensitive measure of prenatal anti-androgen exposure, and in utero exposure to anti-androgens can 
reduce the AGD and result in a diminished sexual dimorphism. 
 
2.2.1 Anogenital distance (AGD) 
Newborn male rats have no scrotum, and the external genitalia are undeveloped, and only a genital 
tubercle is apparent for both sexes. The AGD (Figure 2) is the distance from the anus to the 
insertion of this tubercle, the developing genital bud. The AGD is androgen dependent, and studies 
show that the AGD is normally about twice as long in male as in female rats. Similarly, in newborn 
humans the AGD measure was about two-fold greater in males than in females (Salazar-Martinez et 
al. 2004). 
Significant correlation has been found between AGD and body weight in both rats ad humans. AGD 
has been reported alone and/or with the calculation of AGD/bw ratio, is therefore believed to be a 
more correct way to evaluate the results. It is also suggested that calculating the AGD/cube root of 
body weight is a better measurement since the body increases in 3 dimensions while AGD shows 
linear growth (Gallavan et al. 1999). Measuring the AGD in neonatal humans has been suggested as 
a non-invasive method to predict adult reproductive disorders (Welsh et al. 2008). Very recently, 
changes in AGD among male infants and suppressions of androgen synthesis have been associated 
with anti-androgen exposure in humans (Swan et al. 2005; Main et al. 2006). 
Current regulatory guidelines for reproductive toxicity from US EPA (United States Environmental 
Protection Agency) and OECD (Organisation for Economic Co-operation and Development) 
explicitly define significant alterations of AGD as an adverse effect.  
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Fig.2 Anogenital distance (AGD) in rats (Farris 1949). 
 
 
2.2.2 Nipple retention (NR) 
Mammary gland development begins similarly in male and female rats; however, the further 
development of the nipple is sexually dimorphic (Kratochwil 1971). Female rats have nipples, 
whereas male rats possess only rudimentary mammary glands but no nipples. This is because 
locally produced DHT causes regression or apoptosis of the nipple anlagen in male rats (Imperato-
McGinley et al. 1985; Imperato-McGinley et al. 1986). However, foetal exposure to anti-androgens 
can block this process, and the male offspring displays nipples similarly to their female littermates 
(Figure 3). Therefore, the retention of nipples in male rat pups is an indicator of impaired androgen 
action during the development. 
 
Figure 3. The arrows show the shadows from two retained nipples in an exposed male rat pup on PND 13 (Photo: Bo 
Herbst). 
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2.2.3 External malformations 
Prenatal exposure to endocrine disrupting chemicals that interfere with the androgen signalling 
pathways during sexual differentiation can provoke a failure of urethral canalisation and fusion and 
results in hypospadias (Greek for "hole underneath").  
Hypospadias in humans is one of the most common urogenital congenital anomalies affecting boys  
(Harris 1990). Prevalence estimates in Europe range from 4 to 24 per 10,000 births, depending on 
definition (Dolk et al. 2004) with higher rates of about 5% reported in a Danish study (Boisen et al. 
2005). Little is known about the aetiology of hypospadias, but a role for EDCs have been proposed, 
and especially the anti-androgenic EDCs (Baskin et al. 2001). 
The pattern of malformations in the male depends upon the specific mechanism of action of the 
toxicant, the dosage level administered and the timing of administration during pregnancy (Gray et 
al. 2004). Penile and scrotal fusion may be analogous to palatal shelf and neural tube fusion, in that 
the latter embryonic processes require embryonic cell movements and apposition of the two 
advancing tissues (Gupta and Goldman 1986). 
Hypospadias in male rats (Figure 4) has been related to maternal exposure to the following 
substances: 
1. Potent oestrogens or oestrogenic compounds (e.g. diethylstilbestrol DES) 
2. Compounds that inhibit 5α-reductase (e.g. finasteride) 
3. Drugs, herbicides, and dicarboximide and conazole fungicides that act as androgen receptor 
(AR) antagonists (e.g. flutamide, vinclozolin, procymidone, prochloraz) 
4. Drugs, herbicides and conazole fungicides that inhibit cytochrome P450 enzymes involved 
in steroid hormone synthesis 
5. Phthalate diesters inducing hypospadias by altering foetal testis Leydig cell differentiation 
which results in reduced steroid and peptide hormone production (e.g. di-n-butyl phthalate 
(DBP), di-(2-ethylhexyl) phthalate (DEHP), and benzylbutyl phthalate (BBP). 
6. Compounds that disrupt androgen action by inhibiting the conversion of progesterone to 
testosterone and thereby induce increased testicular progesterone concentrations in male rat 
foetuses (e.g. prochloraz) (Willingham et al. 2006; Agras et al. 2007). 
The background incidences of malformations like hypospadias, spontaneous sex reversals, and / or 
agenesis of sex accessory and epididymal tissues are infinitesimally low in the male laboratory rat, 
if it occurs at all (Gray et al. 2004). 
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Figure 4. Malformations in the male rat (Photo: Bo Herbst) 
 
2.3 The anti-androgens studied and their mechanisms of action 
Androgen (from Greek andros, man and gennaien, to produce) is the name given to any substance, 
which induces the development of the male reproductive tract. Below is a presentation of the 6 anti-
androgens studied in the EDEN project. The studies were model studies investigating a principle, 
and the anti-androgens were selected because they can disrupt male sexual differentiation in 
different ways, by a variety of mechanisms. 
 
Vinclozolin is a common fungicide used in vineyards. It acts by inhibiting the spore germination in 
fungi. Vinclozolin metabolites, M1 and M2 bind to mammalian androgen receptors and act as AR 
antagonists, inhibiting androgen-dependent gene expression in vivo and in vitro by inhibiting AR-
binding to DNA. Vinclozolin-treated male rat offspring display female-like AGD at birth, retained 
nipples, and cleft phallus with hypospadias, undescended testes (cryptorchidism), vaginal pouch, 
epididymal granulomas and small to absent sex accessory glands when exposed to higher doses 
(Gray et al. 1994; Kelce et al. 1994; Gray et al. 1999a; Hellwig et al. 2000). Some dose-response 
curves for vinclozolin exposed rats appear linear in the low dose range but fail to display an obvious 
threshold for AGD, NR and ventral prostate weight while induction of hypospadias and other 
malformations display apparent thresholds (Gray et al. 1997). 
 
Completely split penis 
and visible os penis i.e. 
marked hypospadia 
Blind vaginal opening 
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Procymidone is a dicarboximide fungicide, which appears to display a nearly identical toxicity 
profile as vinclozolin in vitro and in vivo, but is 2 fold less potent. It is also an AR antagonist, and a 
study in rats exposed perinatally to procymidone has shown decreased AGD, increased NR, higher 
incidence of hypospadias and cryptorchidism, and reduced prostate, testis and epididymal weights  
(Ostby et al. 1999).  
 
Flutamide (4´-nitro-3’-trifluoromethyl-isobutyranilide) is a potent non-steroidal drug and AR 
antagonist primarily used to treat human prostate cancer. Studies in rats have demonstrated that pre- 
and postnatal flutamide exposure alter reproductive physiology by incomplete masculinisation of 
the exposed males (Imperato-McGinley et al. 1992). These effects are directly related to the anti-
androgenic properties of flutamide - by competitively binding to the androgen receptors, and 
altering subsequent gene expression (Kelce et al. 1997). Flutamide inhibits testosterone from 
exerting its masculinising effects on sexual differentiation. Flutamide appears to be at least tenfold 
as potent as procymidone and vinclozolin (Gray et al. 2004). Studies with prenatal flutamide 
exposure have shown reduced AGD and increased NR, prostate agenesis and hypospadias in male 
rats (Hib and Ponzio 1995; McIntyre et al. 2001; Miyata et al. 2002).  
DEHP is an abbreviation of di-(2-ethylhexyl) phthalate. DEHP is produced in a very high industrial 
volume and is used as a plasticizer in a wide range of consumer products, including vinyl floors, 
medical products and toys, making it one of the phthalates most abundantly found in the 
environment  (Hellwig and Jäckh 1997; Koch et al. 2003; Müller et al. 2003). Several studies have 
shown that male rats exposed to DEHP during development have reduced AGD, retained nipples, 
reduced organ weights and cryptorchidism (Parks et al. 2000; Gray et al. 2000; Moore et al. 2001; 
Jarfelt et al. 2005). The most likely mechanism by which DEHP exerts its demasculinising effects 
seems to be reduction of testosterone production towards female levels in male rat foetuses during 
critical stages of sex differentiation (Parks et al. 2000; Borch et al. 2004; Wilson et al. 2004; Borch 
et al. 2006). Whether DEHP and the metabolite MEHP also act as anti-androgens by antagonising 
the AR receptor is still debated. Some in vitro studies have shown that neither DEHP nor MEHP are 
androgen receptor antagonists, as they do not compete with androgens for binding to the AR at 
concentrations up to 10 µM (Parks et al. 2000; Takeuchi et al. 2005) while one in vitro study has 
shown that metabolites of MEHP do act as AR antagonists (Stroheker et al. 2005). 
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Finasteride is a synthetic anti-androgen, used in humans as a treatment in benign prostatic 
hyperplasia in low doses and prostate cancer in higher doses. Finasteride acts by inhibiting 5α-
reductase, and thereby blocking the conversion of testosterone to DHT. Studies in rats have shown 
reduced AGD, increased number of nipples and increased incidence of hypospadias in prenatally 
exposed male rats and feminisation of the external genitalia (Clark et al. 1990; Imperato-McGinley 
et al. 1992; Clark et al. 1993; Hib and Ponzio 1995). 
Prochloraz is an imidazole fungicide, which has the potential to interfere with several mechanisms 
leading to effects on various organ systems (Vinggaard et al. 2005; Vinggaard et al. 2006). In vitro, 
prochloraz possesses anti-oestrogenic and anti-androgenic effects, and inhibits the activity of the 
oestrogen synthesising enzyme aromatase and activates the aryl hydrocarbon receptor (AhR)  
(Andersen et al. 2002; Vinggaard et al. 2002). The AhR (or dioxin receptor) is an intracellular 
receptor that mediates the toxic responses of dioxin and related chemicals. In vivo, prochloraz has 
caused an increased pregnancy length and induced incompletely masculinised male rat offspring 
after perinatal exposure (Vinggaard et al. 2005). Prochloraz is also able to induce increased 
testicular progesterone concentrations in male rat foetuses (Vinggaard et al. 2005; Laier et al. 2006; 
Blystone et al. 2007). Also a decreased level of testosterone in both testis and plasma was found in 
several studies as prochloraz inhibits the gonadal steroidogenesis (Laier et al. 2006; Blystone et al. 
2007). 
Furthermore, prochloraz decreased the concentration of thyroxin (T4) and thyroid stimulating 
hormone (TSH) in serum of exposed rats (Vinggaard et al. 2005) indicating interference with the 
thyroid function. Studies have shown that male rats exposed to prochloraz during development 
show a reduced AGD, retained nipples, and mild dysgenesis of the male external genitalia. 
Moreover, an increased AGD indicating virilisation of the in female pups has been observed (Laier 
et al. 2006).  
 
2.4 Mixture studies and prediction of combination effects 
The prediction of combined effects of chemicals is complicated but some models have been 
developed for facilitating this. In the EDEN studies, we have developed an experimental setup that 
for most endpoints enables us to compare the observed mixture toxicity with the calculated effects 
using two models: dose addition (DA) and independent action (IA) (Kortenkamp and Altenburger 
1998). 
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DA and IA are based on different assumptions and are developed separately. However, both models 
assume that the toxicants in the mixture do not influence the toxicity of the other toxicants or that 
there are no interactions in the mixture, and that the toxicants’ modes of actions are known 
(Merino-García et al. 2003). Both concepts allow calculating expected mixture toxicity on the basis 
of known toxicities of the original mixture components (Backhaus et al. 2004). 
Dose addition (DA) is often referred to as concentration addition, simple similar action or Loewe 
additivity (Loewe and Muischnek 1926). The concept has been introduced by Loewe and 
Muischnek in 1926, and the model assumes that all the chemicals in the mixture act on the same 
biological site (receptor or target organ), by the same mechanism of action, and that they differ only 
in their individual potency (Backhaus et al. 2004). The additive effects are described 
mathematically by summing up the doses of the individual chemicals in a mixture adjusted for their 
differences in potencies. The effect can be kept constant when one toxicant is replaced with an 
equal fraction of an equi-effective toxicant and in that way, the compounds in the mixture act as if 
they are dilutions of each other (Kortenkamp and Altenburger 1998). Combination effects based on 
dose addition should also result from toxicants at or below no observed effect levels (NOELs), 
provided sufficiently large numbers of components sum up to a suitably high total effect dose  
(Kortenkamp et al. 2007). 
 
The equation for dose addition (4 components) is:  
1
31 2 4
mixture
1 2 3 4
pp p pEDx
EDx EDx EDx EDx
      
 
Here, EDx1, EDx2, EDx3 and EDx4 are the effect doses of four chemicals that on their own produce 
the same quantitative effect x as the mixture, and p1, p2, p3 and p4 are the relative proportions of the 
corresponding individual doses present in the total mixture dose (“fraction in mixture”). 
 
The concept independent action (IA) is also known as simple dissimilar action, response addition, 
effect multiplication or Bliss independence, and was first applied by Bliss in 1939 (Bliss 1939). IA 
is based on the assumption that the toxic actions of each mixture compounds act on different sub-
systems in organisms and do not interfere with each other but contribute to a common result  
(Reffstrup Klein 2002). IA can only describe the toxicity of mixtures that are composed of 
dissimilarly acting substances and IA is often considered to be the proper reference model when 
using dissimilar acting compounds in a mixture (Backhaus et al. 2004).  
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The equation for Independent action (4 components) is:  
       mix 1 2 3 4E(c ) 1 1 E(c ) 1 E(c ) 1 E(c ) 1 E(c )          
Here, E(c1), E(c2), E(c3), and E(c4) denote the fractional effects (x %) caused by the individual 
concentrations c1, c2, c3, and c4 of the four chemicals respectively, and E(cmix) is the total effect 
of the mixture concentration cmix. The individual effects of mixture compounds E(ci) are estimated 
from the concentration response functions determined for single substances.  
 
This central principle of the concept of independent action is commonly taken to mean that exposed 
subjects are protected from mixture effects as long as the doses of all agents in the combination do 
not exceed their NOAELs. However, this only holds true if the NOAELs are zero effect levels but 
not if the there are small effects, even though statistically insignificant effects at the NOAELs  
(Kortenkamp et al. 2007). For example, in a case where 4 chemicals induce a statistically 
insignificant decrease of 4% of AGD the expected mixture effect is  
 
 E(Cmix) = 1- (1-0.04) 4 = 15% (statistically significant) 
 
In cases where the chemicals in the mixture each induce only small effects and there are a large 
number of chemicals in the mixture, the predictions based on dose addition and independent action 
will both predict a mixture effect. With a limited number of chemicals in the mixture and low doses 
of each chemical, the predictions based on dose addition and independent action may become 
quantitatively similar (Martin Scholze pers. com).  
Several studies have examined the applicability of dose addition. Silva et al. examined multi-
component mixtures of xenooestrogens in a yeast oestrogen-screen (E-screen) (Silva et al. 2002). 
The eight compounds were below their individual NOEC (no observed effect concentration) and 
they used reference models to predict their results. The results showed that DA was the most 
accurate method for prediction of the combination effects. Moreover they found that IA and effect 
summation led to a clear underestimation of the potential combination effects.  
A similar pattern was found in a study where 16 similar and specific toxicants were mixed  
(Altenburger et al. 2000). The chemicals were phenol derivatives anticipated to have a common 
mode of action, and the results showed that the observed mixture toxicity was rather well predicted 
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by both DA and IA concepts. Dose addition showed an excellent predictive power while 
independent action, in contrast, underestimated the EC50-values (the median effective 
concentration) of the mixture by a factor of a little more than three. 
Faust and colleagues tested 16 dissimilarly acting chemicals in tests with freshwater algae. In that 
test system, the concept of dose addition tended to overestimate the combined effect of dissimilarly 
acting chemicals, while the concept of independent action provided a more accurate prediction  
(Faust et al. 2003). There exists some dispute in the understanding of “similar action”, which makes 
it difficult to group the EDCs. In some cases, similar is regarded as an identical molecular 
mechanism of action at the same substructure of a specific receptor or a “same site of primary 
action” (Calamari and Vighi 1992). Others find it sufficient if similar action for mixture toxicities is 
seen as a similar mode of action (e.g. effects on growth or reproduction) (Hermens et al. 1984). 
In the EDEN studies described in this thesis, the concept “similar action” is used literally. Our 
similarly acting chemicals were androgen receptor (AR) antagonists, while the dissimilarly acting 
chemicals have different mechanisms (AR antagonist, 5α-reductase inhibitor, suppress testosterone 
synthesis) and thus, all of the chemicals in the mixture studies acted as anti-androgens disrupting 
male sexual development.  
Chemical mixtures and mixtures of EDCs are as earlier mentioned not considered by default when 
making a risk assessment. Several moves are underway to design approaches that take possible 
combination effects into consideration. A step in this direction has been taken in the EU research 
project SAFE FOODS (Promoting Food Safety through a New Integrated Risk Analysis Approach 
for Foods) in which an approach for a probabilistic cumulative risk assessment of anti-androgenic 
pesticides in foods has been presented ( (Müller et al. 2009), submitted). 
The approach is based on an Integrated Probabilistic Risk Assessment (IPRA) model for single 
substances (Van der Voet and Slob 2007) and extended to a cumulative risk assessment for 3 anti-
androgenic pesticides (vinclozolin, procymidone and prochloraz) by using the Relative Potency 
Factor (RPF) approach (Larsen 2003). RPFs were estimated for several male reproductive endpoints 
using dose-response data from in utero exposure studies performed in our laboratory (Laier et al. 
2006; Hass et al. 2007; Metzdorff et al. 2007). 
In EFSA (European Food Safety Authority), one of the scientific panels is working on a cumulative 
risk assessment for a group of azolfungicides but the report is not yet published.  
A very important recent example is the establishment of a US National Academy of Sciences 
committee on cumulative risk assessment for phthalates and related chemicals, at the request of the 
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US EPA. The report of this committee has appeared in December 2008 and in the summary of this 
report is stated: “Thus, the evidence supports the use of dose-addition as an approximation in 
estimating cumulative risk posed by phthalates and other anti-androgens. The use of a dose-
addition model is also supported by data that show cumulative effects at doses at which individual 
mixture components did not induce observable effects” and moreover; “Cumulative risk assessment 
based on common adverse outcomes is a feasible and physiologically relevant approach to the 
evaluation of the multiplicity of human exposures and directly reflects EPA’s mission to protect 
human health” (NRC 2008).  
Wittassek and Angerer have made some metabolism studies in humans and conclude that the 
concept of a cumulative TDI (tolerable daily intake) value may be more appropriate for the 
consideration of the overall exposure and the potential human health risks resulting from everyday 
and simultaneous exposure to several phthalates (Wittassek and Angerer 2008). 
In the new EU chemical legislation REACH (Registration, Evaluation and Authorisation of 
Chemicals), not much is written on combined exposure and mixtures. However it is stated about 
combined exposure: “In special cases, where exposure occurs to a substance as well as to several 
very closely related and similar acting chemical substances (e.g. different salts of a metal or closely 
related derivatives of organic substances), the exposure evaluation and risk characterisation should 
reflect this aspect. If data are available, the exposure assessment should also include a scenario 
concerning this combined exposure. One way to conduct risk characterisation for combined 
exposure to closely related analogues could be to add exposures and to use a toxicological 
descriptor from a representative substance among the analogues. If data do not allow for a 
quantitative assessment, an attempt should be made to address the issue in a qualitative way” 
(REACH part E) (ECHA 2008).  
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3. The overall purposes of this thesis 
The overall purpose of this thesis is to explore the need for improving the future risk assessments of 
mixtures of EDCs. This is done by examining the following questions:  
 Are there combined effects at NOAEL levels for individual anti-androgens based on the 
effects on anogenital distance, nipple retention and external malformations in male rats?  
 Can the combined effects be predicted based on the model approaches; dose addition or 
independent action? 
 Is sexually dimorphic behaviour in rats affected at lower dose levels of anti-androgens and 
thereby a more sensitive endpoint than morphological effects on the male external 
reproductive organs? 
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4. Experimental setup  
An overview of the 5 in vivo studies included in this thesis is given in Table 1. In all of the studies 
(1 to 5), time-mated nulliparous, young adult Wistar rats (HanTac:WH, Taconic Europe, Ejby, 
Denmark) were supplied at gestation day (GD) 3 of pregnancy. They were dosed by gavage from 
early gestation GD 7 until the day before expected birth, and then from PND 1 until PND 16 to 
cover the most sensitive periods of the development of the reproductive system. The studies were 
performed using 3-4 blocks (with one week in between), and all dose groups were equally 
represented in the blocks. Details about the laboratory animal housing and studies are reported in 
Papers I-V.  
Study 1-3 was range finding and dose-response studies of the six chemicals (vinclozolin, flutamide, 
prochloraz, DEHP, procymidone, finasteride). Study 4 was a mixture study with exposures of 3 AR 
antagonists (vinclozolin, flutamide and procymidone) and study 5 was a mixture study with 4 
dissimilarly acting anti-androgens (vinclozolin, finasteride, DEHP and prochloraz).  
The endpoints AGD, NR, dysgenesis and malformations in the male rats were recorded by the same 
technician who was blinded with respect to exposure groups as mentioned in details in papers I-V. 
AGD and NR was recorded on all pups from all litters (i.e. around 4-5 males and 4-5 females pr. 
litter). The measurements on PND 16 were recorded in all male pups, which were not weaned for 
malformation endpoints and behavioural measurements. The malformations were recorded in 1 
adult male per. litter in the following groups: Control, MIX 7.9, MIX 19.7, MIX 39.3, MIX 70.8, 
VIN 24.5 and VIN 95.9 mg/kg bw/day in the first study and all groups in the second mixture study. 
In both mixture studies the “fixed mixture ratio design” was used as the doses were combined at a 
fixed ratio based on the potencies of the individual chemicals. This approach was chosen in order to 
avoid that one single chemical contributed disproportionately to the overall mixture effect. 
In the first mixture study the ratio of vinclozolin, flutamide, and procymidone was 31:1:18 and in 
the second mixture study the ratio of vinclozolin: finasteride: DEHP: prochloraz was 5:0.01:3:5. 
The mixture ration was based on ED50 for nipple retention in males. The choice of doses in the first 
mixture study was based on the concentration range described by the additivity prediction while the 
individual effect doses were derived from the dose response functions for the individual chemicals 
(paper II). 
The choice of doses in the second mixture study was based on NOAELs as the lowest mixture 
(mix1) dose was equivalent to the sum of the chemicals’ individual NOAELs for retained nipples 
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(NR NOAEL), the middle dose (mix2) was 5-fold higher, and the highest dose (mix3) 10-fold this 
values (paper V). 
 
Study (No.) 
Paper 
Groups and doses 
All dams exposed from GD 7-PND 16 
No. mated per 
group 
(pregnant*) 
(1) Vinclozolin and 
Flutamide, dose-
response  
Prochloraz range 
finding  
(Paper II, III, IV 
and V) 
Control: vehicle-dosed  
Vinclozolin: 5, 10, 20, 40, 80 or 160 mg/kg bw/day  
Flutamide: 0.5, 1, 2, 4, 8 or 16 mg/kg bw/day  
Prochloraz; 50 or 150 mg/kg bw/day 
 
16 (13) 
8 (6-8) 
8 (6-8) 
8 (6-8) 
(2) Finasteride and 
DEHP, dose-
response 
Procymidone range 
finding 
(Paper I, V) 
Control: vehicle-dosed 
Finasteride: 0.001, 0.01, 0.1, 1, 10 or 100a mg/kg bw/day  
DEHP: 10, 30, 100, 300, 600 or 900 mg/kg bw/day  
Procymidone: 25 or 200 mg/kg bw/day 
16 (15) 
8/10 (7-9) 
8(6-8) 
4(2-3) 
(3) Prochloraz, 
Procymidone and 
DEHP, dose-
response  
(Paper I, V) 
Control: vehicle-dosed 
Prochloraz: 5, 10, 25, 50, or 100 mg/kg bw/day 
Procymidone: 5, 10, 25, 50, 100 or 150 mg/kg bw/day 
DEHP: 3, 10, 30, or 100 mg/kg bw/day 
16(15) 
8(5-8) 
8(5-8) 
16/8(6-8/14) 
(4) Mixture study of 
vinclozolin, 
flutamide and 
procymidone 
Mixture ratio 
31:1:18 
(Paper II, III, IV) 
Control: vehicle-dosed 
Mixture: 7.87, 19.67, 39.3, 70.8, or 106.2 mg/kg bw/day 
Vinclozolin: 24.5b or 95.9 mg/kg bw/day 
Flutamide: 0.77 b or 3.86 mg/kg bw/day 
Procymidone: 14.1b or 61.8 mg/kg bw/day 
16(14) 
16(7/12-15) 
16(12-14) 
8(6-7) 
8(5-6) 
(5) Mixture study of 
vinclozolin, 
finasteride, DEHP 
and prochloraz 
Mixture ratio 
500:1:300:500 
(Paper V) 
Control: vehicle-dosed 
Mixture: 13.01, 65.05 or 130.1 mg/kg bw/day 
Vinclozolin: 5c or 50e mg/kg bw/day 
Finasteride: 0.01d or 0.1e mg/kg bw/day 
DEHP: 3 c, 15d or 30 e mg/kg bw/day 
Prochloraz: 5 c, 25 d or 50 e mg/kg bw/day 
16 (13) 
16 (11-16) 
8 (7-8) 
8 (6) 
8 (5-7) 
8 (6-7) 
Table 1. Overview of the studies in this PhD thesis.  
* The number of pregnant rats often differed from chemical to chemical, that is the reason for the intervals. The studies 
were performed using 3-4 blocks (with one week in between), and all dose groups were equally represented in the 
blocks.  
a This dose of finasteride induced perinatal death and low pup weight and had to be decreased to 50 mg/kg bw/day from 
PND1-3 (block 1) and from GD 18 (block 2), from GD 11 (block 3), and in block 4 the dams received 50 mg/kg bw/day 
during the whole dosing period. 50 mg/kg bw/day was used for the data analysis. b Dose of the single chemical included 
in the 39.3 mg/kg bw/day mixture dose Study 4. c Dose of single chemical present in the 13.01 mg/kg bw/day mixture 
dose. d Dose of the single chemical included in the 65.05 mg/kg bw/day mixture dose. e Dose of the single chemical 
included in the 130.1 mg/kg bw/day mixture dose.  
The dose groups in bold are included in the behavioural tests, but in MIX 130.1 (study 5) only the females were 
included. 
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An overview of the postnatal test battery included in this thesis is given in Table 2. 
Typically 1 male and 1 female from each litter were weaned on PND 21, and kept for later 
behavioural testing and for examination of external malformation at PND 47. The weaned offspring 
was housed in pairs of the same sex and exposure status. In some cases two males or two females 
were kept from the same litter to be able to house the animals in pairs.  
 
End point / function Test Age at testing Included in study 
Physical development Anogenital distance 
(AGD) 
PND 0  All studies 
 Nipples (NR) PND 12±1  All studies 
 Dysgenesis (male) 
Malformations (male)  
PND 16  
PND 47 
All studies 
Study 4 & 5 (mixture) 
Play behaviour Rough and tumble play PND 30 Study 2, 3 & 4 
Motor activity Activity 
Habituation 
Young adults 8-9 weeks 
Adults 16-20 weeks  
Study 2 
Study 2-5  
Spatial learning and 
memory 
Morris maze, learning 8-12 weeks  Study 2-5 
 Morris maze, memory 14-16 weeks Study 2-5 
 Morris maze, reversal 
and new learning 
14-16 weeks Study 2-5 
Sweet preference  Two bottle test 19 -23 weeks Study 3-5 
Sexual behaviour 
 
Mating behaviour with 
exposed male and 
female rat 
25-30 weeks Study 4 & 5 (mixture) 
Table 2. Postnatal test battery in the studies.  
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5. Results from this project 
This thesis deals primarily with investigations of the effects of anti-androgenic substances on the 
development of the male rat with special focus on AGD, NR, external malformations and sexual 
dimorphic behavioural effects.  
The thesis is based upon the five papers comprised in part two and the behavioural data presented in 
appendix 1 part two. Below, the aims, results and conclusions of the investigations in these five 
papers will briefly be presented followed by a short presentation of aims, results and conclusions of 
the behavioural studies. The applied methods, study design, and test compounds are summarised in 
Tables 1 and 2. 
5.1 Paper I 
The aim of paper I was to study the whole dose-response curve for the demasculinising effects of 
DEHP in rats as well as investigating low dose effects. Our results from two studies (study 2 and 3) 
demonstrate that DEHP at a relatively low dose of 10 mg/kg bw/day causes adverse anti-androgenic 
effects on male rat development. At this dose level, male AGD distance was decreased, the 
incidence of NR was increased, the weight of the levator ani/bulbocavernosus muscle was reduced, 
and mild external genitalia dysgenesis/malformation was observed. Moreover, higher doses of 
DEHP, i.e. from 100 mg/kg bw/day, additionally induced histopathological effects on the testes, 
reduced testicular and prostate weights, and reduced expression of androgen-regulated genes: PBP 
C3 (Prostate binding protein subunit C3) and ODC (ornithine decarboxylase) mRNA in the 
prostate. The results provide new evidence of low-dose effects of DEHP, supporting that the 
NOAEL of 5 mg/kg bw/day for DEHP that has been established in the EU is appropriate (REF. EU 
RAR).  
Based on the results from these studies with DEHP, we selected 3 mg/kg bw/day as our NOAEL 
value in the mixture study with 4 dissimilar acting anti-androgens (presented in Paper V). 
5.2 Paper II 
The aims of paper II were to assess whether the combined effects of three androgen receptor 
antagonists (vinclozolin, flutamide and procymidone) could be predicted based on dose-response 
data of the individual chemicals by employing the concept of dose addition (Loewe and Muischnek 
1926), and to investigate the ability of low mixture doses to induce disruption of male sexual 
differentiation after in utero and postnatal exposure. Vinclozolin, flutamide and procymidone were 
combined at a mixture ratio (31:1:18) proportional to their individual potencies for causing 
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retention of 6 nipples in male offspring. These individual potencies were based on extensive dose-
response studies with the individual mixture components. 
Focusing on AGD and NR in male rats, the results revealed that the combined effects of the three 
anti-androgens were dose-additive for AGD and that the observed responses for NR were slightly 
higher than those predicted on the basis of dose addition.  
A combination of doses (MIX 19.7) of each chemical, which on their own did not change AGD 
statistically significantly, induced clear combination effects. Furthermore, exposure to low doses of 
the individual chemicals showed only modest effects on NR, while the mixture (MIX 7.9) induced 
NR in the males that clearly approached female values.  
In conclusion, effects of a mixture of similarly acting anti-androgens can be predicted fairly 
accurately based on the potency of the individual mixture components by using dose addition. 
Exposure to anti-androgens, which individually appears to exert only small effects, may induce 
marked responses, in combination with possibly unrecognized, similarly acting chemicals.  
5.3 Paper III 
The paper describes further results from the mixture study of the 3 AR receptor antagonists 
(vinclozolin, flutamide and procymidone). 
This paper focuses on effects at the morphological and molecular level, e.g. changes of reproductive 
organ weights and histopathology, malformations of male external genitals, and gene expression 
levels in prostates from male rat pups were chosen as endpoints for extensive dose-response studies. 
The aim of paper III was to elucidate if the combined effects of the three anti-androgens 
(vinclozolin, flutamide and procymidone) act as dose-additive compounds at these endpoints as 
well, and to determine whether small effects when judged on a chemical-by-chemical approach, 
induces marked responses in combination as previously seen for AGD and NR (Paper II). With all 
reproductive organs weights and expression of PBP C3 mRNA in prostates as the endpoints, the 
combined effects of the three anti-androgens were dose-additive. Histological evaluation showed 
that dysgenesis/malformation and/or hypoplasia of prostates, seminal vesicles, and epididymis was 
seen with the highest doses of the mixture (MIX 106.2). No changes were observed in any of the 
single-compound low-dose groups for any of these lesions. Dysgenesis/malformation of external 
genitalia was observed with all doses of the mixture and severe dysgenesis/malformation was seen 
only with a mixture for which the individual compounds did not cause any such effects (MIX 39.3).  
In conclusion, the results from paper III support the findings of paper II, that combination of 
similarly acting anti-androgens are able to affect the male rat offspring. These effects can be 
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predicted fairly accurately on the basis of information about the potency of the individual mixture 
components by using the concept of dose addition. There are clear indications that anti-androgens 
act together to produce marked combination effects when combined at doses that individually 
produce statistically insignificant responses.  
5.4 Paper IV 
The paper describes further results from the mixture study of the 3 AR receptor antagonists 
(vinclozolin, flutamide and procymidone). 
The aim of paper IV was to assess the frequencies of hypospadias and other external sexual 
malformations in the young adult male rats exposed pre- and postnatally to vinclozolin, flutamide or 
procymidone, or a mixture of these (as described in paper II and III). An additional aim was to 
examine if the anti-androgenic effects observed in the male pups, i.e. AGD, NR and 
malformations/dysgenesis PND 16 were predictive early biomarkers of external malformations 
observed in the sexually mature male rats later in life. Markedly increased frequencies (56%) of 
clear external malformations (hypospadias) were observed after exposure to a mixture of the three 
chemicals compared to administration of the three chemicals alone (0%). AGD at PND 1, NR at 
PND 13, and dysgenesis score at PND 16 were highly correlated with the occurrence of 
hypospadias, and combination effects were seen at doses where each of the individual chemicals 
caused no observable effects. AGD was a good early biomarker, as a 25% reduction in mean AGD 
measured on postnatal day 1 is likely to result in clear malformations in approximately 50% and 
marked malformations in approximately 25% of the adult male rats. Already at approximately 8% 
reduction in mean AGD, the likelihood for slight and clear malformations was increased.  
In conclusion the results from this paper indicate that doses of anti-androgens, which appeared to 
induce no hypospadias when judged on their own, might induce a very high frequency of 
hypospadias when they interact in combination with other anti-androgens. Moreover, changes in the 
early biomarkers ‘AGD, NR and dysgenesis at PND 16’ could predict malformations in the adult 
male rat.  
5.5 Paper V 
Our second mixture study focused on the effects of four dissimilarly acting anti-androgens, i.e. 
vinclozolin (androgen receptor antagonist), DEHP (testosterone synthesis inhibitor), finasteride 
(inhibitor of steroid type II 5α-reductase) and prochloraz (multiple mechanisms incl. androgen 
receptor antagonism and decreased testosterone levels). The 4 chemicals were combined at their 
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respective NOAELs (MIX 13.01), 5 times the NOAELs (MIX 65.05) and 10 times the NOAELs 
(MIX 130.1) based on our dose-response studies. AGD, NR, and reproductive organ weights at 
PND 16 were clearly affected in the mixture groups at dose levels where the individual chemicals 
alone caused no or only minor effects. The combined effects were equally well predicted by dose-
addition or independent action. Alterations in retained nipples were the most sensitive endpoint, 
with effects becoming noticeable at the lowest doses. Changes in AGD were almost as sensitive, 
followed by reductions in prostate and LABC weights, and genital malformations. Finasteride was 
by far the most potent chemical. It exhibited dose-response relationships with very shallow 
gradients for all endpoints. In addition, a very high frequency of external malformations (PND16 
and 47) such as hypospadias was seen for a mixture dose (MIX 130.1) at which the individual 
compounds caused no significant effects on external malformations. At the dose of vinclozolin 
included in this mixture (50 mg/kg bw/day), a low non-significantly increased frequency was 
observed with 4.3% malformations at PND 16 and 12.5% malformations at PND 47. 
The results indicate that dose-addition models may predict the combined effects of anti-androgens 
accurately and that marked effects can occur at doses below NOAELs for the single chemicals.  
Moreover, the experimentally observed responses on malformations exceeded the predictions, 
suggesting that the combined effect of DEHP, vinclozolin, prochloraz and finasteride is synergistic 
with respect to genital malformations.  
 
A summary of the above mentioned results are presented in table 3a (first mixture) and 3b (second 
mixture) to give an overview of the findings in paper I-V.  
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Table 3a. Summary of effects from the first mixture study in male rat pups exposed to flutamide (FLU), vinclozolin 
(VIN), procymidone (PRO), or a mixture of flutamide, vinclozolin, and procymidone (MIX) from GD 7 to PND 16. The 
results are based on paper II, III and VI. All statistically significant results, compared to controls, are shown as a “+” 
while the non-significant are shown as “-“. 
Endpoint FLU  
0.77 
mg/kg 
VIN  
24.5 
mg/kg 
PRO  
14.1 
mg/kg 
MIX  
39.3 
mg/kg 
Dose-
additivity? 
Joint effect compared 
to effect of single 
chemicals 
AGD index, PND 1 
- - - + 
Yes Marked joint effect; no 
significant effect of 
single chemicals 
Nipple retention PND 
13 + + + + 
Yes (slight 
synergy at high 
doses) 
Marked joint effect; 
small significant effect 
of single chemicals 
Right testis, PND 16 
- - - - 
n.a No joint effect; no 
significant effect of 
single chemicals 
Epididymides, PND 
16  + + + + 
n.a Marked joint effect; 
significant effect of 
single chemicals 
Ventral prostate, PND 
16 - + + + 
Yes Marked joint effect; no 
or small significant 
effect of single 
chemicals 
Seminal vesicles, 
PND 16 - - - + 
Yes Marked joint effect; no 
significant effect of 
single chemicals 
LABC#, PND 16  
- + - + 
Yes Marked joint effect; no 
or small significant 
effect of single 
chemicals 
Bulbourethral glands 
PND 16 
- + - + 
n.a Marked joint effect; no 
significant effects of 
FLU and PRO, but 
clear significant effect 
of VIN  
PBP C3 expression in 
prostate, PND 16 - - - + 
Yes Marked joint effect; no 
significant effect of 
single chemicals 
Dysgenesis of 
external reproductive 
organs, PND 16 
- - - + 
n.a Marked joint effect; 
small significant effect 
of single chemicals 
Malformation of 
external reproductive 
organs, PND 47 
- - - + 
n.a Marked joint effect; no 
significant effect of 
single chemicals 
# Levator ani/bulbocavernosus muscles, n.a.: not analysed 
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Table 3b. Summary of effects from the second mixture study in male rat pups exposed to vinclozolin (VIN), finasteride 
(FIN), Di-(2-ethylhexyl) phthalate (DEHP) and prochloraz (PZ), or mixtures of VIN, FIN, DEHP and PZ from GD 7 to 
PND 16. The results are based on paper V. All statistically significant results, compared to controls, are shown as a “+” 
while the non-significant are shown as “-“ 
Endpoint VIN FIN DEHP PZ MIX  
 
Dose-
additivity? 
Joint effect 
compared to effect 
of single chemicals 
AGD index, PND 1, 
NOAEL doses - - - - + 
Yes Joint effect; no 
significant effect of 
single chemicals 
Nipple retention, 
PND 13, number, 
NOAEL doses 
- + - - + 
Yes Joint effect similar to 
effects of finasteride 
Right testis, PND 16, 
% of control, all 
doses 
- - - - - 
n.a. No joint effect; no 
significant effect of 
single chemicals 
Epididymides, PND 
16, % of control, 10 
times NOAEL doses 
+ + - - + 
n.a. Marked joint effect; 
significant effect of 
single chemicals 
Ventral prostate, 
PND 16, % of 
control, 10 times 
NOAEL doses 
- - - - + 
Yes Marked joint effect; 
no significant effect 
of single chemicals 
Seminal vesicles, 
PND 16, % of 
control, 10 times 
NOAEL doses 
- - - - + 
Yes Marked joint effect; 
no significant effect 
of single chemicals 
LABC#, PND 16, % 
of control, 10 times 
NOAEL doses  
- - - - + 
Yes Marked joint effect; 
no significant effect 
of single chemicals 
Bulbourethral 
glands, PND 16, % 
of control, 10 times 
NOAEL doses 
+ - - - + 
n.a. Marked joint effect; 
similar to effect of 
vinclozolin  
Dysgenesis of 
external reproductive 
organs, PND 16, 10 
times NOAEL doses 
- - - - + 
Synergy Marked joint effect; 
no significant effect 
of single chemicals 
Malformations of 
external reproductive 
organs, PND 47, 10 
times NOAEL doses 
- - - - + 
n.a Marked joint effect; 
no significant effect 
of single chemicals 
# Levator ani/bulbocavernosus muscles, n.a.: not analysed 
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5.6 Results from Behavioural studies (appendix 1)  
The results from behavioural studies are presented more in details in appendix 1 and a summary is 
provided in Table 4. 
Chemicals Development of 
reproductive external 
organs (LOAEL ) 
Behavioural (LOAEL) Most sensitive endpoint 
Finasteride 
(FIN) 
 
 
At FIN 0.01 mg/kg bw/day 
effect on NR, while effects 
on AGD and malformations 
were seen at 0.1 and 1 
mg/kg bw/day, respectively 
FIN 10 mg/kg bw/day 
decreased activity in females 
Nipple retention (NR) 
Prochloraz 
(PZ) 
 
 
PZ 50 mg/kg bw/day for 
NR and >100 mg/kg 
bw/day for AGD 
No behavioural effects in 
relation to PZ 10, 25 and 50 
mg/kg bw/day 
NR 
Procymidone 
(PRO) 
 
PRO 14.1 mg/kg bw/day 
for NR and 25 mg/kg 
bw/day for AGD 
PRO 100 mg/kg bw/day 
females increased play 
behaviour 
Both NR and AGD were 
more sensitive endpoints 
than behavioural effects  
DEHP 
 
 
10 mg/kg bw/day for both 
NR, AGD  
No behavioural effects in 
relation to DEHP 100 mg/kg 
bw/day 
Both NR and AGD were 
more sensitive endpoints 
than behavioural effects 
Flutamide 
 
 
0.5 mg/kg bw/day for NR Flutamide exposed rats were 
not included in behavioural 
tests 
NR; behavioural effects 
were not studied 
Vinclozolin 
(VIN) 
 
 
5 mg/kg bw/day for NR and 
10 mg/kg bw/day for AGD 
VIN 24.5 mg/kg bw/day  
-females were more active 
-males swam shorter in the 
learning period  
- males mounted significantly 
more 
NR 
MIX 3 AR 
antagonists 
(Vinclozolin, 
Flutamide, 
Procymidone) 
 
MIX 7.9 mg/kg bw/day for 
NR and weight of 
epididymides 
MIX 19.7 mg/kg bw/day 
also for ventral prostate and 
bulbouretral glands 
MIX 39.3 mg/kg bw/day 
for effect on AGD 
MIX 7.9 and MIX 19.7 
learning impaired in males in 
Morris water maze 
  
Behaviour was just as 
sensitive as the effects on 
the reproductive organs 
MIX 4 
dissimilar 
acting anti-
androgens 
(Finasteride, 
Prochloraz, 
Vinclozolin, 
DEHP) 
MIX 13.01 mg/kg bw/day 
for effect on NR and AGD, 
while MIX 65.05 mg/kg 
bw/day showed 
malformations 
MIX 130.1 mg/kg bw/day 
females showed increased 
intake of sweet preference 
Both AGD, NR and 
malformations were more 
sensitive endpoints than 
behavioural effects 
Table 4 shows an overview of the LOAELs (Lowest adverse effect level) in this thesis and an indication which endpoint 
was the most sensitive in relation to a specific chemical or a mixture of chemicals.  
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Primarily, the aim of including behavioural testing was to study the sensitivity of sexually 
influenced behaviour compared to the development of reproductive external organs. Another reason 
for including these behavioural tests was to observe if the sexual difference in these tests had 
changed after exposure pre- and postnatally to anti-androgens.  
It is expected that anti-androgens that lower the testosterone levels and/or inhibits the aromatase 
activity will contribute to a decreased conversion of testosterone into oestradiol, and thereby lower 
the oestradiol levels needed for complete behavioural masculinisation of the male rat brain. Another 
expectation could be that receptor mediated anti-androgens may block the androgen receptors in the 
brain, and thereby reduce the negative feedback that the endogenous testosterone exerts on the 
hypothalamus and pituitary, which will result in increased LH and testosterone production and 
thereby an increased masculinisation of the developing male rat.  
5.6.1 Finasteride Effects on both motor activity, and learning and memory were found after 
exposure to finasteride. The decreased activity observed in females in two of the finasteride 
exposed groups (0.1 or 10 mg/kg bw/day) indicates behavioural changes in the male direction.  
Behaviour was not the most sensitive endpoint regarding pre- and postnatal exposure to finasteride, 
as the male rats showed NR at a 1000 times smaller dose, and AGD was reduced at a 100 times 
smaller dose. 
5.6.2 Prochloraz No significant effects of exposure to prochloraz (10, 25 and 50 mg/kg bw/day) 
were found on any of the behavioural endpoints tested. Furthermore, no significant effects of 
exposure were seen in the mixture study with four dissimilarly acting anti-androgens, where 
prochloraz was present at doses of 5 and 25 mg/kg bw/day.  
Behaviour was not the most sensitive endpoint with regard to pre- and postnatal exposure to 
prochloraz, as the male rats showed NR at 50 mg/kg bw/day whereas we did not observe any 
behavioural effects at this exposure level. 
5.6.3 Procymidone Increased play behaviour was found in females exposed to PRO 100 mg/kg 
bw/day compared to the control females. This indicates a masculinising effect of procymidone in 
the females. In the Morris water maze, PRO 50 mg/kg bw/day females (memory day 2) performed 
better (i.e. masculine direction), but no dose response relationship was found, as no consistent effect 
on memory of PRO 100 mg/kg bw/day females was observed. In the Morris water maze, PRO 25 
mg/kg bw/day and PRO 50 mg/kg bw/day males (new learning) performed better (i.e. masculine 
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direction). However, in contrast to this, PRO 100 mg/kg bw/day males showed longer latency (i.e. 
feminised direction) so no consistent effects or direct dose-response relationship were found.  
Behaviour was not the most sensitive endpoint when evaluating pre- and postnatal exposure to 
procymidone, as the male rats showed NR at an almost 10 times lower dose level and reduced AGD 
at a 4 times lower dose level than the dose level where the behaviour was affected (increased play 
behaviour in females, impaired learning in males). 
 
5.6.4 Vinclozolin Increased activity was observed during the initial part of the period in females 
exposed to VIN 24.5 compared to control females. 
In the Morris water maze, the VIN 24.5 males swam significantly shorter than control males and in 
mating behaviour, a significantly increased number of mounts were seen in VIN 24.5 exposed 
males.  
Behaviour was not the most sensitive endpoint regarding pre- and postnatal exposure to vinclozolin, 
as the male rats showed NR at 5 mg/kg bw/day and reduced AGD from 10 mg/kg bw/day. The 
study only included the dose VIN 24.5 mg/kg bw/day where behavioural effects were observed 
(Table 4). The females’ behaviour pointed in the direction of a feminised effect (more active) while 
the males’ behaviour pointed in the direction of a masculinising effect (increased learning, 
increased mounting). 
5.6.5 First mixture of 3 AR antagonists (vinclozolin, flutamide and procymidone). 
Increased activity was observed, during the initial part of the period in females exposed to MIX 
19.7 compared to control females. The males exposed to MIX 7.9 were less active (i.e. 
masculinised), but this was only significant in the last period. Furthermore, no dose response 
relationship was observed, as no effects were observed on males exposed to MIX 19.7.  
Learning was impaired (i.e. feminised effect) in males dosed with both MIX 7.9 and MIX 19.7 
when tested in the Morris water maze.  
The behavioural testing showed that male behaviour could be just as sensitive an endpoint as the 
effects on reproductive organs after exposure to mixtures of 3 AR antagonists (vinclozolin, 
flutamide, and procymidone). The learning in Morris water maze was impaired at the same dose 
levels where effects on nipples, weight of epidydimides, ventral prostate and bulbouretral glands 
were affected.  
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5.6.6 Mix study of 4 dissimilarly acting anti-androgens (vinclozolin, finasteride, DEHP 
and prochloraz). The only effect on behaviour observed in this study was that the MIX 130.1 
females showed an increased intake of sweet water compared to control females. This could be 
evaluated as increased feminisation in this group. Behaviour was not the most sensitive endpoint 
regarding pre- and postnatal exposure to a mixture of 4 dissimilarly acting anti-androgens, as the 
male rats showed NR and reduced AGD at a 10 times lower dose level (MIX 13.01 = Mixture of 
NOAELs) than where the effects on female behaviour were seen (MIX 130.1 effects on sweet 
preference in females and severe malformations in males).  
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6. Discussion 
6.1 Effects of single chemicals 
Dose-response analysis of all individual mixture components (flutamide, procymidone, DEHP, 
vinclozolin, prochloraz and finasteride) were carried out to provide a basis for the calculation of the 
expected additive effects for mixtures of specific compositions. The dose-response studies for the 
single chemicals were used to design two large developmental toxicity mixture studies and to 
predict the effects of a combination with constant mixture ratios. The dose response studies were 
performed also to define the NOAELs of the different chemicals. The compounds were given 
individually (by gavage) to pregnant rats throughout gestation and lactation, covering the period 
when male sexual differentiation takes place. 
The observed NOAEL values for nipple retention (NR), the most sensitive endpoint, from these 
dose response studies are general in accordance with regulatory NOAELs as seen in Table 5. 
 
Compound Our NOAEL 
(NR) mg/kg 
bw/day 
Regulatory 
NOAEL 
mg/kg bw/day 
Comments References 
5  
 
Based on effects on 
testes 
 (EU RAR 2004) 
 
DEHP 3  
Between 1 and 10 Based on effects on 
Leydig cells 
 (Kavlock et al. 
2006) 
4  Study of reproductive 
toxicity 
RAR from 
http://www.inchem.org 
Vinclozolin 5  
4.9 
 
2. Generation study in 
rats 
BASF Study 
http://www.inchem.org 
Flutamide 0.5 0.6 *   (Miyata et al. 2002) 
Procymidone 10 12.5 2. Generation study in 
rats 
RAR from  
http://www.inchem.org/d
ocuments/jmpr/jmpmono
/v89pr12.htm  
Prochloraz 5  3.7  Multigenerational 
reproductive toxicity 
in rats 
JMPR 2001 
http://www.inchem.org/d
ocuments/jmpr/jmpmono
/2001pr11.htm 
0.10 
 
Based on hypospadias 
 
0.03 Based on NR 
Finasteride 0.01  
 
0.003 
Based on AGD 
MERCK Propecia® 
(Finasteride) 
Prescribing 
information 
http://www.merck.com/p
roduct/usa/pi_circulars/p
/proscar.html 
Table 5. Comparison of NOAELs estimated for nipple retention (NR) in the present studies with those currently used for regulatory 
purposes in human risk assessment * No regulatory NOAEL value was found for Flutamide and the 0.6 value is reported in a 
research paper (Miyata et al. 2002). 
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6.2 Effects of combined exposure to similarly acting anti-androgens 
Our study has shown clearly that antiandrogens (vinclozolin, flutamide, and procymidone) with a 
similar mode of action (androgen receptor antagonism) act together in an additive way and the 
results could, as expected, be predicted based on dose addition for a broad spectrum of endpoints 
assessed in rat pups before weaning (Hass et al. 2007; Metzdorff et al. 2007). 
These findings are consistent with the previously reported additivity of antiandrogens on other 
endpoints such as AR receptor activation in vitro and in vivo (Nellemann et al. 2003; Birkhøj et al. 
2004). Also, a combination of doses of each chemical that, on its own did not produce significant 
effects, induced marked combination effects on AGD, NR, reproductive organ weights, and PBP C3 
gene expression in the prostate, and caused marked dysgenesis of external reproductive organs on 
PND 16. This phenomenon, somewhat provocatively dubbed “something from ‘nothing’”, has been 
observed with multi-component mixtures of oestrogenic agents in reporter-based assays (Silva et al. 
2002; Rajapakse et al. 2002), the Uterotrophic assay (Tinwell and Ashby 2004), and vitellogenin 
induction in fish (Brian et al. 2005). 
The results in paper IV indicate that the “something from ‘nothing’” phenomenon may also apply to 
hypospadias in young adult male rats exposed to similarly acting anti-androgens during 
development. In this case, a combination of 24.5 mg/kg bw/day vinclozolin, 0.77 mg/kg bw/day 
flutamide and 14.1 mg/kg bw/day procymidone induced hypospadias in almost 60% of the male 
offspring, whereas the incidence after exposure to 24.5 mg/kg bw/day vinclozolin alone was similar 
to the untreated controls, i.e. 0%. This suggests that the presence of flutamide and procymidone in 
the mixture gravely exacerbated the effects of vinclozolin. Taken together, these clear correlations 
demonstrate that the early endpoints in pups (AGD, NR and dysgenesis in the males at PND 16) are 
good predictors of the malformations observable later in adult/sexually mature male rats.  
The findings from the mixture study with similarly acting anti-androgens clearly indicate that risk 
assessment based on NOAELs for single anti-androgens alone underestimate the risk for 
hypospadias and other adverse anti-androgenic effects. 
6.3 Effects of combined exposure to dissimilarly acting anti-androgens  
The second mixture study focused on the effects of four dissimilarly acting anti-androgens. The 
combined effects were equally well predicted by dose-addition or independent action for AGD, NR, 
and weight changes of the prostate and LABC. That this occurred despite the different mechanistic 
premises that underlie the two prediction concepts is coincidental (paper V). 
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When the four chemicals were combined at doses equal to no-observed-adverse-effect levels 
estimated for nipple retention (NR NOAEL), significant reductions in AGD were observed in the 
male offspring. In addition, a very high incidence of external malformations such as hypospadias 
was seen for a mixture for which the individual compound caused no significant effects on 
malformation incidences. This combination effect was synergistic and worse than predicted based 
on dose-addition or independent action ( (Christiansen et al. 2009)submitted, paper V). The male 
rats showed NR and reduced AGD at a 10 times lower dose level (MIX 13.01 = Mixture of 
NOAELs) than the dose level where the malformations in nearly all male offspring were seen.  
The significance of these findings in rats for human risk assessment must be emphasised, because 
they clearly indicate that assessing the potential risk of anti-androgens on a chemical-by-chemical 
approach may severely underestimate the real human risk for hypospadias and other adverse anti-
androgenic effects.  
In conclusion, our findings challenge the widely held view (COT 2002; VKM 2008) that chemical 
mixtures exhibiting various modes of action are without combination effects at levels near supposed 
dose thresholds, used in regulatory toxicology as points of departure for the derivation of tolerable 
human exposures. If this assumption is correct, we should not have been able to observe alterations 
in AGD when all four chemicals were combined at their NOAELs (based on nipple retention). 
Our findings echo the observations made by Cynthia Rider and colleagues. They examined a 
mixture of 7 dissimilarly acting anti-androgens in rats (butyl benzyl phthalate, di-n-butyl phthalate, 
DEHP, vinclozolin, procymidone, linuron, and prochloraz). They found that this mixture disrupted 
the male rat reproductive tract differentiation and induced malformations that exceeded those 
predicted by dose addition (Rider et al. 2008). Because their data for the single chemicals were 
sometimes based on dosing regimens that differed from those used in the mixture experiment, there 
is a degree of uncertainty as to whether the excess malformations in that study represent a true 
synergism. Our evaluations are based on dose-response data for single chemicals and mixtures from 
one large study and therefore substantiate concerns about the synergistic induction of genital 
malformations by mixed-mode of action anti-androgens. 
Recent epidemiological studies suggest an association between an increased risk of hypospadias and 
maternal occupational exposure to phthalates and hair sprays (Ormond et al. 2009).  
Recent studies suggest a previously unidentified role for the progesterone receptor, possibly 
interacting with the androgen receptor, in disturbed genital tubercle development (Willingham et al. 
2006). In utero exposure to natural or synthetic progesterones can increase the risk of hypospadias 
 41
in male mice. Intake of natural or synthetic progesterone during pregnancy in humans has been 
associated with an increased risk of hypospadias (Carmichael et al. 2005; Willingham et al. 2006). 
Prochloraz, one of the chemicals in the mixture, was able to induce increased testicular 
progesterone concentrations in male rat foetuses, and this effect occurred at lower dose levels than 
those present in the mixture investigated here (Vinggaard et al. 2005; Laier et al. 2006; Blystone et 
al. 2007). Thus, elevated progesterone levels due to prochloraz exposure may have a role in the 
synergisms with severe hypospadias that we observed in our study Paper V. The results from our 
study with dissimilar mixtures support what is concluded in Kortenkamp et al. (2007), stating that 
“the view that mixtures of dissimilarly acting chemicals are “safe” at doses below NOAEL does not 
only lack empirical support, it is also based on the erroneous assumption that NOAELs are indeed 
zero effect levels”  (Kortenkamp et al. 2007). 
6.4 Behavioural effects and sensitivity 
In conclusion, it is at present difficult to predict what happens to the behaviour of male and female 
rats pre- and postnatally exposed to anti-androgenic compounds. In some cases, the effects observed 
point in the direction of a masculinising effect on the males and a feminising effect on the females, 
while the morphological anti-androgenic effects are demasculinised male organs.  
The expectation in relation to behaviour of male rats exposed in utero to mixtures of AR antagonists 
is that the negative feedback from testosterone will be reduced, resulting in increased LH and 
testosterone production and thereby an increased masculinisation of the developing male rat.  
In most of the studies in this thesis, the development of the male reproductive organs was a more 
sensitive endpoint than behaviour. Nevertheless, animal behaviour seemed to be just as sensitive as 
the development of reproductive organs when testing the mixtures of 3 AR antagonists. In the 
Morris water maze, the learning was impaired in the males from MIX 7.9 and MIX 19.7 (i.e. results 
are in the direction of a more female like behaviour and thereby incomplete masculinisation).  
This was an unexpected result and could also be a result possibly related to a neurotoxic effect.  
Thus, in future testing of chemical mixtures it will be very relevant to look also at behavioural 
effects as these results could contribute to a broader picture of the toxicity of mixtures of EDCs that 
only takes the development of reproductive organs into account.  
6.5 Input for existing OECD guidelines  
As AGD and NR in these studies as well as many other studies are endocrine sensitive endpoint it is 
considered relevant to include assessment of these endpoints in both F1 and F2 offspring as a 
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standard parameter in the 2-generation study without the need for triggering this by alterations in 
sex ratio or timing of sexual maturation. In addition, the parameters could be included in the one-
generation study and AGD could be included in the reproductive toxicity screening tests, i.e. TG 
421 and TG 422. As mentioned in the background section (2.0) these endpoints are planned to be 
included in the new OECD guideline for the extended One-generation study.  Malformations of 
external sex organs (e.g. hypospadia) in adult males are studied in only one male per litter in the 
existing two-generation study. This was also the case in the studies in this project, but recent power 
calculations presented at an OECD meeting in October 2008 show that the sensitivity can be 
markedly increased by looking at 2-3 males per litter (Hass, pers. com). This is discussed in relation 
to the new OECD guideline and recommended here, because hypospadia is a serious adverse effect 
caused by both single anti-androgens and their combinations in the studies in this thesis.  
6.6 Future perspectives and input for mixture risk assessment  
The research performed in this thesis aims to explore the need for improving the research based 
knowledge for future risk assessment approaches and also to give input to the regulatory system. 
Until now, the regulatory systems have no consistently accepted method for cumulative risk 
assessment for mixtures of chemicals.  
A view that has persisted over the last 30 years is that combination effects do not occur when each 
chemical is present at doses equal to their NOAELs (COT 2002; VKM 2008). This view is 
challenged in the mixture study of dissimilarly acting anti-androgens( (Christiansen et al. 2009), 
submitted, paper V). Alterations in AGD were observed when all four chemicals were combined at 
their NOAELs (based on nipple retention). It can, on that basis, be concluded that a risk assessment 
based on the NOAELs of single chemicals may underestimate the human risk for endocrine 
disrupting effects. It should be considered to take effects of mixtures into account in a risk 
assessment as a considerable part and perform the risk assessment for the anti-androgens in total 
regardless of their anti-androgenic mechanism.  
Clearly it would never be realistic to test the potential effects of all possible combinations of 
chemicals with endocrine disrupting properties to which target groups of humans and/or wildlife 
could be exposed. Instead, it is necessary to develop robust predictive models that allow the effects 
of interactions of mixtures of chemicals with endocrine disrupting properties with common or 
different mechanisms of action to be evaluated. Data from the literature and this thesis suggest that 
the dose addition model adequately describes the effects of mixtures of endocrine disrupting 
chemicals with both similar and dissimilar modes of action  (Kortenkamp 2007; Kortenkamp et al. 
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2007). The concept of dose addition could lead to a “mixture no-observed-adverse-effect level” 
(MNOAEL) for endpoints relevant to endocrine disruption. These could then be combined with an 
assessment factor to arrive at estimates of tolerable human exposure (EDEN 2007). The results 
from the studies in this thesis underline the importance of the ongoing initiatives in both EFSA and 
US Academy of science concerning the development of cumulative risk assessment.   
 
6.7 Recommendations for future research 
The results from the mixture studies will provide strong evidence in future research with mixture 
exposure of endocrine disrupting chemicals.  
In EDEN the focus was on anti-androgens with similar or dissimilar mechanisms of action, but 
humans are exposed to a mixture of chemicals with different modes of action. The Department of 
Toxicology and Risk Assessment is a part of a new ongoing EU project called CONTAMED (2008-
2011). This study will investigate the possible role of mixtures of 10-12 environmentally relevant 
EDCs (e.g. anti-androgens, oestrogens and, other classes of chemicals) in producing adverse 
developmental toxicity effects, including long-term effects, at dose levels at a mixture ratio 
proportional to human exposure, in a large extended developmental toxicity rat study. The results of 
these studies will be analysed jointly using dose-addition modelling, and they are expected to 
provide important information concerning applicability of dose-addition models for prediction of 
combined effects of EDCs and human safety evaluation of mixed exposure to EDCs. 
In planning of experimental studies with simultaneous exposure to several chemicals, it is necessary 
with good dose-response data for the single chemicals. Moreover, it is important with thorough 
considerations concerning choice of dose, mixture of the chemicals and prediction model. It is 
highly recommended in the planning: 
- to choose doses, which cover the whole dose response curves for these combination effects,  
- to evaluate the chemicals according to potency 
- to mimic the actual exposure of humans 
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7. Main conclusions 
In vivo reproduction studies with rats indicate that dose-addition models could in most cases predict 
the combined effects of anti-androgens, and that marked effects can occur at mixture doses below 
NOAELs for the individual chemicals. The significance of these findings for human risk assessment 
must be emphasised, because they clearly indicate that risk assessment based on NOAELs for single 
anti-androgens alone may underestimate severely the risk for hypospadias and other adverse anti-
androgenic effects.  
Our results hold the promise that predictions of combination effects could be obtained in the future 
without conducting mixture experiments, by employing modelling approaches. Considering the 
high cost and long duration of reproductive toxicity studies this might greatly aid efforts in 
regulatory toxicology. Behavioural testing could in some cases provide useful complementary 
information and contribute to a broader picture of the toxicity of the mixtures of EDCs than studies 
that only take the development of reproductive organs into account.  
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Introduction 
During the ‘critical periods’ of development the central nervous system is very sensitive, and 
altered hormone levels as well as chemical exposure can have severe and permanent effects on 
development. This phenomenon may change the course of sexual differentiation. Consequently, a 
new test guideline for testing of potential developmentally neurotoxic chemicals has been 
developed, “OECD Test Guideline 426 for Developmental Neurotoxicity Study” (OECD 2007). 
This guideline study is designed to achieve data on the potential functional and morphological 
hazards to the nervous system, which may arise in the offspring following exposure of the mother 
during pregnancy and lactation. The evaluation of the offspring includes observations to detect 
gross neurological and behavioural abnormalities; to assess physical development, reflex ontogeny, 
motor activity, motor function, sensory function, and learning and memory; and to evaluate brain 
weights and neuropathology. 
The following behavioural endpoints: play behaviour, activity, learning and memory (Morris water 
maze), sweet preference, and mating behaviour were included as a part of this PhD thesis. 
Primarily, the aim of including behaviour was to study the sensitivity of sexually influenced 
behaviour compared to the development of reproductive external organs. Another reason to include 
these behavioural tests was to observe if the differences between sexes in these tests had changed 
after exposure pre- and postnatally to anti-androgens.  
It is well-known that there is a natural sex-difference in the reproductive behaviour of male and 
female rats. In addition, sex differences in a large number of other behavioural endpoints depend on 
early gonadal hormone secretion (MacLusky and Naftolin 1981). Sex differences in central nervous 
function represent the outcome of interactions between several different factors, among which the 
hormones secreted by the gonads during development are of principal importance. In mammals, the 
intrinsic behavioural pattern is generally female, with differentiation towards masculine pattern of 
behaviour occurring in the male as a result of exposure to testicular hormones during development. 
The conversion of testosterone into oestradiol by aromatase in the brain, however, is critical for the 
organization of the male brain in rats (Hotchkiss et al. 2002).  
It has been shown in animal models that female rats show higher spontaneous activity than males 
and that they have a higher preference for sweetened water in a sweet preference test (Valenstein et 
al. 1967; MacLusky and Naftolin 1981). Gender differences for spatial learning abilities have been 
reported in both humans and rodents, where males generally perform better than females (Roof and 
Stein ; Beatty 1979; Williams and Meck 1991). The expected gender differences in the behavioural 
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tests included in this thesis are as follows: Play behaviour, males do more pinnings (Hotchkiss et al. 
2002; Casto et al. 2003); motor activity, males are less active (MacLusky and Naftolin 1981); 
Morris water maze, males perform better than females (Williams and Meck 1991); and sweet 
preference test, females reported to consume more sweetened water in relation to body weight than 
males (Valenstein et al. 1967; Kaya et al. 2002).  
It is expected that anti-androgens that lower the testosterone levels and/or inhibits the aromatase 
activity will contribute to a decreased conversion of testosterone into oestradiol, and thereby lower 
the oestradiol levels needed for complete behavioural masculinisation of the male rat brain. This 
will result in a demasculinisation. An expectation for the receptor mediated anti-androgens is that 
they block the androgen receptors in the brain, and thereby reduce the negative feedback that the 
endogenous testosterone exerts on the hypothalamus and pituitary, which will result in increased 
LH and testosterone production and thereby an increased masculinisation of the developing male 
rat.  
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Materials & methods 
Study design 
Behaviour was examined in offspring from study 2-5 and the different chemical exposures and dose 
groups are presented in Table 1. Time mated nulliparous, young adult Wistar rats (HanTac:WH, 
Taconic Europe, Ejby, Denmark) were supplied at day 3 (GD 3) of pregnancy. They were dosed by 
gavage from early gestation GD 7 until the day before expected birth, and then from PND 1 until 
PND 16. The studies were performed using 3-4 blocks (with one week in between), and all dose 
groups were equally represented in the blocks. Further details about the laboratory animal housing 
and studies are reported in Papers I-V.  
Study (No.) 
Paper 
Groups and doses 
All dams exposed from GD 7-PND 16 
No. mated per 
group 
(pregnant*) 
(2) Finasteride and 
DEHP, dose-
response 
Procymidone range 
finding (Paper I, V) 
Control: vehicle-dosed 
Finasteride: 0.001, 0.01, 0.1, 1, 10 or 100a mg/kg bw/day  
DEHP: 10, 30, 100, 300, 600 or 900 mg/kg bw/day  
Procymidone: 25 or 200 mg/kg bw/day 
16 (15) 
8/10 (7-9) 
8(6-8) 
4(2-3) 
(3) Prochloraz, 
Procymidone and 
DEHP, dose-
response (Paper I, 
V) 
Control: vehicle-dosed 
Prochloraz: 5, 10, 25, 50, or 100 mg/kg bw/day 
Procymidone: 5, 10, 25, 50, 100 or 150 mg/kg bw/day 
DEHP: 3, 10, 30, or 100 mg/kg bw/day 
16(15) 
8(5-8) 
8(5-8) 
16/8(6-8/14) 
(4) Mixture study of 
vinclozolin, 
flutamide and 
procymidone 
Mixture ratio 
31:1:18 
(Paper II, III, IV) 
Control: vehicle-dosed 
Mixture: 7.9, 19.7, 39.3, 70.8, or 106.2 mg/kg bw/day 
Vinclozolin: 24.5b or 95.9 mg/kg bw/day 
Flutamide: 0.77 b or 3.86 mg/kg bw/day 
Procymidone: 14.1b or 61.8 mg/kg bw/day 
16(14) 
16(7/12-15) 
16(12-14) 
8(6-7) 
8(5-6) 
(5) Mixture study of 
vinclozolin, 
finasteride, DEHP 
and prochloraz 
Mixture ratio 
5:0.01:3:5 
(Paper V) 
Control: vehicle-dosed 
Mixture: 13.01, 65.05 or 130.1 mg/kg bw/day 
Vinclozolin: 5c or 50e mg/kg bw/day 
Finasteride: 0.01d or 0.1e mg/kg bw/day 
DEHP: 3 c, 15d or 30 e mg/kg bw/day 
Prochloraz: 5 c, 25 d or 50 e mg/kg bw/day 
16 (13) 
16 (11-16) 
8 (7-8) 
8 (6) 
8 (5-7) 
8 (6-7) 
Table 1. Overview of the 4 studies that include behaviour in this PhD thesis. * The number of pregnant rats often 
differed from chemical to chemical, that is the reason for the intervals. The studies were performed using 3-4 blocks 
(with one week in between), and all dose groups were equally represented in the blocks.  
a This dose of finasteride induced perinatal death and low pup weight and had to be decreased to 50 mg/kg bw/day from 
PND1-3 (block 1) and from GD 18 (block 2), from GD 11 (block 3), and in block 4 the dams received 50 mg/kg bw/day 
during the whole dosing period. 50 mg/kg bw/day was used for the data analysis. b Dose of the single chemical included 
in the 39.3 mg/kg bw/day mixture dose Study 4. c Dose of single chemical present in the 13.01 mg/kg bw/day mixture 
dose. d Dose of the single chemical included in the 65.05 mg/kg bw/day mixture dose. e Dose of the single chemical 
included in the 130.1 mg/kg bw/day mixture dose.  
The dose groups in bold are included in the behavioural tests, but in MIX 130.1 (study 5) only the females were 
included. 
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Behavioural testing 
All investigations of behaviour were performed between 9.00 a.m. and 4 p.m. during the animals’ 
dark cycle, i.e. their active period. The behaviour was recorded by technicians who were blinded 
with respect to exposure groups. Exposed and control animals were tested alternately and so were 
females and males (except in the mating behaviour testing). Table 2 presents the test battery and 
describes the ages at which the testing was performed. 
 
End point / function Test Age at testing Included in study 
Physical development Anogenital distance PND 0  All studies 
 Nipples PND 12±1  All studies 
 Dysgenesis (male) 
Malformations (male)  
PND 16  
PND 47 
All studies 
Study 4 & 5 (mixture) 
Play behaviour Rough and tumble play PND 30 Study 2, 3 & 4 
Motor activity Activity 
Habituation 
Young adults 8-9 weeks 
Adults 16-20 weeks  
Study 2 
Study 2-5  
Spatial learning and 
memory 
Morris maze, learning 8-12 weeks  Study 2-5 
 Morris maze, memory 14-16 weeks Study 2-5 
 Morris maze, reversal 
and new learning 
14-16 weeks Study 2-5 
Sweet preference  Two bottle test 19 -23 weeks Study 3-5 
Sexual behaviour 
 
Mating behaviour with 
exposed male and 
female rat 
25-30 weeks Study 4 & 5 (mixture) 
Table 2. Postnatal test battery in the studies.  
 
Play behaviour 
The play behaviour was observed, as two rats of the same sex and treatment were put together in the 
same cage for a period of 10 minutes. The endpoints scored for each pair of playing rats was the 
latency to the first pinning and the number of pinnings. A pinning was defined as either one of the 
rats standing over the opponent with its forepaws on the ventral surface of the other one. The play 
behaviour was recorded using a video camera with infrared light, making it possible to perform the 
test in an unlit room and without an observer present during testing (the same camera were used in 
the mating behavioural testing). The tested pairs of rats were separated for 48 hours before the 
observation, to increase their motivation for play, and the test was performed in their original 
“home cage” to make their environment as familiar as possible.  
Motor activity and habituation capability 
The testing of activity and habituation capacity has been described earlier by Axelstad et al (2008). 
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The animals were placed individually in clean plastic cages without bedding, and the cages were 
placed in activity boxes with photocells, which measured horizontal activity for 30 min (Fig. 1). 
The position of the cages in the activity boxes was adjusted in height, depending on the age of the 
rats. Neither food nor water was supplied during the measurement period. A computer in an 
adjoining room automatically recorded the output of the photocells and collected data for each of 10 
three-minute intervals. The total activity during the 30 min observation period was used as a 
measure of general activity. In order to assess habituation, the 30 minutes were divided into two 
periods of 15 minutes. 
 
 
  
 
 
 
Figure 1. The set up for the activity test, with the photocells 
shown at the right side (photo: Bo Herbst) 
Learning and memory in Morris water maze.  
The testing in Morris water maze has been described earlier by Hass et al., Hougaard et al. and 
Axelstad et al. and was carried out with minor modifications (Hass et al. 1995; Hougaard et al. 
1999; Hass et al. 1999; Axelstad et al. 2008). The pool had a diameter of 220 cm, and a circular 
transparent platform was situated on a solid support and submerged 1 cm below the water surface, 
and thus invisible from water level. The animals were tested in four daily trials using four different 
starting points along the rim of the pool. When the rats reached and climbed onto the platform, the 
trial was completed. If the animal failed to locate the platform within 60 sec, it was led to the 
platform. A video-tracking device (Viewpoint video tracking system, Sandown Scientific, 
Middlesex, England) tracked the route of the animals, and the latencies to find the platform, the 
path lengths, and swimming speeds were used as endpoints.  
The following scheme was used:  
Learning. With the platform situated at the same place, the animals were trained in four trials per 
day for 5 consecutive days, until a stable performance was established. 
Memory. Four weeks after the learning period, the animals were tested again with the platform still 
in the same quadrant of the pool. The animals were given four trials on each of 2 consecutive days. 
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New platform position (reversal learning and new learning). The day after the memory testing, the 
animals were tested in a reversal procedure (reversal learning) with the platform placed opposite to 
the original location. The following day, the platform was located in the centre of the maze (new 
learning). In both tests the animals were tested for four trials. 
Sweet preference test 
Figure 2. The set up for the sweet preference test, showing 
two bottles for each rat (photo: Bo Herbst) 
The weeks before testing the animals were housed one per cage, and habituated to drinking from 
two bottles with tap water (Fig. 2). During the week of testing the animals were given a choice 
between tap water and water sweetened with 0.25% saccharin (Sigma-Aldrich). Position of the 
saccharin and water bottles were counterbalanced in each group to avoid position preferences. Each 
day the intake from both bottles was measured, and the bottles were refilled if needed. Body 
weights were registered in the same week and used for calculation of saccharin intake per 100 g 
body weight.  
Mating behaviour 
The male rats should be sexually experienced before the mating session with the exposed females as 
described by Chahoud and Faqi (Chahoud and Faqi 1998). For this purpose, non-ovariectomised 
sexually mature female Wistar rats (weight 170 g ± 20g) were purchased from Taconic Europe. 
These female rats were treated with β-oestradiol-3-benzoate (25 μg/rat) 48 hours before the mating 
and progesterone (500 μg/rat) 4 hours before mating to become in ‘chemical oestrus’. Both 
solutions were injected subcutaneously. The effects of progesterone dosing last for about 4 hours 
and the females can be used several times for this purpose. The males were exposed to a female in 
‘chemical oestrus’ for a maximum of 20 minutes. It was required that the female showed proceptive 
behaviour (described below) otherwise it was replaced by another female rat. The male rats had two 
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training trials in the test described below. If the male rat ejaculated before the 20 min, the training 
test was stopped otherwise the testing lasted for 20 minutes. 
  
Figure 3. The Vaginal Impedance checker and measuring of impedance 
Before each mating behaviour session with exposed female rats, a Rat Vaginal Impedance checker 
(MK-10C from Muromachi) was used. With this apparatus (Fig. 3) the electrical impedance of the 
epithelial cell layer of vaginal mucosa is measured at the frequency of 1 kHz by insertion of the 
probe into the vagina. In the pro-oestrus stage significantly higher impedance is produced compared 
to the other stages of the oestrus cycle. Behavioural oestrus corresponds to vaginal pro-oestrus, the 
12-hour period before ovulation (Bartos 1977; Ramos et al. 2001). 
In the morning between 9-11.30 am (in their active period), the impedance for the female rats was 
measured (Ramos et al. 2001). An impedance value at or above 3 kohm (kΩ, electrical impedance) 
indicated pro-oestrus and the female rat was selected for examining mating behaviour that day. The 
mating pairs consisted of a male and a female from the same exposure group and the person 
observing the mating behaviour was blinded with regard to exposure group.  
One of the problems with this design of mating behaviour is that both males and females are 
exposed and as a result of this, it is unknown whether the observed behaviour is an effect of the 
female or the male exposure. This could also be the case in relation to play behaviour where both 
“players” are similar exposed.  
The mating test was performed between 12 and 16 am (in the active period of the animals). The 
male from the couple was placed in a transparent polycarbonat cage (59.5 x 38 x 20cm (D x W x 
H)) with a flat lid and with no bedding in an unlit room. A female in prooestrus was then introduced 
into the male cage. The same cage was used for all animals in the study. The copulatory behaviour 
was recorded using a standard Phillips CCD-MOS video camera (black and white) with sensitivity 
in the infra- red area (800-950 nm). The camera was placed so that it could record all behaviour 
from the side of the cage. It was connected to a hard disk/DVD recorder (LVW-545 HDD+DVD 
recorder) and the recordings of mating behaviour were saved at this recorder. After 20 minutes the 
female was removed and vaginal smear taken. 
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All mating behaviour data were scored using a Psion Workabout (ProInfo) with the software Pocket 
Observer® (Noldus, The Netherlands) installed. This was done by trained observers blind to 
experimental groups until data processing in The Observer program was completed. The observer 
looked at the recordings of mating behaviour on a computer and registered the behavioural elements 
by pressing the following buttons on the Psion Workabout.  
 K = Kick (female) 
 V= Ear wiggling (female) 
 L= Lordosis (female) 
 M= Mount (male) 
 I= Intromission (male) 
 E= Ejaculation (male) 
All of the elements are described below.  
During behavioural oestrus or vaginal pro-oestrus, the female solicits the male to prompt him into 
mounting her. She darts towards him and runs or hops away. She may repeat this approach-retreat 
sequence several times, wiggling her ears. The male rat appears to finding these proceptive 
behaviours very attractive and if he mounts her, the pressure he exerts on her flanks, lower back, 
and anogenital area triggers lordosis, the female mating posture that enables copulation (Nelson 
1995).  
Kick: The normal female, when not in oestrus, will frequently kick the approaching male. 
Ear wiggle: Female vibrates her ears rapidly. Ear wiggling is part of a suite of solicitation 
behaviours in which the female initiates and maintains mounting behaviour by the male. Ear 
wiggling occurs when the female is in behavioural oestrus, about every 4-5 days. 
Lordosis: Is a female mating posture and is the females’ response to the male mount. Female stands 
immobile, with her back arched downward toward the floor, her rump pushed upward and tail 
deflected to the side. Her vulva, which normally faces the floor, rotates almost 90 degrees to the 
vertical, backward-facing position. Without lordosis, copulation would be impossible. Lordosis is a 
reflexive behaviour that is triggered by a touch on the lower back, flanks, or genital region (Fig. 5).  
Mount: One rat places its forequarters on another rat's rump from behind (Fig. 4). Mounting is the 
male copulatory position, and is seen when a male mounts a female prior to mating. Mounting is 
also sometimes seen between rats of the same sex, usually in an aggressive context. 
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Figure 4. Mounting modified from (Hart 1969).  
Intromission 
Intromission is a sexual behaviour in which the male rat inserts his penis into the vagina during 
copulation. An intromission occurs during a mount, during which intra-vaginal penile insertion 
occurs and several high frequency thrusting movements occur (Fig. 5). After an intromission the 
male rat “jumps” away from the female rat. 
 
Figure 5.Intromission and lordosis modified from (Hart 1969).  
Ejaculation  
Ejaculation is the release of semen into the vagina. The thrusting is more prolonged during 
ejaculation, and the male often rises up behind the female post-ejaculation in a “freeze posture” in 
2-3 seconds. 
Statistical analysis 
The litter was generally considered the statistical unit. When more than one pup per litter is 
investigated, two closely related statistical strategies are available to avoid inflation of sample size  
(Holson and Pearce 1992). The first alternative uses one score per litter, either a litter mean or the 
score of a single animal per litter. Second, one can include litter as an independent, random and 
nested factor in ANOVA (one way analysis of variance). The latter approach controls for litter 
effects and was generally applied for the statistical evaluation of behavioural data in these studies. 
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The two approaches are mathematically identical in their test for treatment effects  (Holson and 
Pearce 1992).  
The alpha level was set at 0.05 and tendencies reported were below 0.1. Data were examined for 
normal distribution and homogeneity of variance before using ANOVA in a mixed linear model 
(“Proc mixed nobound” in SAS).  
In cases where normal distribution and homogeneity of variance could not be obtained by data 
transformation, a non-parametric Kruskall-Wallis test was used on one score per litter, followed by 
Wilcoxon’s test for pair-wise comparisons.  
The data from Morris maze (learning and memory) were analysed on a day by day basis for the 
endpoints length, latency and speed, thus not with repeated measures. If the overall analysis showed 
a significant gender difference in any of the endpoints in play behaviour, Morris water maze 
(leaning and memory) or the Sweet preference test, data from the two genders were also analysed 
separately. Pairwise comparisons were made with a Dunnett test.  
Mating behaviour was analysed using a non parametric test (Fisher exact test).   
Asterisks in figures, indicate a statistically significant difference compared to controls *: p< 0.05. 
All analyses were done using SAS Enterprise Guide (version 3.0), SAS Institute Inc, Cary, NC, 
USA. 
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Results 
Behavioural studies were not included in study 1 (vinclozolin and flutamide dose response study 
and prochloraz range finding study). 
Study 2 Finasteride 
In this study, offspring from the following groups were included in the behavioural studies: control, 
and finasteride (FIN): 0.1; 1 and 10 mg/kg bw/day. The number of animals was 12 males and 12-14 
females from each group, representing 8 (FIN) and 12 (control) litters per group. 
Play behaviour 
No significant gender difference or effect of exposure was found. 
Motor activity  
In the young adults, no significant gender difference was found in the control group. Decreased 
activity in FIN 0.1 mg/kg bw/day and FIN 10 mg/kg bw/day was found in females during the last 
part of the testing period (p<0.02), but no significant effect on activity in females exposed to 1 
mg/kg bw/day. Motor activity in young adults was not included in any of the later studies. 
In the adult rats, no statistically significant gender difference was found in the control group. A 
statistically significantly decreased activity was seen in the group exposed to FIN 0.1 mg/kg bw/day 
(p=0.008), but only a tendency towards decreased activity was seen in FIN 10 mg/kg bw/day. This 
effect was most pronounced in females during the last part of the testing period (last 15 minutes). 
No significant effect on motor activity was found in the females exposed to FIN 1 mg/kg bw/day. 
These results showed decreased activity in the female rats exposed to FIN 0.1 and FIN 10 mg/kg 
bw/day at both ages tested. There is no clear dose-response relationship as no significant effects 
were seen in the intermediate group exposed to FIN 1 mg/kg bw/day. Consequently, the effect on 
motor activity observed in the lowest dose tested, FIN 0.1 mg/kg bw/day is questionable and may 
be a chance finding. However, the effect on female activity observed at the highest dose level of 
finasteride (FIN 10 mg/kg bw/day) is likely to be a true finding. 
Morris water maze 
In the 5-day learning period, no significant gender difference was found in the control group. In trial 
5, a decreased latency to finding the platform was found in males exposed to FIN 0.1 mg/kg bw/day 
(p=0.03) and FIN 10 mg/kg bw/day (p=0.04), but no significant effect was observed in the 
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intermediate group exposed to FIN 1 mg/kg bw/day. No significant effects of exposure were 
observed in the females. 
During memory and reversal learning, a significant gender difference (p<0.02) was found at day 1, 
day 2 and day , but no significant effect of exposure was found in relation to swim length, latency 
or swim speed in both males and females.  
During the new learning testing period (platform located in the centre of the maze), a significant 
gender difference was found (p=0.002). Increased swim length (p=0.03) and latency to finding the 
platform (p=0.006) was found in males exposed to FIN 1 mg/kg bw/day compared to control males, 
but was not seen in the males exposed to FIN 10 mg/kg bw/day. In females, there were no 
significant effects of the exposure. 
These results may indicate improved initial learning, but also an impairment of new learning ability 
in the finasteride exposed males. In both cases, however, there was no clear dose-response 
relationship. 
Study 3 Prochloraz, procymidone and DEHP  
In this study, offspring from the following groups were included in the behavioural studies: control, 
prochloraz (PZ) groups 10, 25 and 50 mg/kg bw/day; procymidone (PRO) groups: 25, 50 and 100 
mg/kg bw/day; and DEHP group 100 mg/kg bw/day. The number of animals was 10-16 males and 
10-16 females in each group representing 4-15 litters per group. Only statistically significant effects 
on the procymidone exposed rats is reported below as no significant behavioural effects of DEHP 
and prochloraz exposed rats were observed. 
Play behaviour 
No overall significant effect of group or gender was found in this test. The females exposed to PRO 
100 mg/kg bw/day showed increased play behaviour compared to the control females (p=0.003 for 
pinnings, p=0.004 for latency to the first pinning, and p=0.01 for pinnings pr minute). These results 
indicate that the females exposed to PRO 100 mg/kg bw/day played significantly more compared to 
control females.  
Activity adults  
No significant gender difference or effects of exposure was found. 
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Morris water maze 
In the learning period, no gender difference was found for any of the variables (swim length, 
latency or swim speed) and no significant effect of exposure was observed in males and females. 
On day 1 in the memory testing period, a significant gender difference was found (p=0.003), but 
there was no effect of exposure. On day 2, a significant gender difference was found (p=0.01). The 
females exposed to PRO 50 mg/kg bw/day showed shorter swim length (p=0.03) and shorter 
latency to finding the platform (p=0.02) than control females, but this was not seen in the PRO 100 
mg/kg bw/day group. No significant effect of exposure was seen in the males. During reversal 
learning, no significant gender or exposure related differences were observed.  
During new learning, a significant gender difference for the endpoint latency to finding the platform 
was found. The males in the groups exposed to PRO 25 and PRO 50 mg/kg bw/day showed shorter 
latency than the control males (p=0.03), while the PRO 100 mg/kg bw/day males showed a 
tendency to longer latency to finding the platform (Fig 6). 
The results indicate effects on some of the procymidone exposed groups, as the females exposed to 
PRO 50 mg/kg bw/day in memory day 2 and the males exposed to PRO 25 and PRO 50 mg/kg 
bw/day performed better in the new learning. As the males exposed to PRO 100 mg/kg bw/day 
showed a tendency to a longer latency, there is no effect on new learning that points in the same 
direction and therefore no dose-response relationship.  
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Figure 6. New learning in Morris water maze, males. Only group means are shown. p = 0.05 (indicated by an asterisk) statistically 
different from control. The PRO 25 and PRO 50 mg/kg bw/day males showed shorter latency than the control males, while the PRO 
100 mg/kg bw/day males showed a tendency to longer latency to finding the platform.  
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Sweet Preference 
There was a significant gender difference (p=0.04) as females drank more sweetened water than the 
males (relative to body weight), but no significant effect of exposure on the sweet preference test 
was found. 
Study 4 A mixture of 3 AR antagonists vinclozolin, flutamide and procymidone 
In this study, offspring from the following groups were included in the behavioural studies: control, 
MIX 7.9 and MIX 19.7, and vinclozolin (VIN) 24.5 mg/kg bw/day. The 24.5 mg/kg bw/day was a 
higher amount of vinclozolin than the amount of vinclozolin in MIX 7.9 and MIX 19.7. The number 
of animals was 14 males and 14 females in each group, representing 11-13 litters per group. For the 
play behaviour and the mating behaviour a total of 11-14 pairs were included from each group. 
Play behaviour 
No significant gender difference or effect of exposure was found and play behaviour was not 
included in study 5. 
Activity adults 
No significant gender difference for total activity was found in the control group. The females from 
VIN 24.5 mg/kg bw/day were more active than the controls (p=0.009), and showed a higher number 
of break counts (p=0.004). During the first part of the testing period, female activity was 
significantly higher in both the MIX 19.7 (p=0.02) and the VIN 24.5 mg/kg bw/day (p=0.002) 
groups compared to female controls (Fig. 7). During the last part of the testing period, the MIX 7.9 
males were less active than the male controls (p=0.003), but no significant differences were seen in 
relation to MIX 19.7 and VIN 24.5 mg/kg bw/day.  
The results from the activity test indicated that the females exposed to MIX 19.7 and VIN 24.5 
mg/kg bw/day, but not to MIX 7.9 showed hyperactivity compared to control, but this was not 
significant in the last testing period. The MIX 7.9 males were less active, but this was only 
significant in the last period and no dose response was seen. 
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 Mixture of 3 AR antagonists vinclozolin, flutamide and procymidone and vinclozolin alone
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Figure 7. Activity counts in female adults. Only group means are shown. p = 0.05 (indicated by an asterisk) statistically different 
from control.  
Morris water maze 
No overall gender difference was seen in the control group during learning and memory testing. 
During the learning period (day 1 to 5 in total), the males from MIX 19.7 showed increased latency 
to finding the platform (p=0.045). Both MIX 7.9 and MIX 19.7 males showed increased swim 
length (p=0.049 and p=0.02) compared to controls in the learning period, while the VIN 24.5 males 
swam significantly shorter (p=0.02%) than control males (Fig. 8).The results indicate that the 
learning is impaired in the mixture-exposed males. On the other hand the vinclozolin exposed males 
(VIN 24.5 mg/kg bw/day) swam statistically significantly shorter than the controls. 
Mixture of 3 AR antagonists vinclozolin, flutamide and procymidone and vinclozolin alone
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Figure 8. Morris water maze learning (day 1-5 in total) (measured as swim length), males. Only group means are shown. p= 0.05 
(indicated by an asterisk) statistically different from control.  
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Sweet Preference 
There was a significant gender difference (p<0.001) as females drank more sweetened water than 
the males (relative to body weight), but no significant effect of exposure was found on this 
endpoint. 
Mating behaviour 
A statistic significant effect of exposure was found for the parameter “mounting”, as VIN 24.5 
mg/kg bw/day males mounted significantly more than control males (p= 0.04) (Fig. 9). More of the 
males from the MIX 7.9 group tended to ejaculate (p=0.05) compared to controls and a significantly 
higher number of the MIX 7.9 males ejaculated (p=0.014) compared to VIN 24.5. There was no 
dose response relationship, as no consistent effect on ejaculation in MIX 19.7 males was observed. 
No significant difference was observed between the exposed and control groups for the parameter 
“intromission” in the male rats or the lordosis quotient in the female rats.  
The results showed an effect on mating behaviour in the males exposed to vinclozolin alone (VIN 
24.5 mg/kg bw/day). 
Mixture of 3 AR antagonists vinclozolin, flutamide and procymidone and vinclozolin alone
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Figure 9. Mating behaviour, number of mounts during a 20 min. period. Only group mean values are shown. p=0.05 (indicated by an 
asterisk) statistically different from control.  
Study 5 A mixture of 4 dissimilarly anti-androgens: vinclozolin, finasteride, DEHP 
and prochloraz 
In this study, offspring from the following groups were included in the behavioural studies: control, 
mixture groups: MIX 13.01; MIX 65.05 and MIX 130.1 (only females because the males in MIX 
130.1 were necropsied because of severe malformations). The number of animals was 13-16 males 
and 14-16 females in each group representing 9-16 litters per group. For the mating behaviour, a 
total of 13-16 pairs were included from each dose group. 
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Activity adults  
No significant gender difference or effect of exposure was found. 
Morris water maze 
A significant gender difference was found for most learning endpoints, as the females showed 
longer latency to finding the platform and lower swimming speeds on most of the days than the 
males. In the memory period, this gender difference was not observed. In the females, we found a 
significantly reduced swim speed in MIX 65.05 (p=0.02), but this was not seen in MIX 130.1. 
When only looking at the males, there were no statistical significant effects of exposure on either 
learning or memory.  
The results showed no consistent effect of exposure and there are no findings indicating an effect on 
learning. 
Sweet Preference 
There was a significant gender difference (p<0.0001) in controls as females drank more sweetened 
water than the males (relative to body weight). An overall significant effect of exposure (p= 0.02) 
was observed, and the females from MIX 130.1 showed a significant increased (p=0.04) intake of 
sweetened water relative to the controls females (Fig. 10).  
The results showed an increased sweet preference in MIX 130.1 females. 
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Figure 10. Sweet preference, intake of sweetened water in mL, females. p=0.05 (indicated by an asterisk) statistically different 
from control.  
Mating behaviour 
No significant differences in mating behaviour were revealed between the two groups exposed to 
the mixtures (MIX 13.01 and MIX 65.05) compared to control. Even through we had a high number 
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of pairs in each group (13-16 pairs), no significant differences for the parameters: “mount”, 
“intromission” (frequency and latency), “ejaculation” or “lordosis quotient” between control and 
exposed rats were observed. 
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Summary of results  
Table 2 shows an overview of the results in this thesis and an indication which endpoint was the 
most sensitive in relation to chemical or mixture of chemicals.  
Chemicals Development of 
reproductive external 
organs (LOAEL ) 
Behavioural (LOAEL) Most sensitive endpoint 
Finasteride 
(FIN) 
 
 
At FIN 0.01 mg/kg bw/day 
effect on NR, while effects 
on AGD and malformations 
were seen at 0.1 and 1 
mg/kg bw/day, respectively 
FIN 10 mg/kg bw/day 
decreased activity in females 
Nipple retention 
Prochloraz 
(PZ) 
 
 
PZ 50 mg/kg bw/day for 
NR and >100 mg/kg 
bw/day for AGD 
No behavioural effects in 
relation to PZ 10, 25 and 50 
mg/kg bw/day 
Nipple retention 
Procymidone 
(PRO) 
 
PRO 14.1 mg/kg bw/day 
for NR and 25 mg/kg 
bw/day for AGD 
PRO 100 mg/kg bw/day 
females increased play 
behaviour 
Both nipple retention and 
AGD were more sensitive 
endpoints than behavioural 
effects  
DEHP 
 
 
10 mg/kg bw/day for both 
NR, AGD  
No behavioural effects in 
relation to DEHP 100 mg/kg 
bw/day 
Both nipple retention and 
AGD were more sensitive 
endpoints than behavioural 
effects 
Flutamide 
 
 
0.5 mg/kg bw/day for NR Flutamide exposed rats were 
not included in behavioural 
tests 
Nipple retention; 
behavioural effects were 
not studied 
Vinclozolin 
(VIN) 
 
 
5 mg/kg bw/day for NR and 
10 mg/kg bw/day for AGD 
VIN 24.5 mg/kg bw/day  
-females were more active 
-males swam shorter in the 
learning period  
- males mounted significantly 
more 
Nipple retention 
MIX 3 AR 
antagonists 
(Vinclozolin, 
Flutamide, 
Procymidone) 
 
MIX 7.9 mg/kg bw/day for 
NR and weight of 
epididymides 
MIX 19.7 mg/kg bw/day 
also for ventral prostate and 
bulbouretral glands 
MIX 39.3 mg/kg bw/day 
for effect on AGD 
MIX 7.9 and MIX 19.7 
learning impaired in males in 
Morris water maze 
  
Behaviour was just as 
sensitive as the effects on 
the reproductive organs 
MIX 4 
dissimilar 
acting anti-
androgens 
(Finasteride, 
Prochloraz, 
Vinclozolin, 
DEHP) 
MIX 13.01 mg/kg bw/day 
for effect on NR and AGD, 
while MIX 65.05 mg/kg 
bw/day showed 
malformations 
MIX 130.1 mg/kg bw/day 
females showed increased 
intake of sweet preference 
Both AGD, nipple retention 
and malformations were 
more sensitive endpoints 
than behavioural effects 
Table 2 shows an overview of the LOAELs (Lowest adverse effect level) in this thesis and an indication which endpoint was the 
most sensitive in relation to a specific chemical or a mixture of chemicals.  
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Discussion 
The physiological anti-androgenic effects of the anti-androgen exposure were very clear in the male 
offspring – most of the exposed male animals had reduced anogenital distances, retained nipples 
and some of the dose groups showed external malformations of the reproductive organs. The anti-
androgen exposure also affected the sexually dimorphic behaviour in some of the behavioural tests, 
but the effects were more complex. In some cases the results indicated a masculinised behaviour 
whereas in other cases incomplete masculinisation was indicated. 
This complexity of exposure effects could be due to the fact that the behavioural tests in these 
studies frequently lacked the otherwise expected gender differences. In these cases where the 
behavioural tests did not show significant gender differences in the control groups the test would 
likely not be especially sensitive to show effects on sexual dimorphic behaviour. 
A reason for the different sensitivity of morphological versus behavioural measures (table 2) could 
be that although the group sizes (i.e. number of litters) are similar, the number of pups examined pr. 
litter for behavioural effects is lower than those examined for morphological effects before 
weaning. To increase the sensitivity of behavioural measures it could be an advantage to include 
more than 1 rat pr. litter. 
Below the results for effects of both single chemicals and mixture of chemicals are presented.  
Finasteride 
Effects on both motor activity, and learning and memory were found after exposure to finasteride. 
The decreased activity observed in females in two of the finasteride exposed groups (0.1 or 10 
mg/kg bw/day) indicates incomplete feminisation in relation to the activity behaviour in females.  
In the learning and memory test (Morris water maze), the exposed males showed both improved 
initial learning (i.e. masculinisation), but also impairment of new learning ability (i.e. incomplete 
masculinisation). In both cases, however, there was no clear dose-response relationship and 
therefore, the findings are inconclusive.  
No references were found in literature concerning pre- and postnatal exposure to finasteride and 
effects on motor activity, or learning and memory. 
Behaviour was not the most sensitive endpoint regarding pre- and postnatal exposure to finasteride, 
as the male rats showed nipple retention at a 1000 times smaller dose and AGD was reduced at a 
100 times smaller dose (Table 2). 
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Prochloraz 
No significant effects of exposure to prochloraz (10, 25 and 50 mg/kg bw/day) were found on any 
of the behavioural endpoints tested. Furthermore, no significant effects of exposure were seen in the 
mixture study with four dissimilarly acting anti-androgens, where prochloraz was present at doses 
of 5 and 25 mg/kg bw/day.  
Only Vinggaard et al., from our laboratory, have reported effects on behaviour after perinatal 
exposure to prochloraz (Vinggaard et al. 2005) Pregnant rats were exposed to 30 mg/kg bw/day of 
prochloraz or a mixture containing prochloraz (20 mg/kg bw/day) and 4 other pesticides (each in a 
dose of 1.25 mg/kg bw/day). They found a statistically significant gender difference in the motor 
activity test, and reported that the prochloraz-exposed adult males showed a statistically 
significantly increased level of motor activity. The sweet preference test showed a clear gender 
difference, with females exhibiting higher preference for sweetened water than males. The males 
exposed to prochloraz (30 mg/kg bw/day) generally showed a higher preference than control males 
during the 3 days of the test, but the differences were only statistically significant on the second 
day. The findings in Vinggaard et al. could not be repeated in the studies included in this thesis. The 
reason for not being able to repeat the findings remains unanswered as we in the behavioural testing 
included a higher dose of prochloraz (50 mg/kg bw/day) than was included in Vinggaard et al. (30 
mg/kg bw/day) (Vinggaard et al. 2005). 
Behaviour was not the most sensitive endpoint with regard to pre- and postnatal exposure to 
prochloraz, as the male rats showed nipple retention at 50 mg/kg bw/day where we did not observe 
any behavioural effects of exposure (Table 2). 
Procymidone 
Increased play behaviour was found in females exposed to PRO 100 mg/kg bw/day compared to the 
control females. This indicates a masculinising effect of procymidone in the females. In the Morris 
water maze, PRO 50 mg/kg bw/day females (memory day 2) performed better (i.e. masculine 
direction), but no dose response relationship was found, as no consistent effect on memory of PRO 
100 mg/kg bw/day females was observed. In the Morris water maze, PRO 25 mg/kg bw/day and 
PRO 50 mg/kg bw/day males (new learning) performed better (i.e. masculine direction). However, 
in contrast to this, PRO 100 mg/kg bw/day males showed longer latency (i.e. feminised direction) 
so no consistent effects or direct dose-response relationship were found. 
Numerous studies have shown that rough-and-tumble play is a sexually dimorphic behaviour that is 
affected by the levels of pre- and postnatal sex hormones. There is general agreement that play 
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behaviour is one of the few sexually dimorphic behaviours where the behaviour of the males is 
organized by the testosterone itself and not by oestradiol aromatised from testosterone in the brain 
(Meaney and Stewart 1981; Meaney et al. 1983; Gray and Ostby 1998). Since PRO exerts its anti-
androgenic actions by binding to the androgen receptors, we expected the prenatal PRO exposure to 
result in demasculinisation of male and female play behaviour. We found an indication of the 
opposite effect in females, but the results from other studies where play behaviour has been tested 
after perinatal anti-androgenic exposure have been ambiguous as well. 
No references were found in literature on the topic of pre- and postnatal exposure to procymidone 
and effects on play behaviour and learning and memory.  
Behaviour was not the most sensitive endpoint when evaluating pre- and postnatal exposure to 
procymidone, as the male rats showed nipple retention at an almost 10 times lower dose level (14.1) 
and reduced AGD at a 4 times lower dose level ( PRO 25) than where the behaviour was affected 
(increased play behaviour in females) (Table 2). 
Vinclozolin 
Increased activity was observed during the initial part of the period in females exposed to VIN 24.5 
compared to control females. 
In the Morris water maze, the VIN 24.5 males swam significantly shorter than control males and in 
mating behaviour, a significantly increased number of mounts were seen in VIN 24.5 exposed 
males.  
Despite the fact that it has been known for a long time that the activity level is a non-reproductive 
behaviour, organised by gonadal hormones during development (Dawson et al. 1975; Beatty 1979), 
only few studies have tested the effects on activity after developmental exposure to anti-androgenic 
compounds. Flynn et al. tested the effects of perinatal exposure to vinclozolin (60 mg/kg bw/day 
dosed from GD7-PND77) on running wheel and open field motor activity levels (Flynn et al. 2001). 
In the open field, they did not find any significant effects of vinclozolin exposure, neither in males 
nor in females. However, they did not find the expected gender differences. In the running wheel 
activity test, Flynn et al. did show a gender difference, but still did not observe any significant 
effects on the activity levels of the males (Flynn et al. 2001). They did, however, find a decreased 
running wheel activity in the females, which they explained by a possible masculinising effect of 
vinclozolin when dosed in adulthood (activational rather that organisational effect). This result 
could, however, also fit our theory about the masculinising effect on the brain by perinatal anti-
androgen exposure.  
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The differences between our results and the results from Flynn et al. may be due to differences in 
the methods used (Flynn et al. 2001). Even though both studies have tried to assess the activity 
levels of animals exposed perinatally to an anti-androgenic compound, no clear picture has been 
found. This is probably due to the many differences in the experimental setups. First of all, the two 
studies used different dosing periods, pre- and postnatal vinclozolin exposure versus exposure until 
adulthood. Another important difference was the method used to assess activity level (open field 
and running wheel vs. activity box). This is obviously quite an important parameter, since the 
results from the Flynn et al. study showed different results depending on the activity measurement 
used, even though all the other parameters were the same (Flynn et al. 2001). In conclusion, it is at 
present difficult to predict what happens to the activity level of male and female animals perinatally 
exposed to anti-androgenic compounds, but nothing points in the direction of a demasculinising 
effect on the males. 
In literature it has been reported that male rats which have morphological abnormalities of the 
external genitalia due to maternal exposure of vinclozolin show disturbances of mating behaviour 
such as reduces intromissions, ejaculation, and consequently reduced fertility despite no changes in 
mounting behaviour (Gray et al. 1994). The dosing period and dose level are not comparable with 
the one in our study, and all males in the study by Gray et al. showed malformations of the external 
sex organs (Gray et al. 1994). 
Behaviour was not the most sensitive endpoint regarding pre- and postnatal exposure to vinclozolin, 
as the male rats showed nipple retention at 5 mg/kg bw/day and reduced AGD from 10 mg/kg 
bw/day. The behavioural studies did not include lower doses of vinclozolin than the dose VIN 24.5 
mg/kg bw/day, where behavioural effects were observed (Table 2). The females’ behaviour pointed 
in the direction of a feminised effect (more active) while the males’ behaviour pointed in the 
direction of a masculinising effect (increased learning, increased mounting). 
Mixture findings 
Mixture of 3 AR antagonists 
Increased activity was observed, during the initial part of the period in females exposed to MIX 
19.7 compared to control females. The males exposed to MIX 7.9 were less active (i.e. 
masculinised), but this was only significant in the last period. Furthermore, no dose response 
relationship was observed, as no effects were observed on males exposed to MIX 19.7.  
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Learning was impaired (i.e. feminised effect) in males dosed with both MIX 7.9 and MIX 19.7 
when tested in the Morris water maze. In these groups, no significant effects were seen on the 
developmental endpoint AGD, but effects were seen for nipple retention at both MIX 7.9 and MIX 
19.7( (Hass et al. 2007), paper II). The males exposed to MIX 7.9 showed significantly decreased 
weights of epididymis, while the males exposed to MIX 19.7 showed decreased weights of 
epididymis, ventral prostate and bulbouretral glands as reported in Metzdorff et al.( (Metzdorff et 
al. 2007), paper III). The malformations seen in MIX 7.9 and MIX 19.7 groups were few and mild 
both at PND 16( (Metzdorff et al. 2007), Paper III) and PND 47( (Christiansen et al. 2008), paper 
IV). 
A tendency to an increasing number of ejaculating males from MIX 7.9 was observed, but this was 
not seen in MIX 19.7. Apart from that, no effects of the exposure were seen on mating behaviour in 
the mixture-exposed rats, while a significantly increased number of mounts were seen in VIN 24.5. 
The dose of vinclozolin used in this group is 24.5 mg/kg bw/day, while it is present in doses of 4.9 
mg/kg bw/day and 12.2 mg/kg bw/day in MIX 7.9 and MIX 19.7, respectively. The doses could 
easily be converted to flutamide equivalents (as the mixture is based on the potency of vinclozolin: 
flutamide; procymidone at the ratio; 31:1:18). The VIN 24.5 consists of 0.77 flutamide equivalents, 
while in the MIX 7.9 and MIX 19.7 VIN is present in doses of 1.16 and 0.47 flutamide equivalents, 
respectively. Thus, VIN 24.5 is in between the two mixture doses according to potency. In this 
study, neither the metabolism of the 3 anti-androgens nor their ability to penetrate the blood-brain 
barrier was investigated, which could have provided possible explanations for not finding a 
significant effect of the mixture exposure in relation to mating behaviour. Another possible 
explanation of the lack of effects could be that testosterone was elevated in the male rats. In some 
studies, treatment with another AR antagonist, flutamide has resulted in increased levels of LH and 
testosterone in the blood. This effect has been seen several times after flutamide treatment of adult 
rats (Södersten et al. 1975; Viguier-Martinez et al. 1983), but also prepubertal (Rulli et al. 1995), 
and neonatal (Pakarinen et al. 1994) flutamide treatment has been shown to have this effect. The 
elevated levels of LH and testosterone found in these experiments can be explained by the fact that 
AR antagonists blocks the androgen receptors in the brain, thereby reducing the negative feedback 
that the endogenous testosterone exerts on the hypothalamus and pituitary, which in turn will result 
in increased LH and testosterone production.  
If receptor mediated anti-androgenic exposure during the prenatal period of brain development has 
the overall effect of higher circulating levels of testosterone, this could lead to an increased amount 
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of substrate for aromatisation, and thereby increased availability of oestradiol in the brain. If this is 
what happened to the anti-androgen exposed animals in our studies, it can explain why we, in some 
of the behavioural tests, did not see demasculinisation of the male offspring - and in some of the 
tests even saw a masculinising effect of anti-androgen (receptor mediated) exposure (e.g. more 
mating activity).  
Some of the behavioural tests showed that behaviour could be just as sensitive an endpoint as the 
development of reproductive organs after exposure to combinations of 3 AR antagonists 
(vinclozolin, flutamide, and procymidone). The learning in Morris water maze was impaired at the 
same dose levels where effects on nipple retention, and weight of epidydimides, ventral prostate and 
bulbouretral glands were seen.  
Mixture of 4 dissimilarly anti-androgens  
The only effect on behaviour observed in this study was that the MIX 130.1 females showed an 
increased intake of sweet water compared to control females. This could be evaluated as increased 
feminisation in this group. Behaviour was not the most sensitive endpoint regarding pre- and 
postnatal exposure to a mixture of 4 dissimilarly acting anti-androgens, as the male rats showed 
nipple retention and reduced AGD at a 10 times lower dose level (MIX 13.01 = Mixture of 
NOAELs) than where the effects on female behaviour were seen (MIX 130.1, effects on sweet 
preference in females). 
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Short conclusion 
In conclusion, it is at present difficult to predict what happens to the behaviour of male and female 
rats pre- and postnatally exposed to anti-androgenic compounds. In some cases, the effect observed 
points in the direction of a masculinising effect on the males and a feminised effect on the females, 
while the physiological anti-androgenic effects are demasculinised male organs. The behavioural 
tests used in this thesis commonly lacked the expected gender differences in the control group and 
this may have contributed to the lack of clear exposure effects. Consequently, the methods needs to 
be further developed and modified to obtain the expected gender differences in the future.  
A part of this thesis was to develop and use a new test for mating behaviour in rats. This method 
development is still ongoing and the applicability can therefore not be evaluated at present. There is 
a need for further studies and also for validation of chemicals known to affect mating behaviour. 
The work will continue in the new EU project CONTAMED with mixtures of anti-androgens and 
estrogens. 
In most of the studies in this thesis, the development of reproductive organs was a more sensitive 
endpoint than behaviour. Nevertheless, animal behaviour (learning in Morris water maze) seemed to 
be just as sensitive as the development of reproductive organs when testing the mixtures of 3 AR 
antagonists (in study 4). Thus, in future testing of chemical mixtures it will be very relevant to look 
also at behavioural effects as these results could contribute to a broader picture of the toxicity of 
mixtures of EDCs than studies that only takes the development of reproductive organs into account.  
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Low-Dose Perinatal Exposure to Di(2-ethylhexyl) Phthalate induces Anti-androgenic Effects 
in Male Rats 
Abstract  
Developmental exposure to di(2-ethylhexyl) phthalate (DEHP) demasculinizes male rat 
offspring by reducing anogenital distance (AGD), causing nipple retention (NR), and 
malformations and weight reductions of some reproductive organs.  
We investigated the effects of perinatal DEHP exposure in part A and B from a study, in 
which time-mated Wistar rats were gavaged from gestation day 7 to postnatal day 16 with 0, 
10, 30, 100, 300, 600 and 900 mg/kg bw/day and 0, 3, 10, 30 and 100 mg/kg/day, 
respectively. The dose levels were selected with the aim of covering the whole dose-response 
curve for the demasculinizing effects of DEHP as well as investigating low dose effects.  
Our results demonstrate that DEHP at a relatively low dose of 10 mg/kg causes adverse anti-
androgenic effects on male rat development. At this dose level, male anogenital distance was 
decreased, the incidence of nipple retention was increased, weight of levator 
ani/bulbocavernosus muscle was reduced and mild external genitalia dysgenesis was 
observed. Higher doses of DEHP, i.e. from 100 mg/kg, additionally induced 
histopathological effects on the testes, reduced testicular and prostate weight, and reduced 
expression of androgen-regulated genes (PBP C3 and ODC mRNA) in the prostate.  
The results provide new evidence of low-dose effects of DEHP, supporting that the cautious 
NOAEL of 5 mg/kg for DEHP that has been decided in EU is appropriate. Our results also 
indicate a reason for concern about the current exposure level of the human population.  
Key words Diethylhexyl phthalate, DEHP, low-dose, phthalates, endocrine disrupters, 
developmental toxicity, rats
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Di(2-ethylhexyl) phthalate (DEHP) is a high production volume chemical. It is used as a 
plasticizer in a wide range of consumer products, including vinyl floors, food wrapping 
materials, cosmetics, medical products and toys, making it one of the phthalates most 
abundantly found in the environment[1,2,3] . It is well known that humans, and in particular 
children, are exposed to phthalates in considerable doses and the mean adult phthalate 
exposure to DEHP, DBP, DINP and DIDP collectively is presently estimated to be 
approximately 0.16 mg/kg bw/day)[3]. For DEHP alone, adult exposure, via the 
environment, is calculated to be maximally 0.02 mg/kg/day, while the maximal exposure 
level for a small child is 0.10 mg/kg/day [3]. The exposure in the children is calculated to be 
5 times higher primarily because of the expected exposure from PVC toys. 
Recently published studies reveal the presence of various phthalate monoesters in breast 
milk, including mono(2-ethylhexyl) phthalate (MEHP) the primary metabolite of DEHP, and 
presence of some of these phthalate monoesters seems to be correlated with increased levels 
of sex hormone-binding globulin (SHBG), luteinizing hormone (LH) and an increased ratio 
of LH/Free testosterone in boys at three month of age [4]. Furthermore, Swan et al have 
reported associations between phthalate exposure and shortened anogenital index 
(AGD/weight) in infant boys whose mothers had elevated urine levels of phthalate 
metabolites during pregnancy [5]. These studies clearly show that humans are exposed to 
phthalates during sensitive periods of perinatal development and indicate that exposure to 
phthalates may cause developmental effects in human infants. 
Numerous rodent studies have shown clear anti-androgenic effects caused by developmental 
exposure to DEHP at medium and high levels, i.e. exposure above 100 mg/kg [6-9], but only 
few rat studies have investigated DEHP at lower doses [10-12].  
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Developing and prepubertal rats have been found to be more sensitive to DEHP than adult 
rats, as young animals have shown adverse effects after exposure to much lower doses than 
adults  [12-14]. Moreover, gestation and lactation are even more sensitive periods, and 
exposure of rats during these periods can cause irreversible effects at dose levels resulting in 
minimal effects in adult animals [12,15].  
Normal male masculinization and development is dependent on the presence of the two 
androgens, testosterone and 5α-dihydrotestosterone (DHT). The specific development of the 
male external genitalia as well as the ventral prostate is DHT-dependent [16]. DHT is also 
responsible for apoptosis of nipple anlagen in male rats, causing lack of nipple development. 
Therefore, male rats do not normally exhibit nipples or areolas as female offspring do. 
Furthermore, DHT is responsible for the development of external male genitalia and for 
growth of the perineum to produce a normal male anogenital distance (AGD), which is 
defined as the distance between the anus and the genital bud [16-19]. At the time of birth, 
AGD in male control rats is approximately twice as long as it is in females. AGD and nipple 
retention (NR) are two very sensitive and non-invasive endpoints, when investigating anti-
androgenic compounds during the critical periods of prenatal development [20-23]. In 
addition to the effects on AGD and nipple retention, the anti-androgenic action of DEHP also 
affects the development of reproductive organs. Testicular morphology is affected [12,15] 
and the weights of androgen-dependent organs such as the ventral prostate and seminal 
vesicle are reduced [11,24].   
The most likely mechanism by which DEHP exerts its demasculinizing effects seems to be 
the lowering of testosterone production towards female levels in male rat foetuses during 
critical stages of sex differentiation [6,9,25,26]. Whether DEHP and MEHP also act as anti-
androgens by antagonising the AR receptor is still debated. Some studies have shown that 
 Page 4 
   
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
neither DEHP nor MEHP are androgen receptor antagonists, as they do not compete with 
androgens for binding to the AR at concentrations up to 10 µM [5,7,27] while another study 
has shown that metabolites of MEHP do act as AR antagonists in vitro [28]. The aim of our 
work was to study the developmental toxicity of DEHP in rats, and especially to focus on 
low dose effects. Two studies were performed, in which dams were dosed with different 
doses of DEHP during the gestation and lactation period. The purpose of part A was to cover 
the whole dose-response curve, including a dose level where no effects were expected. The 
doses were: 10, 30, 100, 300, 600, 900 mg/kg. The results from this part, somewhat 
unexpectedly, showed anti-androgenic effects at the lowest dose level (10 mg/kg/day). 
Consequently, it was decided to repeat the three lowest doses in a second part (B) and to 
include a lower dose of 3 mg/kg. 
 In both parts of the study measurements of AGD and NR in male rat offspring were 
performed, along with investigations of other endpoints found to be sensitive to anti-andro-
genic chemicals in male offspring. These were weights and histopathology of reproductive 
organs, malformations of male external genitals and the expression of androgen-regulated 
genes in the prostate. To further investigate the testicular effects of DEHP, 
immunohistochemical staining for Sertoli cell specific markers was performed, and serum 
levels of inhibin B was measured as a marker of Sertoli cell function.  
Results from both DEHP studies and from a combination of the two studies are reported 
here.  
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Chemicals. DEHP (di(2-ethylhexyl) phthalate), CAS No. 117-81-7, purity 99% was obtained 
from VWR & Bie & Berntsen (Herlev, Denmark). DEHP was dissolved in corn oil (VWR & 
Bie & Berntsen), which was used as the vehicle. 
Animals and exposure. In part A, 64 time-mated nulliparous, young adult Wistar rats 
(HanTac: WH, Taconic Europe, Denmark, body weight approximately 200 g) were supplied 
at day 3 of pregnancy. The day following mating was designated gestational day (GD) 1, and 
postnatal day (PND) 1 was the day of birth. The dams were, at the day after arrival i.e. GD 4, 
randomly distributed according to body weight (bw) into a control group of 16 dams and 6 
DEHP groups of 8 dams. The dams were housed in pairs until GD 21 and single-housed 
thereafter under standard conditions; semitransparent plastic cages (15x27x43cm) with 
Aspen bedding (Tapvei), situated in an animal room with controlled environmental 
conditions (12 h light-dark cycles with light starting at 9 p.m., light intensity 500 lux, 
temperature 21 ± 2°C, humidity 50% ± 5%, ventilation 8 air changes per h). A complete 
rodent diet for growing animals ALTROMIN 1314 (Soy- and alfalfa-free ALTROMIN 
GmbH, Lage, Germany) was given to all dams. Acidified tap water (to prevent microbial 
growth) was provided ad libitum. An acclimatization period of 4 days was allowed before 
the exposure-period started. The animals were weighed every day to calculate the dosing 
volume of 2 ml/kg bw and they were gavaged with vehicle (corn oil) or 10, 30, 100, 300, 
600, or 900 mg DEHP/kg bw/day (mg/kg) from GD 7 to the day before expected birth (GD 
21), and from the day after birth (PND 1) until PND 16. This day was chosen as the last day 
of dosing, because the pups graduately stop suckling and starts eating at this age. Animals 
were inspected for general toxicity twice daily. Part A was divided into 4 blocks (with one 
week in between), and each dose group was represented equally in all 4 blocks.  
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In part B, 56 time-mated nulliparous, young adult Wistar rats (HanTac: WH, Taconic 
Europe, Denmark, body weight approximately 200 g) were supplied at day 3 of pregnancy. 
The dams were housed similarly as in study 1, and also similarly distributed into 4 blocks. At 
GD 4, the dams were randomized according to weight into 5 groups of either 16 dams 
(control group and the group dosed with 3 mg/kg) or 8 dams per group (10, 30, or 100 mg 
DEHP/kg) and dosed during the same exposure periods and conditions as in part A. Number 
of rats in the different groups and in the two studies is mentioned in table 1.  
Postnatal development. After birth (PND 1), all live pups in the litter were weighted, sexed 
and anogenital distance (AGD) was measured using a stereomicroscope. At PND 12±1 all 
pups were examined for the presence of nipples/areolas (NR), described as a dark focal area 
(with or without a nipple bud) located where nipples are normally present in female 
offspring. The nipples were counted and no distinction was made between the retention of an 
areola or a nipple. AGD and NR was recorded blindly to exposure group by the same 
technician in both studies. 
Autopsy of offspring on PND 16. The male offspring underwent a thorough autopsy at PND 
16. Male external genitals were investigated, and the organs listed below were excised, 
weighed, and used for either histopathological investigation or gene expression analysis.  
Furthermore, trunk blood was taken from all male pups and analyzed for inhibin B in serum 
as described in [6]. Blood samples were pooled within litters. 
Investigation of male external genitals. The external genitalia were inspected blinded to the 
observer at PND 16 in all males from all litters. The changes were scored on a scale from 0 
to 3 in order to investigate whether male external genitals were demasculinized. The follow-
ing criteria were used: 
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Score 0, no effect: normal genital tubercle, the urethral opening is found at the tip of the 
genital tubercle and the preputial skin is intact. In the perineal area, thick fur extends 
caudally from the base of the genital tubercle and half the distance to the anus. A furless area 
circumscribes the anus.  
Score 1, mild dysgenesis of the external genitalia: a small cavity on the caudal surface of the 
genital tubercle or a minor cleft in the preputial opening is observed, estimated 0.5-1.4 on an 
arbitrary scale. The furless area around anus expands towards the base of the genital tubercle, 
but thick fur is still present at the base of the genital tubercle.  
Score 2, moderate dysgenesis of the external genitalia: the preputial cleft is larger, estimated 
1.5-2.4 on an arbitrary scale. The urethral opening is situated half way down the inferior side 
of the genital tubercle (hypospadia). Partly furless e.g. thin fur is noted in the perineal area 
ranging from the base of the genital tubercle and caudally to the furless area circumscribing 
the anus.  
Score 3, severe dysgenesis of the external genitalia: The preputial cleft is large, estimated 
2.5-3.5 on an arbitrary scale. The urethral opening is situated further than half way down the 
inferior side of the genital tubercle to the base of the genital tubercle. At the base of the 
genital tubercle a groove extending laterally is observed (similar to control females at PND 
16). The rat is totally furless in the whole perineal area. 
Organ weight, histopathology, and estimation of seminiferous tubule diameter. Body 
weights of all male pups were recorded. In one male per litter the following organs were 
excised and weighed: liver, kidneys, adrenals, testes, epididymides, seminal vesicles, ventral 
prostate, bulbourethal glands, and the levator ani/bulbocavernosus muscles (LABC). In the 
analysis of body and testis weight generally one to four males per litter were used. 
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From 1 or 2 males per litter, the right or left testes were alternately fixed in Bouin’s fixative, 
paraffin embedded, and stained with haematoxylin and eosin. The contra lateral testis was 
fixed in formalin and used for immunohistochemistry. The following organs were fixed in 
formalin: epididymides, seminal vesicles and ventral prostate. All fixed organs were 
embedded in paraffin and examined by light microscopy after staining with haematoxylin 
and eosin. Generally, testis histopathology was investigated in one to two males per litter. 
Diameters of the seminiferous tubules were investigated semiquantitatively in one cross 
section per testis in one to two males litter (in part A, n=16 in the control group, n=8 in the 
dosed groups, in study 2, n=8 in all groups). The diameter was estimated by systematic 
random sampling of 80-100 seminiferous tubules per testis cross section using a computer 
assisted microscope (Olympus BH2, Denmark) described in details by [29]. 
Immunhistochemistry Vimentin, Androgen receptor (AR), and Antimüllerian hormone 
(AMH). Immunohistochemistry was performed on one section per testis. Following 
microwave pre-treatment for either 2x5 min (vimentin and AR) or 1x5 min (AMH) in citrate 
buffer pH 6 at 100oC, sections were blocked for endogenous peroxidase activity in 3% H2O2 
in PBS, and blocked in 1% bovine serum albumin in PBS. Sections were then incubated over 
night at 4˚C with the following antibodies: vimentin 1:2000 (clone V9, DAKO), AMH 
1:8000 (also called Müllerian inhibiting substance, MIS, DAKO), or AR 1:200 
(N20SC816P, Santa Cruz).  
Sections were then incubated for 30 min with secondary antibody anti-mouse 
EnVision+ (DAKO) for Vimentin, and rabbit anti-goat antibody (DAKO) enhanced with 
anti-rabbit EnVision+ for AMH staining, and anti-rabbit EnVision+ for AR. Sections were 
stained in diaminobenzidine (DAB+ Substrate Chromogen System, DAKO, Glostrup, 
Denmark) and counterstained in Meyer’s haematoxylin. 
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Gene expression levels determined by real-time RT-PCR. Ventral prostate from one male 
per litter were weighed and stored in RNAlater (Qiagen) for gene expression analyses. Total 
RNA was isolated using RNeasy-mini kit and RNase-Free DNase set (Qiagen), and cDNA 
was synthesized using the Omniscript Reverse Transcription kit (Qiagen). Expression levels 
of the two androgen-regulated genes: prostate binding protein subunit C3 (PBPC3) and 
ornithine decarboxylase (ODC) were quantified on the 7900HT Fast Real-Time PCR System 
(Applied Biosystems) by standard TaqMan technology using TaqMan Fast Universal PCR 
Master Mix. Expression levels of each target gene were normalized to the expression level of 
the housekeeping gene 18S rRNA. All genes were quantified from standard curves. Primers 
and probes for PBP C3, ODC and 18S rRNA have previous been published in [30]. 
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Statistical analysis. Data were examined for normal distribution and homogeneity of 
variance, and if relevant, data were ln-transformed. In cases where normal distribution and 
homogeneity of variance could not be obtained by data transformation, a non-parametric 
Kruskall-Wallis test was used, followed by Wilcoxon’s test for pair wise comparison. 
Statistical analysis of the effect of DEHP dosing on macroscopic lesions, histopathology, 
vimentin staining and incidence of litters and pups with nipple/areola retention > 2, were 
done using Fisher’s Exact Test.  
For statistical evaluation of gene expression data, AGD, NR, body weights and organ 
weights, one-way ANOVA was employed for all groups. Dunnett’s test was performed to 
determine differences between treated and control group means. When more than one pup 
from each litter was examined, statistical analyses was adjusted using litter as an 
independent, random and nested factor in ANOVA. When we pooled data from both parts, 
‘study’ was included in the statistical analysis as a dichotomous factor. Pooled data are only 
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reported if no significant effect of ‘study’ and no interaction between ‘study’ and ‘dose’ were 
observed. Data analysis of AGD included the cubic root of body weight as a covariate in the 
analysis, to correct for the relationship between body size and AGD. In the analysis of organ 
weights PND 16, body weight was used as a covariate. For the analysis of birth weight, AGD 
and NR data from all offspring were analyzed. For the analysis of terminal body weight and 
organ weights PND 16, 1-4 males/litter were included, while 1-2 males/litter were included 
in the analysis of the diameter of the seminiferous tubules. Generalized linear models (GLM) 
in combination with generalized estimating equations in order to account for the nested litter 
correlation analyzed the number of nipples. P-value adjustments were carried out by the 
ROM procedure, a powerful step-up procedure for protecting the global error rate α= 5% 
[31]. Asterisks in tables and figures, indicate a statistically significant difference compared to 
controls *: p≤ 0.05; **: p< 0.01. Gene expression data were analyzed in Sigma stat version 
2.0. All other analyses were done using the SAS procedure PROC GLM, PROC MIXED, 
PROC GENMOD and PROC MULTTEST (SAS version 8, SAS Institute Inc, Cary, NC, 
USA).  
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Pregnancy data, postnatal growth and general toxicity. In both studies, no general toxicity 
was observed. Pregnancy and litter data from part A are presented in Table 2a. DEHP had no 
effect on the maternal weight gain from GD 7 to GD 21 or on the maternal weight on PND 1, 
and the mean pregnancy length was also unaffected. Significant decreases in the male birth 
weights were seen at 300, 600 and 900 mg/kg and in the females at 900 mg/kg. On PND 
12±1 the body weight of the males was significantly higher at 100 mg/kg and significantly 
decreased at 900 mg/kg as seen in table 2a, whereas no significant effect on the weight of the 
females was seen. No effects on sex ratio or postimplantation - perinatal loss were detected.  
Pregnancy and litter data from part B are presented in Table 2b. In this part, no effects on 
maternal and pup weights, litter size or pregnancy length was observed, but the postimplan-
tation-perinatal loss was significantly elevated at 10 mg/kg as seen in table 2b.  
Anogenital distance (AGD). The anogenital distance is normally approximately twice as 
long in male as in female control offspring. However, in part A, the prenatal exposure to 
DEHP significantly decreased AGD in male offspring in a dose-related manner (Table 2a).  
In part B, AGD was significantly different from control values at 100 mg/kg (Table 2b).  
Analysis of the combined data showed that prenatal exposure to DEHP significantly 
decreased AGD in male offspring at all dose levels of DEHP above 3 mg/kg (Figure 1).  
Nipple retention (NR). The number of nipples in female rats is normally 12, versus zero in 
males, but in part A, perinatal DEHP exposure induced NR in male offspring at all dose 
levels. However, the dose-response relationship was unusual, as 10 mg/kg induced a more 
marked effect than 30 and 100 mg/kg (Table 2a). In part B, there appeared to be a higher 
number of nipples at 10 and 100 mg/kg (Table 2b), although the difference was not 
statistically significant.  
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The combined analysis of data from both studies showed that, at doses above 3 mg/kg, an 
increased NR was observed (Figure 2). The combined dose response curve remained 
unusual, as the dose of 10 mg/kg still seemed to induce a more marked effect than 30 and 
100 mg/kg. 
The incidence of litters and offspring with NR above 2 is shown in Table 3. When the data 
from the two studies were combined, significant effects were found at 10 mg/kg when litter 
was the statistical unit, and at all dose levels, from 3 mg/kg to 100 mg/kg, when the 
individual pup was used as the statistical unit. 
Incidence of mild changes of the male external genitals. Mild dysgenesis of the external 
genitals (score 1) was observed in all groups (Table 4). When the two studies were combined 
the incidence of mild dysgenesis was significantly increased at 10 and 100 mg/kg, but not at 
300 mg/kg. 
Muscle and organ weights. LABC was very sensitive to DEHP and in part A, the weight of 
LABC was statistically significantly decreased from 10 mg/kg and in part B this weight was 
decreased at 10 and 30 mg/kg (Table 5). When combining the data from both studies, a 
significant decrease in weight of LABC was found at all doses above 3 mg/kg. Testis 
weights were reduced in part A at 100, 600, and 900 mg/kg (left testis) and at 600 and 900 
mg/kg (right testis) (Table 5). A reduction in the weights of the adrenals was found in part A 
at 10, 100 and 900 mg/kg. The liver weight was significantly elevated in part A at 300, 600 
and 900 mg/kg.  
Histopathological effects. In part A, testis histopathology was investigated in one section 
from 1 to 3 males per litter in all dose groups. No histopathological effects were observed in 
the groups receiving 10, 30, or 100 mg/kg and the diameters of the seminiferous tubules 
were comparable to controls. At 300, 600, and 900 mg/kg, the testes were more immature 
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with a delay in the development of the seminiferous epithelium (figure 3A and 3B). Fever 
germ cells were present and focal Leydig cell hyperplasia was observed. These effects were 
most pronounced in the group receiving 900 mg/kg. The diameter of the seminiferous 
tubules was decreased dose-dependently from 300 mg/kg (Table 5 and figure 3A and 3B). In 
testes from part B, no dose-related histopathological changes caused by DEHP were 
observed. No histopathological effects were observed in epididymides, ventral prostate or 
seminal vesicles in part A and therefore these organs were not investigated in part B. 
Immunohistochemistry. Immunohistological staining of vimentin in testis was scored by an 
investigator blinded to treatment groups. The high dose group (900 mg/kg) had a more 
intensive staining, which extended more diffusely throughout the cytoplasm of the Sertoli 
cells in 6 out of 9 male testes compared to 1 out of 9 in controls (Figure 3C and 3D). This 
effect was only observed in one testis in the group dosed with 600 mg/kg and therefore 
vimentin staining was neither investigated in the groups receiving lower doses in part A nor 
in any of the groups in part B. No effect on testis AR or AMH was observed in any of the 
dose groups.  
Gene expression levels. Expression of the androgen-regulated genes PBP C3 and ODC in 
PND 16 males was investigated in ventral prostate (Figure 4). In part A, PBP C3 mRNA was 
significantly reduced after exposure to 300 and 900 mg/kg DEHP. In part B, both PBP C3 
and ODC were significantly reduced at 30 and 100 mg/kg. 
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Our studies show that perinatal exposure to low doses of DEHP induces anti-androgenic 
effects such as reduced AGD, increased NR, weight reduction of LABC and mild external 
genitalia dysgenesis in male rats. Higher doses of DEHP, i.e. from 100 mg/kg, additionally 
induced histopathological effects in the testes (in part A), reduced testicular and prostate 
weight and reduced expression of androgen-regulated genes in the prostate.  
Testicular histopathological effects following perinatal DEHP exposure have been reported 
in several studies. A dose-dependent reduction in testis weight, an increased number of 
testicular histological alterations, and absence of spermatocytes were reported in male 
offspring at 21 and 28 days of age in dams exposed to DEHP during gestation and lactation 
via the drinking water at estimated doses of 3.5 and 35 mg/kg [12]. In another study, small or 
aplastic testes and seminiferous tubular atrophy in male offspring was found at a dose level 
of 300 ppm in the diet (corresponding to approximately 14 mg/kg), while higher doses also 
caused histopathological changes in the epididymides and deceased weights of several male 
reproductive organs [15]. 
In the current study, testis changes were further characterized by measurement of 
seminiferous tubular diameter and immunohistochemical staining for the structural protein 
vimentin present in Sertoli cells. In the highest dose groups, Sertoli cells appeared to be 
affected by DEHP treatment, as vimentin staining was more intense and extended more 
diffusely throughout the cytoplasm of the Sertoli cells, and tubular diameter and testis weight 
were reduced. Sertoli cell number is known to relate closely to testis size [32]. Another 
marker of Sertoli cell number and function is the serum inhibin B level, which is altered with 
experimental manipulation of Sertoli cell number [33]. In our previous studies with higher 
doses (750 mg/kg bw) of DEHP, serum inhibin B levels were reduced at PND 22, but in the 
 Page 15
   
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
current study no changes were seen at PND 16. This indicates that the effects on inhibin B 
and thereby on Sertoli cell number and/or function have not emerged at PND16 but rather 
initiates at a later time point.  
The expression levels of androgen-regulated genes were sensitive markers of anti-androgenic 
effects on the prostate. PBP C3 and ODC contain an androgen-responsive-element in the 
promoter region and their expression is thereby influenced by the amount of androgen or 
anti-androgen available. Transcript levels of both PBPC3 and ODC were reduced with 30 
mg/kg DEHP in part B. In part A, reductions were seen from 100 mg/kg but were not 
statistically significant, possibly due to small group sizes and large variations within groups. 
This supports the anti-androgenic effects of DEHP and may be secondary to decreased 
testosterone formation or the AR antagonistic effect of metabolites of DEHP. Reduced ODC 
and PBP C3 expression levels have previously been reported in ventral prostates after 
exposure to AR antagonists such as vinclozolin, fenarimol and prochloraz [30,34,35], but 
this is the first paper to describe alterations after perinatal DEHP exposure.  
Anti-androgenic effects of DEHP similar to those described here have been demonstrated in 
numerous rat studies using dose levels above 100 mg/kg. Gray et al. [7] found effects on 
AGD, NR and reproductive organ weights at 750 mg/kg. Jarfelt et al. [8] found that DEHP 
decreased AGD and increased retention of nipples in male offspring at 300 and 750 mg/kg. 
In the same study, dosed males also showed decreased weights of ventral prostate and 
LABC, and histopathological investigations revealed alterations in testis morphology in both 
juvenile and adult males. In a two-generation study by Wolfe and Layton, incomplete 
masculinization and increased sensitivity was observed in male pups dosed perinatally, as the 
F1 and F2 generations showed more severe effects than the parental generation who were 
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exposed only as adults. DEHP caused decreased weight of male reproductive organs such as 
the testes, epididymides, and the prostate, reduced AGD and increased NR [15].  
A more limited number of studies have investigated effects of perinatal dose levels below 
100 mg/kg. Andrade and co-workers [36] looked at effects on aromatase activity in pups 
prenatally exposed to DEHP. The doses were 0.015, 0.045, 0.135, 0.405, 1.215, 15, 45, and 
405 mg/kg/day. Aromatase activity was significantly inhibited at PND 1 at the low doses 
(0.135 and 0.405mg/kg), while an increased activity was observed at 15, 45 and 405 mg/kg. 
In the same study a reduction in daily sperm production was observed in animals exposed to 
15, 45, 135 and 405 mg/kg/day and a low incidence of cryptorchidism was observed also in 
the 5 mg/kg dose group [11]. Effects on testes have been reported at a dose level of 300 ppm 
in the diet (about 14 mg/kg) and around 3.5 and 35 mg/kg via drinking water [12,15]. These 
results were included in an EU Risk Assessment Report of DEHP and resulted in a 
regulatory NOAEL (No Observed Adverse Effect Level) of 5 mg/kg for developmental 
toxicity [37]. In November 2005 US CERHR (Center For The Evaluation of Risk To Human 
Reproduction) published an update on the reproductive and developmental toxicity of DEHP, 
in which a NOAEL between 1 and 10 mg/kg for oral DEHP exposure in rats was supported 
[38]. 
Our results extend the database for low dose effects of DEHP on male sexual differentiation, 
as the two studies included low dose levels of DEHP, i.e. 3, 10 and 30 mg/kg.  
The results from the two studies presented here are not identical, as for example significantly 
decreased AGD and increased NR were found in part A at 10 mg/kg and higher, while AGD 
only differed significantly from control values at 100 mg/kg in part B. Also, the incidence of 
male offspring with mild external genital dysgenesis was significantly different from control 
at 100 mg/kg and higher in part A, while in part B significant effects were found at 3 and 100 
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mg/kg. Effects on gene expression were found after exposure to 30 mg/kg in part B, while in 
part A, no statistically significant effect was observed until dose 300 mg/kg, although a 
tendency was already present at 100 mg/kg. This indicates that animals in part B were more 
affected at this endpoint compared to the animals in part A. These discrepancies between the 
two parts are surprising, but could be due to the relatively low number of animals per group 
and the biological variation in the investigated parameters. The postimplantation – perinatal 
loss at 10 mg/kg (in part B) should be discussed because the low number of animals may 
contribute substantially to the discrepancies between part A and B. Therefore, an important 
consideration when performing low dose studies is to include sufficient number of animals 
per group to avoid false-positive or false-negative results.  
Our combined analysis of the data from the two studies is based on a more sufficient group 
size of 16 litters and therefore provides a more clear and reliable picture of the anti-
androgenic effects of DEHP. The combined results show that perinatal exposure to low doses 
of DEHP induces anti-androgenic effects such as reduced AGD, increased NR, weight 
reduction of LABC and mild external dysgenesis in male rats at 10 mg/kg  
Some indications of anti-androgenic effects were also found at the lowest dose of 3 mg/kg, 
as the incidence of male offspring having mild external genital dysgenesis and more than 2 
nipples were increased. These results indicate that although this dose level did not induce 
significant effects on AGD, mean number of nipples or reproductive organ weights, subtle 
anti-androgenic effects may occur. Further studies, however, will be needed for a clear 
evaluation of the potential anti-androgenic effects of DEHP at 3 mg/kg and lower doses.  
As mentioned in the introduction, DEHP is not a clear AR receptor antagonist like the 3 
chemicals vinclozolin, procymidone and flutamide [39]. These AR receptor antagonists 
showed monotonous dose response curves on the same endpoints as investigated in the 
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current study. Our DEHP results seemed to show non-monotonous dose response curves at 
the low doses in relation to NR, incidence of male offspring with mild external 
malformations, and weight of LABC, with more pronounced effects at 10 mg/kg. These 
endpoints are all measured during the later part of the lactation period. The unusual dose 
response curves therefore might be due to special mechanisms or toxicokinetics during this 
period. However, biological variation for these endpoints may also be part of the 
explanation. Gee et al. found a non-monotonous (biphasic) effect on Leydig cell function 
when exposing male rats to DEHP in the prepubertal period (PND21-48) [36]. Andrade et al 
also found a non- monotonous dose response profile, a J-shaped curve while the aromatase 
activity was inhibited at low doses and increased at high doses in DEHP exposed (GD6-
PND21) males PND1 [36,40]. 
In summary, our results demonstrate that DEHP at a relatively low dose of 10 mg/kg causes 
adverse anti-androgenic effects on male rat development. At this dose level, male AGD was 
decreased, the incidence of NR was increased, reproductive organ weight was reduced and 
mild external genitalia dysgenesis was observed. The results provide new evidence of low-
dose effects of DEHP, supporting that the cautious NOAEL of 5 mg/kg for DEHP that has 
been decided in EU is appropriate. Our results also indicate a reason for concern about the 
current exposure level of the human population. 
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Tables 
 
Table 1. The number of litters in part A and part B is shown here and in parenthesis the number of mated 
animals is given.  
DEHP 
(mg/kg 
bw/day) 
Control 3 10 30 100 300 600 900 
Part A 15 (16) - 8 (8) 7 (8) 7 (8) 7 (8) 6 (8) 7 (8) 
Part B 15 (16) 14 (16) 6 (8) 6 (8) 8 (8) - - - 
Total 30 14 14 13 15 7 6 7 
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Table 2a. Pregnancy and litter data from part A  
                                         DEHP (mg/kg bw/day) 
 Control  10 30 100 300 600 900 
Number of litters 15 8 7 7 7 6 7 
Maternal weight 
gain GD7-21 (g) 86.2 ± 5.4 77.1 ± 6.1 93.4 ± 6.7 87.6 ± 9.6 80.4 ± 9.0 97.5 ± 9.3 74.3 ± 8.2 
Maternal weight 
PND 1 (g) 235.5 ± 6.7 228.1 ± 5.1 237.0 ± 5.2 245.3 ± 8.8 234.1 ± 8.7 233.8 ± 7.5 224.9 ± 6.0 
Pregnancy 
length (days) 22.7 ± 0.1 22.8 ± 0.2 22.7 ± 0.2 22.4 ± 0.2 22.7 ± 0.2 22.7 ± 0.2 22.4 ± 0.2 
Birth weight (g) 
 – Males 
 – Females 
 
6.47 ± 0.16 
6.12 ± 0.13 
 
6.63 ± 0.13 
6.09 ± 0.11 
 
6.49 ± 0.06 
6.14 ± 0.11 
 
6.40 ± 0.21 
5.83 ± 0.27* 
 
5.91 ± 0.15* 
5.76 ± 0.18 
 
5.61 ± 0.26** 
5.75 ± 0.13 
 
5.70 ± 0.20** 
5.29 ± 0.28** 
Male pups (%) 53 ± 7 53 ± 7 41 ± 8 45 ± 5 34 ± 7 46 ± 7 52 ± 8 
Live born per 
litter 9.6 ± 1.0 8.0 ± 1.2 10.3 ± 1.2 8.4 ± 1.1 9.4 ± 1.4 10.2 ± 1.0 8.4 ± 1.3 
Postimplantation
-perinatal loss 
(%) # 
17.3 ± 7.0 20.9 ± 6.1 9.2 ± 3.6 14.1 ± 3.5 20.8 ± 11.0 18.1 ± 3.5 30.7 ± 12.2 
AGD in males, 
at birth (mm) 3.68 ± 0.11 3.37 ± 0.11** 3.35 ± 0.12** 3.38 ± 0.12** 3.37 ± 0.12** 3.26 ± 0.12** 3.18 ± 0.12** 
Body weight. 
day 12 ±1 (g) 
– Males 
– Females 
 
27.75 ± 1.0 
26.43 ± 0.9 
 
29.27 ± 1.3 
28.4 ± 1.4 
 
27.08 ± 1.4 
25.64 ± 1.4 
 
31.38 ± 1.3* 
29.53 ± 1.1 
 
24.23 ± 0.9 
24.74 ± 1.2 
 
24.35 ± 0.8 
24.22 ± 0.8 
 
23.38 ± 1.5* 
23.39 ± 1.5 
Nipples in 
males, day 12 ±1 
(number) 
 
0.22 ± 0.08 
 
 
3.14 ± 0.94** 
 
 
1.81 ± 0.82** 
 
1.23 ± 0.68** 5.21 ± 1.25** 4.63 ± 1.72** 5.01 ± 1.36** 
Data represent group means ± SEM  
# (No. implantations - live pups at PND 6)/no. implantations  
The AGD values are corrected for birth weight and LSmeans values are presented. 
* Indicates a value differs from control by p < 0.05  
** Indicates a value differs from control by p < 0.01  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Page 25
   
 
Table 2b. Pregnancy and litter data from part B  
  DEHP (mg/kg bw/day) 
 Control  3 10 30 100 
Number of litters 15 14 6 6 8 
Maternal weight gain GD7-
21 (g) 79.6 ± 4.6 84.2 ± 4.4 79.7 ± 9.3 84.5 ±6.6 81.1±5.1 
Maternal weight PND 1 (g) 249.9 ± 5.1 244.0 ± 5.0 250.4 ± 14.6 251.2 ± 6.3 244.3 ± 5.4 
Pregnancy length (days) 22.5 ± 0.1 22.5 ± 0.1 22.5 ± 0.2 22.3 ± 0.2 22.5 ± 0.2 
Birth weight, (g) 
– Males 
– Females 
6.25 ± 0.12 
6.00 ± 0.16 
6.22 ± 0.10 
5.92 ± 0.12 
6.14 ± 0.14 
5.88 ± 0.14 
5.88 ± 0.19 
5.55 ± 0.15 
5.87 ± 0.23 
5.48 ± 0.23 
Male pups (%) 47 ± 4 43 ± 4 38 ± 9 51 ± 4 44 ± 4 
Live born per litter 9.4 ± 0.8 10.9 ± 0.7 8.1 ± 2.0 10.5 ± 1.1 11.3 ± 1.1 
Postimplantation-perinatal 
loss (%) # 19.3 ± 3.6 9.8 ± 2.5 37.0 ± 13.5* 17.0 ± 4.7 14.8 ± 3.4 
AGD in males, at birth (mm) 3.40 ± 0.07 3.36 ± 0.07 3.36 ± 0.08 3.38 ± 0.08 3.25 ± 0.07 * 
Body weight, day 12 ±1 (g)  
– Males 
– Females 
 
30.56 ± 1.0 
30.3 ± 1.0 
 
29.31 ± 0.7 
28.71 ± 0.8 
 
30.97 ± 1.5 
29.95 ± 1.5 
 
28.54 ± 1.7 
28.45 ± 2.0 
 
28.93 ± 1.9 
27.94 ± 1.8 
Nipples in males, day 12 ±1 
(number) 0.38 ± 0.92 0.59 ± 0.99 1.13 ± 1.26 0.31 ± 0.40 0.86 ± 1.23 
Data represent group means ± SEM  
# (No. implantations - live pups at PND 6)/no. implantations  
The AGD values are corrected for birth weight and LSmeans values are presented. 
* Indicates a value differs from control by p < 0.05  
** Indicates a value differs from control by p < 0.01  
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Table 3. Incidence of litters and offspring with nipple retention > 2 in males 
DEHP, 
mg/kg 
bw/day 
Control  3 10 30 100 300 600 900 
Litters          
Study 1 0% (0/15)  50% (4/8)** 50% (3/6)* 14% (1/7) 83%** (5/6) 50%* (3/6) 83%** 5/6) 
Study 2 7% (1/15) 14% (2/14) 17% (1/6) 0% (0/6) 13% (1/8)    
Study 
1+2 3% (1/30) 14% (2/14) 36%(5/14)** 25% (3/12) 14% (2/15)    
Offspring         
Study 1 2% (1/62)  68%(19/28)** 31%(8/26)** 26%(6/23)** 77%(26/34)** 70%(16/23)** 65%(17/26)**
Study 2 5% (3/56) 15% (9/59) 24% (5/21) 0% (0/26) 16% (5/32)    
Study 
1+2 3% (4/118) 15%(9/59)* 49%(24/49)** 15%(8/52)* 20%(11/55)*    
Data shown are percent affected (affected/total) 
* Statistical significant different compared to controls (p < 0.05) 
** Statistical significant different compared to controls (p < 0.01) 
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Table 4. Incidence of male offspring with mild external genital dysgenesis 
 DEHP mg/kg bw/day 
  Control 3 10 30 100 300 600 900 
Affected males of total males study 1 2% (1/48)  14% (4/28) 4% (1/26) 17% (4/23)* 17% (4/23)* 17% (4/23)* 50% (13/26)* 
Affected males of total males study 2 0% (0/37) 12% (6/49)* 10% (2/26)  8% (2/26) 15% (3/20)*    
Affected males of total males study 1 and 2 0.1%(1/85)  11% (6/54)* 6% (3/52) 16% (7/43)**    
Affected litters of total litters study 1 7% (1/15)  38% (3/8) 14% (1/7) 57% (4/7)* 43% (3/7) 50% (3/6)* 67% (4/6)* 
Affected litters of total litters study 2 0% (0/15) 29% (4/14)* 17% (1/6) 33% (2/6) 25% (2/8)    
Affected litters of total litters study 1and 2 3%(1/30)  29% (4/14)* 23% (3/13) 40% (6/15)**     
Analysed by a Fisher's exact test         
* Statistical significant different compared to controls (p < 0.05)       
** Statistical significant different compared to controls (p < 0.01)       
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Study 1 Control 3mg 10 mg 30 mg 100 mg 300 mg 600 mg 900 mg 
Body weights (g) 34 ± 1  38 ± 1 33 ± 2 38 ± 2* 30 ± 2* 30 ± 2* 29 ± 2* 
Right testis (mg)§ 63.8 ± 1.2  63.0 ± 1.6 62.7 ± 1.6 58.8 ± 1.7* 60.5 ± 1.7 59.1 ± 1.7* 54.7 ± 1.8** 
Left testis (mg)§ 63.5 ± 1.5  63.5 ± 2.0 63.7 ± 2.1 59.4 ± 2.2 60.6 ± 2.1 56.5 ± 2.2** 55.8 ± 2.2** 
Epididymides (mg)§ 24.7 ± 1.0  24.0 ± 1.3 21.4 ± 1.4 22.2 ± 1.4 22.5 ± 1.4 22.4 ± 1.4 22.0 ± 1.5 
Ventral prostate (mg)§ 15.1 ± 0.6  13.6 ± 0.8 13.2 ± 0.9* 13.0 ± 0.9* 12.5 ± 0.9* 12.2 ± 0.9** 11.1 ± 0.9** 
Seminal vesicles (mg) 14.4 ± 1.0  14.4 ± 1.5 14.5 ± 1.7 12.7 ± 1.6 18.7 ± 1.6 15.4 ± 1.6 15.2 ± 1.7 
LABC #  (mg)§ 23.7 ± 1.1  19.1 ± 1.3** 20.0 ± 1.4* 20.1 ± 1.4* 20.0 ± 1.5* 21.0 ± 1.4 19.6 ± 1.5* 
Bulbourethral glands (mg) 1.8 ± 0.1  1.6 ± 0.2 1.5 ± 0.2 1.7 ± 0.2 1.5 ± 0.2 1.5 ± 0.2 2.0 ± 0.2 
Adrenals (mg)§ 10.0 ±0.3  8.8 ± 0.4** 9.4 ± 0.4 8.8 ± 0.4* 9.5 ± 0.4 9.3 ± 0.4 8.8 ± 0.4* 
Kidneys (mg)§ 348 ± 32  410 ± 44 425 ± 46 336 ± 50 344 ± 52 357 ± 51 351 ± 55 
Liver (mg)§ 884 ± 8.1  89 8 ± 12 876 ± 12 905 ± 13 922 ± 13* 916 ± 12* 955 ± 13** 
Diameter, sem.tub. ¤(m) 91.6 ± 1.7  92.2 ± 2.4 88.2 ± 2.6 87.2 ± 2.5 85.1 ± 2.5* 85.0 ± 2.6* 82.8 ± 2.6* 
Study 2         
Body weights (g)  38 ± 1 36 ± 1 38 ± 2 35 ± 2 36 ± 2    
Right testis (mg)§ 64.5 ± 1.3 67.3 ± 1.2 65.7 ± 1.9 64.7 ± 1.8 66.2 ± 1.7    
Left testis (mg)§ 64.9 ± 1.5 67.0 ± 1.4 65.1 ± 2.2 63.9 ± 2.1 67.6 ± 1.9    
epididymides (mg) 25.0 ± 1.6 24.3 ± 1.6 23.4 ± 1.8 22.4 ± 1.9 25.7 ± 1.8    
Ventral prostate (mg)§ 17.1± 0.9 16.7 ± 0.9 15.2 ± 1.3 14.6 ± 1.3 17.6 ± 1.1    
Seminal vesicles (mg) 13.4 ± 0.9 12.6 ± 1.0 11.3 ± 1.5 11.1 ± 1.5 12.1 ± 1.3    
LABC # (mg)  24.7 ± 1.3 23.4 ± 1.3 17.6 ± 1.8** 20.1 ± 1.8* 22.1 ± 1.6    
Bulbourethral glands (mg) 2.0 ± 0.1 1.9 ± 0.2 1.6 ± 0.2 1.8 ± 0.2 1.8 ± 0.2    
Adrenals (mg)§ 10.3 ± 0.4 10.1 ± 0.4 9.5 ± 0.6 10.2 ± 0.6 10.4 ± 0.5    
Kidneys (mg)§ 383 ± 5.5 380 ± 5.8 380 ± 8.5 380 ±8.6 379 ± 7.4    
Liver (mg)§ 981 ± 12 958 ± 13 999 ± 19 949 ± 19 974 ± 16    
Diameter, sem.tub. ¤ (m) 89.4 ± 2.8 88.2 ± 2.6 90.4 ± 3.0 85.1 ± 3.0 88.7 ± 2.6    
Study 1 and 2         
Body weights (g) 36 ± 1  38 ± 1 34 ± 1 37 ± 1    
Epididymides (mg) § 25.1 ± 0.94  24.3 ± 1.1 22.1 ± 1.2 24.5 ± 1.1    
Ventral prostate (mg) § 16.5 ± 0.5  14.9 ± 0.7 14.2 ± 0.8 15.5 ± 0.7    
LABC # (mg)  24.4 ± 0.7  18.8 ± 1.0** 20.3 ± 1.1** 21.6 ± 1.0*    
Bulbourethral glands (mg) 1.9 ± 0.1  1.6 ± 0.1 1.6 ± 0.1 1.7 ± 0.1    
Adrenals (mg) § 10.5 ± 0.2  9.4 ± 0.3 10.0 ± 0.4 9.7 ± 0.3    
Kidneys (mg) § 376 ± 3.8  370 ± 5.5 372 ± 6.0 372 ± 5.3    
Diameter, sem.tub. ¤(m) 91.0 ± 1.5  91.4 ± 1.9 87.0 ± 1.9 87.9 ± 1.8    
Data represent least squares means ± SEM. The combined data for study 1 and 2 are shown 
only for endpoints for which the factor ‘study’ was not significant in the statistical analysis.  
* Statistical significant different compared to controls (p < 0.05)  
** Statistical significant different compared to controls (p < 0.01)  
# Seminiferous tubules abbreviated sem.tub.  
¤ levator ani/bulbocavernosus muscles abbreviated LABC  
 § Statistical significant effect of the covariate, body weight (p < 0.05)  
 
                     Table 5. Body and organ weights for DEHP-exposed male pups at PND 16
   
 
Figure legends 
 
 
Figure 1 
Mean anogenital distance (AGD) measured on PND 1 in male rat offspring of dams 
administered corn oil (control), 3, 10, 30 or 100 mg/kg bw/day DEHP from GD 7 to PND 16. 
Least square means + SEM are shown and the data are corrected for body weight and litter 
effect. Data represent the combined analysis of part A and B. ** Indicates p < 0.01. 
Gestational exposure to DEHP significantly reduces AGD in male rat offspring at 10, 30, and 
100 mg/kg bw/day.  
 
Figure 2 
Mean number of nipples (NR) in male rat offspring of dams exposed to corn oil (control), 3, 
10, 30 or 100 mg/kg bw/day DEHP from GD 7 to PND 16. Results are based on analysis of 
litter means and are presented as mean + SEM. Data represents the combined analysis of part 
A and B. * Indicates p ≤ 0.05, ** indicates p < 0.01.The exposure statistically significantly 
increased NR in male rat offspring at 10, 30, and 100 mg/kg bw/day.  
 
Figure 3 
Testicular histopathology at PND 16 in rats exposed to vehicle (A, C), or 900 mg DEHP/kg 
bw/day (B, D) from GD 7 to PND 16. A and B: H&E staining; C and D: 
immunohistochemical staining for vimentin. In DEHP-exposed offspring, testes appeared 
immature with a reduced number of germ cells and a reduced seminiferous tubule diameter 
compared to controls (A, B). Focal Leydig cell hyperplasia was observed (#). Vimentin 
staining showed a more intense staining in Sertoli cells of DEHP exposed animals compared 
to controls (C, D). 
 
Figure 4 
Expression of PBPC3 and ODC mRNA in ventral prostate relative to the expression of the 
house-keeping gene 18SrRNA determined by real-time (RT) PCR after DEHP exposure 
(PND16). Part A: 0, 10, 30, 100, 300, 600 and 900 mg/kg bw/day DEHP (n=5 to 8). 
Part B: 0, 3, 10, 30 and 100 mg/kg bw/day DEHP (n=4 to 12). Results are shown in means ± 
SEM * Indicates p < 0.05; ** Indicates p < 0.01 compared to control group 
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Figure 3A-D 
 
 
 
 
 
 
 
 
 
 Page 33
  
 
 
Page 34 
Figure 4 
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Androgens are key regulators of male sexual
differentiation during the in utero and early
postnatal development. Exposure to chemi-
cals that counteract androgen action at some
stage in this period can permanently demas-
culinize male fetuses and lead to malforma-
tions of the reproductive tract. Examples of
chemicals known to disrupt sexual differenti-
ation in this way include pesticides and their
metabolites, such as vinclozolin, procymi-
done, 1,1-dichloro-2,2-bis(4-chlorophenyl)
ethylene (p,p´-DDE), and linuron, and cer-
tain phthalate esters such as di-ethylhexyl
phthalate and di-butyl phthalate (Gray et al.
2000, 2001). Reduced anogenital distance,
retention of nipples or areolas, hypospadias,
agenesis of sex accessory tissues, and unde-
scended testes have been described as conse-
quences of disruption of androgen action in
the developing rat. These effects are thought
to arise through antagonism of androgens at
the steroid receptor level and/or via suppres-
sion of testosterone synthesis in Leydig cells
(Fisher 2004; Gray et al. 2001).
Many anti-androgenic chemicals have
been found as mixtures in humans (Blount
et al. 2000; Swan et al. 2005), including chil-
dren (Brock et al. 2002; Main et al. 2006),
and in wildlife (Guillette 2000). These find-
ings have stimulated interest in exploring the
consequences of combined exposures to anti-
androgens, although relatively few studies
have addressed the issue. There is good evi-
dence that inhibition of androgen binding
and other receptor-mediated events occur in
an additive fashion (Birkhoj et al. 2004; Gray
et al. 2001; Nellemann et al. 2003), but little
is known about the developmental effects of
in utero and early postnatal exposure to multi-
ple anti-androgenic chemicals.
In this article, we present data from
detailed investigations of the ability of combi-
nations of androgen receptor (AR) antagonists
to induce disruption of male sexual differenti-
ation after long-term exposures in utero and
postnatally. We selected a mixture of vinclo-
zolin, procymidone, and flutamide for our
experiments. Vinclozolin metabolites compete
with androgens for AR binding (Kelce et al.
1994), suppress androgen-dependent gene
transcription (Kelce et al. 1997), and affect
reproductive development. Procymidone and
flutamide also antagonize competitively the
AR binding of androgens, with consequent
inhibition of AR-mediated gene expression
(Ostby et al. 1999; Simard et al. 1986).
Common developmental effects of all three
chemicals after in utero exposure of male rats
include reduced anogenital distance (AGD),
nipple retention (NR), hypospadia, dimin-
ished prostate weight, reduced testis and epi-
didymal weights, and altered behavior in male
offspring (Foster and McIntyre 2002; Gray
et al. 1994; Hellwig et al. 2000; Hib and
Ponzio 1995; Hotchkiss et al. 2002; McIntyre
et al. 2001; Miyata et al. 2002; Ostby et al.
1999; Shimamura et al. 2002). There is no
particular environmental relevance to this
mixture. The choice of compounds was moti-
vated by our interest to explore the pre-
dictability of combination effects caused by
similarly acting anti-androgens rather than to
emulate “real world” mixtures.
Conclusive answers to the question of
combination effect predictability require
quantitative comparisons between predicted
and experimentally observed mixture effects.
Experimentally, we have approached this task
in a step-wise fashion: a) Dose–response
curves for all single-mixture components were
recorded. b) These data were used for the cal-
culation of additivity expectations for a mix-
ture of specific composition using “fixed
mixture ratio design” (Altenburger et al.
2000; Hewlett and Plackett 1959). c) The
mixture experiments were conducted. d) The
observed combination effects were compared
with the predicted responses.
The choice of an appropriate model for
the calculation of additivity expectations is
essential for assessments of mixture effects
because it is in relation to these additivity
expectations that combination effects are
judged in terms of synergisms or antago-
nisms. Several concepts for the computation
of expected additive effects of anti-androgens
have been used. The simple method of sum-
ming the individual effects of chemicals in
the combination, termed “effect summation,”
has been drawn on previously (Gray et al.
This article is part of the monograph “Endocrine
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Points, and Low-Dose and Mixture Effects.”
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OBJECTIVE: The aim of this study was to assess whether the joint effects of three androgen receptor
antagonists (vinclozolin, flutamide, procymidone) on male sexual differentiation after in utero and
postnatal exposures can be predicted based on dose–response data of the individual chemicals. 
METHODS: Test chemicals and mixtures were administered by gavage to time-mated nulliparous,
young adult Wistar rats from gestational day 7 to the day before expected birth, and from postnatal
days 1–16. Changes in anogenital distance (AGD) and nipple retention (NR) in male offspring rats
were chosen as end points for extensive dose–response studies. Vinclozolin, flutamide, and pro-
cymidone were combined at a mixture ratio proportional to their individual potencies for causing
retention of six nipples in male offspring. 
RESULTS: With AGD as the end point, the joint effects of the three anti-androgens were essentially
dose additive. The observed responses for NR were slightly higher than those expected on the basis of
dose addition. A combination of doses of each chemical, which on its own did not produce statistically
significant AGD alterations, induced half-maximal mixture effects. At individual doses associated with
only modest effects on NR, the mixture induced NR approaching female values in the males. 
CONCLUSIONS: Effects of a mixture of similarly acting anti-androgens can be predicted fairly accu-
rately on the basis of the potency of the individual mixture components by using the dose addition
concept. Exposure to anti-androgens, which individually appears to exert only small effects, may
induce marked responses in concert with, possibly unrecognized, similarly acting chemicals.
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2001) but produces unreliable results with
sigmoidal dose–response curves (Kortenkamp
and Altenburger 1998). The concept of dose
addition, also referred to as “concentration
addition” (Loewe and Muischnek 1926), is
usually employed for combinations of chemi-
cals with similar modes of action. It has previ-
ously given additivity expectations well in
agreement with experimental observations for
inhibition of AR binding and AR-mediated
responses in vitro and in vivo (Birkhoj et al.
2004; Nellemann et al. 2003). In light of
these observations, we reasoned that dose
addition would also produce valid additivity
expectations for developmental effects after
prolonged in utero and postnatal exposures.
Although a series of articles have been
published describing the successful applica-
tion of the fixed mixture ratio approach to
in vitro systems (Altenburger et al. 2000;
Backhaus et al. 2000; Payne et al. 2001;
Rajapakse et al. 2002, 2004; Silva et al.
2002), there is comparatively little experience
with in vivo assays. In the endocrine disruptor
field, Brian et al. (2005) have recently
demonstrated the usefulness of this method to
the assessment of multicomponent mixtures
of estrogenic chemicals in fish, but there are
as yet no examples with mammalian assays
in vivo. Thus, to make the assessment of
developmental effects of mixtures of chemi-
cals a viable proposition, a number of practi-
cal requirements had to be considered. Of
particular importance were demands of mini-
mal data variation and high reproducibility.
When dealing with several mixture compo-
nents and a large number of dose levels, the
parallel testing of all agents and their mixtures
is not a realistic option, especially not with
in vivo experiments. Thus, reliance had to be
made on historical data, in some cases
recorded more than a year before commence-
ment of the mixture experiments, and this
placed great emphasis on the reproducibility
of test outcomes. We considered that the high
demands in terms of data variation were more
likely to be met with developmental end
points that lend themselves to straight-for-
ward quantification. For these reasons, we
selected changes in AGD and NR in male off-
spring of rats as main end points for our mix-
ture experiments. Both these end points are
sensitive to anti-androgen exposure.
The aim of our studies was to assess
whether the joint effects of mixtures of AR
antagonists can be predicted accurately over a
large effect range on the basis of dose–response
data of the individual components. We rea-
soned that if there are demonstrable consistent
relationships between the potency of individ-
ual chemicals and the ways in which they act
together, powerful tools for prospective risk
assessment would become available. These
tools could open the way to make productive
use of existing single-chemical databases for
the prediction of mixture effects. A second
aim was to determine whether there would be
joint effects when every mixture component
was present at doses that individually do not
produce observable responses.
Materials and Methods
Chemicals. The chemicals used were vinclo-
zolin (CAS No. 50471-44-8, purity 99%,
ChemService catalogue no. PS-1049; Bie &
Berntsen, Herlev, Denmark), procymidone
(CAS No. 32809-16-8, purity 99%, Chem-
Service catalogue no. PS-2126; Bie &
Berntsen), flutamide (CAS No. 13311-84-7,
purity 99%, catalogue no. F9397; Sigma
Aldrich, Brønby, Denmark), and corn oil
used as vehicle (Bie & Berntsen).
Studies and dose levels. Before the mixture
experiment, dose–response studies for each
chemical were conducted. The dose ranges
were chosen with the aim to cover the entire
range of effects from no effect up to maximum
effects, as determined by measurement of
AGD and NR. At the same time, it was
attempted to select doses that would not cause
marked effects on body weights in the dams,
and especially in the offspring, as this would
complicate evaluation of the effects on AGD
and NR. The dose levels selected for the
dose–response studies were based on the
reductions of AGD and increase of NR
reported for vinclozolin (Gray et al. 1994,
1999; Hellwig et al. 2000; Hotchkiss et al.
2002; Shimamura et al. 2002), flutamide
(Foster and McIntyre 2002; Hib and Ponzio
1995; Hotchkiss AK et al. 2002; McIntyre
et al. 2001; Miyata et al. 2002), and procymi-
done (Ostby et al. 1999). As data on procymi-
done were relatively limited, a range-finding
study was performed before the dose–response
study. To gain information about variability
of effects between studies, we ran selected
doses of vinclozolin, flutamide, and procymi-
done in parallel with the mixture experiment.
An overview of the studies including dose
levels and number of animals is shown in
Table 1. A similar study design was used for
all studies (see below).
For the mixture study, a master mixture
was prepared by combining doses of vinclo-
zolin, flutamide, and procymidone that all
induced a half-maximal degree of NR (six nip-
ples) in male offspring. This approach was cho-
sen to avoid one single chemical contributing
disproportionately to the overall mixture effect.
The resulting mixture ratio of vinclozolin, flu-
tamide, and procymidone was 31:1:18 based
on weight (Table 2), and the master mixture
contained 22,026 mg vinclozolin, 696.6 mg
flutamide, and 12,675 mg procymidon in
600 mL corn oil. It was diluted into five doses
of the mixture (1:14, 1:5, 1:2, 6:4, and 9:1).
These dose levels were chosen with the aim of
covering the entire dose–response curve. 
Animals and dosing. The animals were
treated humanely and with regard for alleviation
of suffering. The studies were performed under
conditions approved by the Danish Agency for
Protection of Experimental Animals and by the
inhouse Animal Welfare Committee. 
Time-mated nulliparous, young adult
Wistar rats (HanTac:WH, Taconic Europe,
Ejby, Denmark; body weight approximately
200 g) were supplied at day 3 of pregnancy.
The day after mating was designated gestational
day (GD) 1, and postnatal day (PND) 0 was
the day of birth. On the day after arrival
(GD4), the dams were distributed pseudoran-
domly into groups of 16 or 8 animals with sim-
ilar body weight (bw) distributions. They were
housed in pairs until GD21 and alone there-
after under standard conditions in semitrans-
parent plastic cages (15 × 27 × 43 cm) with
Aspen bedding (Tapvei, Gentofte, Denmark)
situated in an animal room with controlled
environmental conditions (12-hr light–dark
cycles with light starting at 2100 hours, light
intensity 500 lux, temperature 21 ± 2°C,
humidity 50% ± 5%, ventilation eight air
changes per hour). A complete rodent diet for
growing animals ALTROMIN 1314 (soy- and
alfalfa-free; ALTROMIN GmbH, Lage,
Germany) and acidified tap water (to prevent
microbial growth) were provided ad libitum. 
Test chemicals and mixtures were admin-
istered by gavage from GD7 to the day
before expected birth (GD21) and from
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Table 1. Studies, groups, doses, and number of time-mated animals per group.
No. of animals
Study Groups and doses per group
1. Vinclozolin and flutamide, Control: vehicle-dosed 16
dose–response 6 doses of vinclozolin: 5, 10, 20, 40, 80, or 160 mg/kg/day 8
6 doses of flutamide: 0.5, 1.0, 2.0, 4.0, 8.0, or 16 mg/kg/day 8
2. Procymidone, range-finding Control: vehicle-dosed 16
2 doses of procymidone: 25 or 200 mg/kg/day 4
3. Procymidone, dose–response Control: vehicle-dosed 16
6 doses of procymidone: 5, 10, 25, 50, 100, or 150 mg/kg/day 8
4. Mixture study of vinclozolin, Control: vehicle-dosed 16
flutamide, and procymidone 5 doses of mixture: 7.87, 19.67, 39.33, 70.80, or 106.19 mg/kg/day 16
2 doses of vinclozolin: 24.5 or 95.9 mg/kg/day 16
2 doses of flutamide: 0.77 or 3.86 mg/kg/day 8
2 doses of procymidone: 14.1 or 61.8 mg/kg/day 8
Anti-androgen mixture: AGD and nipple retention
PND1 until PND16. The dosing volume of
2 mL/kg bw was calculated on the basis of
the body weight of the animal on the day of
dosing. The dose levels and group sizes are
shown in Table 1. Animals were inspected
for general toxicity twice daily. The studies
were performed using four blocks (with
1 week in between), and all dose groups were
equally represented in the blocks. 
Anogenital distance and nipple retention.
In all studies, AGD and NR were recorded by
the same technician who was blinded with
respect to exposure groups. After birth all live
pups in the litter were weighed, sexed, and
AGD was measured using a stereomicroscope.
The sex of several of the pups in the highest
dose groups could not be determined based on
the AGD, as the AGDs were similar to female
values in all pups in some litters. In these cases,
the sex of the pups was determined later by
internal inspection of reproductive organs with
the presence of testes defining a male. The
highest AGD values obtained in the litter were
used as the values for male pups. This
approach was chosen because these values were
most likely to represent the males, as males
normally have longer AGDs than females. For
dose–response analysis, AGD data were ana-
lyzed by the calculated AGD-index, namely,
AGD divided by the cube root of body weight.
The cube root was used because this converts a
three-dimensional end point (weight) into a
one-dimensional such as the AGD (Gray et al.
1999; Robert et al. 1999). This ratio assumes
that the relationship between AGD and trans-
formed body weight is directly proportional
and linear. To assess the validity of this
assumption, we explored using the transformed
body weight as a co-variable in statistical analy-
ses. However, we did not detect any relevant
difference between these two approaches, and
in the interest of keeping the model parameters
low, we decided to base all statistical analyses
on the AGD index. 
The body weights of all pups were
recorded on PND 12 ± 1, together with the
number of nipples/areolas, defined as a dark
focal area (with or without a nipple bud)
located where nipples are normally present in
female offspring. Females normally have 12
nipples, but may in a few cases show up to 14. 
Data normalizations and dose–response
analysis. Slight differences in absolute control
values between studies were controlled for by
standardizing the absolute AGD indices to rel-
ative values between one (no effect on male
AGD index) and zero (complete feminiza-
tion). The mean AGD indices from unex-
posed male and female pups were used to
define the minimum and maximum responses,
respectively. Regression analyses were based on
normalized AGD indices. In contrast, absolute
AGD indices were used for estimations of no
observed adverse effect levels (NOAELs).
Because NR is a quantal end point, data nor-
malization was not necessary in this case.
Statistical dose–response regression analy-
ses for both end points were carried out by
applying a best-fit approach (Scholze et al.
2001). Various nonlinear regression models
(logit, probit Weibull, generalized logit),
which all describe monotonic sigmoidal dose-
response relationships, were fitted indepen-
dently to the same data set and the best-fitting
model was selected on the basis of a statistical
goodness-of-fit criterion, the information cri-
terion of Schwarz (1978).
To control for litter effects on AGD,
dose–response data for the normalized AGD
indices were analyzed by a generalized nonlin-
ear mixed-model approach (Vonesh and
Chinchilli 1996), with the litter as a random
effect modifier for individual AGD data.
To take account of uncertainties in the
mean control estimates for AGD during the
scaling of effects, we included an upper and
lower asymptote in the regression models.
However, neither for the individual com-
pounds nor for the mixture were the resulting
model parameters significantly different from 0
and 1, respectively. To avoid overparameteriza-
tion, upper and lower asymptotes were there-
fore not estimated, but instead set a priori to 0
and 1 (see θmax = 1 in Table 2). Statistical
analyses of AGD data were carried out using
the SAS procedure PROC NLMIXED (SAS
Institute Inc., Cary, NC, USA). 
The number of nipples/areolas was
assumed to follow a binomial distribution
with a response range between 0 and θmax,
with θmax being equal to the biologically possi-
ble maximal number of nipples in rats, either
12 or 13 (Table 2). The choice of θmax was
decided on considering the global fit (informa-
tion criterion of Schwarz). To account for lit-
ter effects on NR, correlation structures
between number of nipples/areolas and litter
were modeled by the generalized estimating
equations method (Vonesh and Chinchilli
1996). All statistical analysis was performed
using the SAS procedure PROC GENMOD
(SAS Institute, Inc., Cary, NC, USA).
The analyses for single compounds were
carried out using effect data pooled from the
initial dose–response studies (Table 1, stud-
ies 1–3) and the repeat experiments run con-
currently with the mixture study (Table 1,
study 4). “Study run” was implemented as an
additional model factor in data analysis. The
effect doses (EDx) shown in Table 2 were
selected for low and median response levels and
were calculated from the functional inverse of
the best-fitting model. Statistical uncertainties
for the estimated effect doses were expressed as
95% confidence belts and approximately deter-
mined by applying the bootstrap method
(Efron and Tibshirani 1993).
NOAELs were estimated using multiple
contrast tests (Hothorn 2004). These tests
were chosen as they are already implemented
in the SAS procedures PROC NLMIXED and
PROC GENMOD. Corresponding optimal
contrasts were determined according to the
best-fit regression model (Bretz et al. 2005).
Calculation of mixture–effect predictions
using dose addition. To assess whether the
joint effect of the three chemicals was dose
additive, we predicted mixture effects based on
information about the dose–effect relationships
of all individual mixture components. These
data were derived from the best-fit regression
Hass et al.
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Table 2. Statistical dose–effect descriptors for single and mixture exposures.
Fraction in Dose–response function Effect doses (mg/kg/day) NOAELa
Substance mixtureb RMc θˆ1 θˆ2 θˆ3 θˆmax Medium Low (mg/kg/day)
Nipple retention ED6d (95% CI) ED1d (95% CI)
Vinclozolin 0.622301 BP-probit –1.76 0.025 1.024 12 67.18 (55.78–77.08) 5.73 (0.67–25.58) < 5.0
Flutamide 0.019558 Probit –0.61 2.01 — 12 2.02 (1.71–2.40) 0.41 (0.28–0.60) < 0.5
Procymidon 0.358141 BP-logit –5.09 1.21 0.1 12 33.91 (24.81–45.74) 7.51 (> 0.1–10.76) 10.0
Mixture bw-Weibull –19.66 16.83 –0.8 13 20.78 (17.76–23.52) 8.21 (6.67–10.42) < 7.87
AGD index ED50e (95% CI) ED90e (95% CI)
Vinclozolin 0.622301 Logit –6.80 3.59 — 1 78.65 (67.43–93.32) 9.21 (11.57–29.08) 5.0
Flutamide 0.019558 Weibull –1.38 1.85 — 1 3.54 (2.84–4.37) 0.34 (0.19–0.57) < 0.5
Procymidon 0.358141 bw-Weibull –6.31 2.087 –0.20 1 69.38 (56.69–86.38) 1.84 (4.12–22.47) 10.0
Mixture Glogit II –9.24 7.21 0.29 1 39.77 (32.51–49.48) 4.68 (6.79–20.73) 19.67
aNOAEL – no observed adverse effect level, marked as “<” when the lowest tested dose already produced a significant effect. bRatio of the dose of each compound to total mixture dose.
cRM – regression models as defined by Scholze et al. (2001); for more details see “Material and Methods”; θˆ1, θˆ3, θˆ3,– statistical estimates of model parameters, given for doses expressed
as mg/kg/day (rounded values); θˆmax– upper model asymptote. dED6, ED1 – effect doses for 6 and 1 nipples, calculated from the respective dose–response function. eED50, ED90 – effect
doses for 50% and 90% normalized AGD index, calculated from the respective dose–response function; 95% CI – 95% confidence intervals for mean effect doses given in mg/kg/day.
functions (Table 2) and used to calculate the
expected responses of a mixture with defined
mixture ratio over a large range of responses
(“fixed mixture ratio design”) (Faust et al.
2001). The choice of doses was based on the
concentration range described by the additiv-
ity prediction, which is defined for a multi-
component mixture of three components as
. [1]
Here, EDx1, EDx2, and EDx3 are the effect
doses of vinclozolin, flutamide, and procymi-
don that on their own produce the same quan-
titative effect x as the mixture, and p1, p2, and
p3 are the relative proportions of the corre-
sponding individual doses present in the total
mixture dose (see Table 2, “Fraction in mix-
ture”). The individual effect doses were derived
from the dose–response functions for vinclo-
zolin, flutamide, and procymidone by using
their inverse functional form. Equation 1
allows calculation of any effect dose of a mix-
ture under the hypothesis of dose additivity,
provided the dose–response functions of all
mixture components and the mixture ratio are
known. Graphs of predicted mixture dose–
response curves (Figure 1) were obtained by
calculating numerous EDxmixture values, with x
varying from 10 to 90% for the normalized
AGD index and from 1 to 11 for nipples. The
statistical uncertainty for the predicted mix-
ture–effect doses EDxmixture was determined by
using the bootstrap method (Efron and
Tibshirani 1993) and expressed as 95% confi-
dence intervals (CIs) for the predicted mean
estimate. Differences between predicted and
observed effect doses were deemed statistically
significant when the 95% confidence belts of
the prediction did not overlap with those of
the experimentally observed mixture effects.
Results
Pregnancy and litter data. No clinical signs
of general toxicity were observed during the
daily observations. The maternal body weight
gain from GD7 to PND1 was significantly
decreased (12.8 ± 14.6 g compared with 24.3 ±
9.4 g in the control group) in dams receiving
the highest dose of vinclozolin (160 mg/kg/
day), but none of the other doses of vinclozolin
provoked this effect. Pregnancy length, litter
sizes, birth weight of male and female off-
spring, and sex ratios in the litters remained
unaltered in all vinclozolin-dosed groups when
compared to controls. None of the tested doses
of flutamide induced reductions of maternal
weight gain, or other signs of maternal toxicity.
In the range-finding study with procymidone
(Table 1, study 2), litter sizes were markedly
decreased at the highest dose of 200 mg/kg/day.
The dose–response study (Table 1, study 3)
using 150 mg/kg/day as the highest dose did
not show effects on pregnancy length, litter
sizes, birth weights, or sex ratios in the litters.
Maternal body weight gain from GD7 to
PND1 was decreased in the dams exposed to
25 mg/kg/day procymidone and higher, but
no clear dose–response relationship was appar-
ent with these weight gain changes.
In dams exposed to the two highest doses
of the mixture of vinclozolin, flutamide, and
procymidone (Table 1, study 4), maternal
body weight gain from GD7 to PND1 was
decreased. Among the groups of pregnant rats
that were dosed with the single agents in paral-
lel with the mixture experiment (Table 1,
study 4), those receiving the higher dose of
procymidone (61.8 mg/kg/day) also had
diminished weight gain. Decreased litter sizes
were observed at the high dose of flutamide
(3.86 mg/kg/day). As this was not found in the
previous dose–response study at the similar
dose level of 4 mg/kg/day, or at the higher
doses of 8 and 16 mg/kg/day, this is considered
a random finding unrelated to exposure to flu-
tamide. None of the mixture doses caused sig-
nificant effects on pregnancy length, litter sizes,
birth weights, and sex ratios in the litters. 
Effects of vinclozolin, flutamide, and
procymidone on AGD and NR. All chemicals
produced dose-dependent changes in AGD
index and NR and the resulting dose–response
curves were observed to be quite steep. The
entire effect range from control levels to maxi-
mal responses could be covered by dose
changes of only two orders of magnitude
(Figure 2). While vinclozolin and procymi-
done were of similar potency, flutamide was
effective at approximately 10-fold lower doses.
Compared with the AGD index, NR was
generally the more sensitive end point. At the
lowest tested doses of 5 and 0.5 mg/kg/day,
respectively, vinclozolin and flutamide induced
statistically significant changes in NR, whereas
the respective AGD indices did not differ sig-
nificantly from those of controls at these doses.
NOAELs could therefore not be defined for
vinclozolin and flutamide. For procymidone a
NOAEL of 10 mg/kg/day was estimated.
To gain an impression of variability
among studies, selected dose levels of all three
chemicals were retested in parallel with the
mixture experiment. The reproducibility of
effects observed in the earlier studies (Table 1,
studies 1–3) was generally good. At the lower
doses, the animals in the repeat studies were
slightly less responsive in terms of changes in
AGD index, but the NR effects tended to be
a little higher upon retesting (Figure 2;
Table 3). Table 2 summarizes key parameters
characterizing the dose–response relationships
of each single substance. Generally, our data
are in broad agreement with results published
by others (Foster and McIntyre 2002; Gray
et al. 1999; Hellwig et al. 2000; Hib and
Ponzio 1995; Hotchkiss et al. 2002; McIntyre
et al. 2001; Miyata et al. 2002; Ostby et al.
1999; Shimamura et al. 2002). However,
because of the unprecedented level of detail in
our dose–response analyses, more in-depth
comparisons are not possible. 
Combination effects of vinclozolin,
flutamide, and procymidone. The mixture of
vinclozolin, flutamide, and procymidone pro-
duced dose-dependent changes in AGD index
and NR (Figure 1). The NOAEL for changes
in AGD index was 19.67 mg/kg/day, but the
lowest tested mixture dose of 7.87 mg/kg/day
induced statistically significant changes in NR
(Table 2). Therefore, the overall mixture
NOAEL is lower than 7.87 mg/kg/day. 
The dose–response data for the single
agents, pooled from all studies (Figure 2;
Table 2), were used to compute predicted
dose-additive combination effects covering
the entire range of effects (Figure 1, green
curves). For both end points, the anticipated
combination effects fell within the range of
the effects that were observed experimentally.
Numerical comparisons between predicted
and observed AGD index (Table 3) revealed
fairly good agreement. Despite the long period
that had elapsed between the recording of the
effects of the individual mixture components
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Anti-androgen mixture: AGD and nipple retention
Figure 1. Effects of mixed exposure to vinclozolin, flutamide, and procymidone on AGD (A) and NR (B).
Results shown are group mean ± SE (red), litter means (black), mean dose–response curve ± 95% confi-
dence belt based on regression analysis (blue) and mean predicted mixture effect ± 95% confidence belt
(green). Dashed horizontal lines show male and female control values. See text for details. 
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and the mixture experiment itself, the
predicted effect doses in the median and high
effect ranges differed by only a factor of 1.3
from those experimentally observed. Whether
the anticipated combination effects were cal-
culated using the data from the concurrent
studies or using the pooled data sets including
the historical data had little influence on the
quality of the prediction. The joint effects of
vinclozolin, flutamide, and procymidone on
reductions of AGD in male rats were essen-
tially dose additive.
In contrast, the deviations between predic-
tion and observation were generally larger for
NR than for AGD index, with observed NR
responses exceeding the predicted mixture
effects (Table 3; Figure 1). The effect doses
predicted on the basis of the pooled single
agent data were higher than the observed mix-
ture–effect doses in the median- and high-
effect range (6 and 10 retained nipples/areolas).
This was not the case for the low-effect range
(1 retained nipple/areola). Predictions based on
the responses seen with single agents run in
parallel with the mixture study (Table 1,
study 4) produced lower effect doses in the
median- and high-effect range, in better agree-
ment with the observed results.
Mixture effects at low doses of individual
mixture components. Because the doses of the
single chemicals present in the mixture were
quite low, we assessed whether there were sig-
nificant combination effects when all compo-
nents were present at doses that individually
did not induce observable effects. At a dose of
39.37 mg/kg/day, the mixture induced a
marked effect on the AGD index (around
50% reduction). This mixture contained
24.5 mg/kg/day vinclozolin, 0.77 mg/kg/day
flutamide and 14.1 mg/kg/day procymidone,
and individually these doses did not induce
significant reductions in the AGD index
(Figure 3). With NR as the end point, the
single-chemical effects were small but statisti-
cally significant at these doses, whereas the
combined exposure induced a marked effect. 
Discussion
Previous work with anti-androgens has
focused mainly on events surrounding AR
binding and activation and has shown that
combinations of these chemicals are able to
act together in an additive fashion (Birkhoj
et al. 2004; Nellemann et al. 2003). These
studies have prepared the ground for address-
ing the question as to whether there are also
joint effects with responses further removed
from receptor binding and activation, such as
those related to male sexual differentiation.
For the first time, we have addressed this
question by using the fixed mixture ratio
approach for studying combination effects on
the disruption of male sexual development.
With reductions of AGD as the end
point, the experimentally observed mixture
effects were in good agreement with the dose
additivity expectation calculated on the basis
of the individual dose–response relationships
for vinclozolin, flutamide, and procymidone.
Although the predicted mixture effects for
NR also fell within the limits of the lowest
experimentally recorded responses, the
Hass et al.
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Figure 2. Effects of vinclozolin (A,B), flutamide (C,D), and procymidone (E,F), given individually, on AGD
(left) and NR (right). Results shown are group mean ± SE (red), litter means from the dose–response stud-
ies (black), litter means from the single doses within mixture study (grey), and the mean dose–response
curve ± 95% confidence belt based on regression analysis (blue). Dashed horizontal lines show male and
female control values. See text for details.
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Table 3. Statistical uncertainty of predicted and observed effect doses for the mixture of vinclozolin, flu-
tamide, and procymidone.
Effect doses for the mixture (mg/kg/day)
Observeda Predicted by DApooledb Predicted by DAconfirmationc
Effect level [Mean (95% CI)] [Mean (95% CI)] [Mean (95% CI)]
Relative AGD index (%)
90 14.68 (6.79–20.73) 8.29 (5.06–11.17) 14.98 (4.22–19.80)
50 39.77 (32.51–49.48) 53.75 (48.22–60.34) 52.58 (44.17–75.98)
20 112.45 (77.79–184.51) 143.19 (113.05–193.54) 129.34 (100.67–204.49)
Number of nipples/areolas
1 8.21 (6.67–10.42) 7.43 (0.11–9.36) 7.45 (3.06–11.73)
6 20.78 (17.76–23.52) 33.88 (29.23–38.41) 27.98 (22.04–34.07)
10 45.33 (38.91–55.86) 73.66 (67.25–82.05) 57.31 (50.17–67.58)
aEffect doses as calculated from the dose–response functions given in Table 2. bDA, dose addition; predicted effect doses
are based on pooled data from studies 1–4 for vinclozolin, flutamide, and procymidone and were calculated from the
respective dose–response functions given in Table 2. cPredicted effect doses are based on data for vinclozolin, flutamide,
and procymidone from study 4 only, where two doses each of these chemicals were run in parallel with the mixture
experiment. Predicted mixture–effect doses were estimated by linear regression (model estimates not shown).
NR responses in the median and high end
indicated that the mixture was more potent
than predicted. The movement away from the
anticipated combination effects can be partly
attributed to the fact that the single agent
responses seen concurrently with the mixture
study were slightly higher than previously
recorded, particularly in the high-effect range.
When the mixture–effect prediction was based
solely on the data from the concurrently run
single agent studies, the differences between
anticipated and observed effect doses for NR
became smaller. This could indicate that the
animals used for the mixture experiment
showed subtle differences in their responses to
the anti-androgens compared with the rats
used for the earlier dose–response studies. The
reason such differences should have become
apparent only in terms of altered NR, but not
in relation to AGD, may lie partly in the
greater sensitivity of NR as an anti-androgenic
end point. However, other as yet unrecog-
nized factors may also have played a role. Seen
in this light, we hesitate to interpret the joint
effects of the mixture on NR as weakly syner-
gistic, although the numerical discrepancies
between observed and anticipated additive
effects would support such a conclusion.
Much larger studies would be required to
resolve conclusively whether vinclozolin, flu-
tamide, and procymidone exhibit a weak
synergism with respect to NR. Nevertheless,
in view of the complexity of the events leading
to alterations in AGD and NR, and consider-
ing the experimental challenges in recording
such effects reliably and reproducibly over a
long period, we were surprised that the com-
bined effects of the three anti-androgens could
be predicted quite accurately. We therefore
conclude that the dose addition approach pro-
vides an excellent basis for prediction of the
joint effects of multicomponent mixtures of
similarly acting anti-androgens.
Although the primary aim of our work
was to assess the predictability of mixture
effects of anti-androgens, the results of our
study also allow assessments of the question as
to whether there are joint effects when all mix-
ture components are present at doses that
individually do not induce detectable effects.
This phenomenon, somewhat provocatively
dubbed “something from ‘nothing’” (Silva
et al. 2002), has been observed with multi-
component mixtures of estrogenic agents in
reporter-based assays (Rajapakse et al. 2002;
Silva et al. 2002), the uterotrophic assay
(Tinwell and Ashby 2004), and vitellogenin
induction in fish (Brian et al. 2005). The basis
of the something from nothing phenomenon
derives from the theoretical assumptions that
underlie the concept of dose addition.
According to dose addition, every agent at any
dose contributes, in proportion to its toxic
unit, to the overall effect of a mixture. Because
every mixture component can be replaced
totally or in part by an equal fraction of an
equi-effective dose of another, it does not mat-
ter whether the individual doses are also effec-
tive on their own. “Something from nothing”
effects should occur even when individual toxi-
cants are present at doses below effect thresh-
olds, provided sufficiently large numbers of
components sum up to a suitably high total-
effect dose.
The results shown in Figure 3 support the
idea that the “something from nothing” phe-
nomenon also applies to alterations in the
AGD of male rats exposed to anti-androgens
during development. In this case a com-
bination of 24.5 mg/kg/day vinclozolin,
0.77 mg/kg/day flutamide and 14.1 mg/kg/day
procymidone induced half-maximal AGD
alterations, but the effects induced by each
chemical on its own did not reach statistical
significance when compared with effects in
untreated controls. However, whether the
doses of the chemicals present in the mixture
were indeed equivalent to nothing in the sense
of zero effect levels is debatable. Regression
analysis of the dose–response data for the three
chemicals (Figure 2) showed that the effects
associated with these doses were between 5
and 10% of a biologically possible maximal
effect. In addition, in the earlier dose–response
study, vinclozolin actually induced a signifi-
cant effect on AGD at a lower dose than the
24.5 mg/kg/day present in the mixture.
Generally, these results show that lack of sta-
tistical significance cannot be equated with an
absence of biological effects. 
Because of the apparently greater sensitiv-
ity of NR as an anti-androgenic end point,
the something from nothing effect could
not be evaluated with a combination of
24.5 mg/kg/day vinclozolin, 0.77 mg/kg/day
flutamide and 14.1 mg/kg/day procymidone,
because the individual doses induced NR
that clearly reached statistical significance
(Figure 3). The results, however, illustrate
something not too dissimilar from the some-
thing from nothing phenomenon, which could
be called “marked effects from small effects”:
The mixture-induced NR approaching com-
plete feminization of the males, whereas the
individual doses caused only modest effects. In
general, our findings do not contradict theoreti-
cal expectations and are consistent with the ear-
lier observations made with mixtures of
estrogenic chemicals (Brian et al. 2005;
Rajapakse et al. 2002; Silva et al. 2002; Tinwell
and Ashby 2004). The something from noth-
ing phenomenon would most probably have
been demonstrated also with NR as the end
point, had lower doses been employed or had
more mixture components been combined.
In conclusion, our results show that com-
binations of similarly acting anti-androgens
are able to produce developmental effects in
male offspring of rats. These effects can be
predicted fairly accurately on the basis of
information about the potency of the individ-
ual mixture components by using the dose
addition concept. There are indications that
anti-androgens act together to produce
marked joint effects when combined at doses
that individually produce small, statistically
insignificant responses. The significance of
these findings for human and environmental
risk assessment cannot be overstated; doses of
endocrine-active chemicals, which appear to
exert only small effects when judged on their
own, may induce marked responses when
they act in concert with numerous, possibly
unrecognized, similarly acting agents.
Environmental Health Perspectives • VOLUME 115 | DECEMBER 1 | December 2007 127
Anti-androgen mixture: AGD and nipple retention
Figure 3. Mixture effects on AGD (A) and NR (B) at low doses of individual mixture components. Results
shown are group mean ± 95% confidence belt for control males and females (gray), individual doses of
24.5 mg/kg vinclozolin (VZ), 0.77 mg/kg flutamide (FLUT), and 14.1 mg/kg prycymidone (PRO) (blue), the
combined mixture dose of 39.37 mg/kg (blue), and the predicted mixture effect (white). Open circles repre-
sent litter means.
*p < 0.05 compared to control. 
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We investigated the ability of a mixture of three androgen
receptor antagonists to induce disruption of male sexual differ-
entiation after perinatal exposure. The aim was to assess whether
the joint effects of vinclozolin, flutamide, and procymidone can be
predicted based on dose-response data of the individual chemicals.
Chemicals were administered orally to pregnant Wistar rats from
gestational day 7 to postnatal day 16. Changes in reproductive
organ weights and of androgen-regulated gene expression in
prostates from male rat pups were chosen as end points for
extensive dose-response studies. With all end points, the joint
effects of the three antiandrogens were dose additive. Histological
evaluations showed that dysgenesis and hypoplasia of prostates,
seminal vesicles, and epididymis were seen with the highest
mixture doses. No changes were observed in any single-compound
low-dose group for these lesions, nor were there histopathological
changes in the testes. Pronounced dysgenesis of external genitals
was observed with all doses of the mixture, and severe dysgenesis
was seen with a mixture for which the individual compounds
caused no effects. A combination of doses of each chemical that
on its own did not produce significant reductions in the weights
of seminal vesicles and PBP C3 expression induced a marked
mixture effect. Thus, antiandrogens cause additive effects on end
points of various molecular complexities such as alterations at the
morphological and the molecular level. Exposure to antiandro-
gens, which appears to exert only small effects when judged on
a chemical-by-chemical basis, may induce marked responses in
concert with, possibly unrecognized, similarly acting chemicals.
Key Words:mixtures; androgen receptor antagonist; vinclozolin;
flutamide; procymidone; developmental toxicity; gene expression;
rat; endocrine disrupters.
Since the early 1990’s, an increasing incidence of disorders
such as cryptorchidism and hypospadia in newborn boys,
decreased sperm counts in young men, and a rising incidence
of hormone-related testicular cancer have been observed in the
human population. Each of these endocrine disorders can be
associated with subnormal androgen action in fetal life which
may lead to these reproductive abnormalities, also commonly
characterized as the testicular dysgenesis syndrome (TDS)
(Skakkebaek et al., 2001). Environmental antiandrogens,
which can arise from many different sources, including
pesticides, industrial chemicals, pharmaceuticals, and phy-
tochemicals, are potential endocrine disrupters. Such antian-
drogens have the potential to perturb male reproductive
development and act via a variety of mechanisms, including
decreased androgen synthesis, disturbance of the pituitary-
gonadal axis, and by blocking the androgen receptor (AR)
(reviewed by Sharpe, 2006). Although evidence of a causal
relationship between prenatal exposure and TDS is inherently
difficult to establish in human studies, a few studies have
recently found correlations between human levels of environ-
mental antiandrogens (i.e., phthalates) and anogenital distance
(AGD) (Swan et al., 2005) and hormone levels in newborn
boys (Main et al., 2006), indicating that exposure to endocrine
disrupters may cause developmental effects in human infants.
Human exposure to single antiandrogens is generally con-
sidered low. However, as several antiandrogenic chemicals
have been found to occur as mixtures in humans (Blount et al.,
2000; Swan et al., 2005), including children (Brock et al.,
2002; Main et al., 2006) and in wildlife (Guillette, 2000), the
consequences of combined exposures to antiandrogens warrant
attention in order to assess the human health risk. Only a few
studies have addressed mixture effects of endocrine disrupting
chemicals, focusing on antiandrogenic effects in vivo (Birkhoj
et al., 2004;Gray et al., 2001;Hass et al., 2007;Nellemann et al.,
2003). Until recently, little was known about the developmental
effects of in utero and early postnatal exposure to multiple
antiandrogenic chemicals. Consequently, we designed amixture
study of three AR antagonists: vinclozolin and procymidone,
two fungicides that share a common antiandrogenicmechanism,
and flutamide, a pharmaceutical used to treat prostate cancer, to
study disruption of male sexual differentiation in male rat pups
after gestational and lactational exposure (Hass et al., 2007).
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Common developmental effects of all three single chemicals
after perinatal exposure ofmale rats include alteredAGD, nipple
retention (NR), hypospadias, reduced reproductive organ
weights, and altered behavior in male offspring (Foster and
McIntyre, 2002; Gray et al., 1994; Hellwig et al., 2000; Hib and
Ponzio, 1995; Hotchkiss et al., 2002; McIntyre et al., 2001;
Miyata et al., 2002; Ostby et al., 1999; Shimamura et al., 2002).
In a previous study (Hass et al., 2007), we investigated
whether the joint developmental effects of these three anti-
androgens could be predicted based on dose-response data of
the individual chemicals by employing the concept of dose
addition (Loewe and Muischnek, 1926). In the paper by Hass
et al. (2007), the focus was on AGD and NR as the end points
for assessment, and the results revealed that the combined
effects of the three antiandrogens were dose additive for AGD
and that the observed responses for NR were slightly higher
than those expected on the basis of dose addition. Doses of
each chemical that individually did not induce statistically
significant changes in AGD led to marked effects when
combined as a mixture. Furthermore, as individual doses
correlated with only modest effects on NR, the mixture induced
NR that approached complete ‘‘feminization’’ of the males
(Hass et al., 2007). These results revealed that exposure to
a mixture of antiandrogens with similar mechanism of action
can induce marked effects even when each chemical is present
at doses associated with only weak, if any, effects. This is
consistent with theoretical expectations, and with earlier
observations made with mixtures of estrogenic chemicals
(Brian et al., 2005; Rajapakse et al., 2002; Silva et al., 2002;
Tinwell and Ashby, 2004), and it highlights the importance of
these findings for human and environmental risk assessment.
In the present paper, we broaden the range of end points
relevant to antiandrogen action and present additional results
from our original three-component mixture study with vinclo-
zolin, flutamide, and procymidone. Our interest was to explore
whether combinations of these antiandrogens followed dose
additivity when end points representative of antiandrogen action
at different levels of biological complexity, ranging from the
molecular to the macroscopic, were chosen as the basis for
evaluation. The end points selected for quantitative dose-
response analysis included reproductive organ weights and
perturbations of gene expression in the prostate. An additional
aimwas to determinewhether small effects induced by lowdoses
of single-mixture components would lead to exacerbations when
the chemicals acted in concert, as previously seen for AGD and
NR. To fulfill this goal, malformations of male external genitals
were scored in addition to histological lesions and weights
of reproductive organs as well as prostate gene expression.
MATERIALS AND METHODS
Test compounds. Vinclozolin, 99% pure (CAS no. 50471-44-8) (Bie &
Berntsen, ChemService cat. no. PS-1049), flutamide, 99% pure (CAS no.
13311-84-7) (Sigma Aldrich, Brøndby, Denmark cat. no. F9397), and
procymidone, 99% pure (CAS no. 32809-16-8) (Bie & Berntsen, ChemService
cat. no. PS-2126) were used. Test compounds were dissolved in corn oil (Bie &
Berntsen, Herlev, Denmark), which was employed as vehicle.
Studies and dose levels. Dose-response studies for each test compound
were performed prior to the mixture study in order to cover the entire range of
effects, from no effect up to clear effects, without causing marked general
toxicity to dams and offspring.
Dose-response study 1 involved a vehicle-dosed control group (16 dams),
six doses of vinclozolin: 5, 10, 20, 40, 80, or 160 mg/kg/day and six doses of
flutamide: 0.5, 1.0, 2.0, 4.0, 8.0, or 15 mg/kg/day (eight dams per dose group).
Dose-response study 2 included a vehicle-dosed control group (16 dams)
and six doses of procymidone: 5, 10, 25, 50, 100, or 150 mg/kg/day (eight dams
per dose group).
In the Mix study, a master mixture was prepared by combining doses of
vinclozolin, flutamide, and procymidone that all induced a half-maximal degree
of NR (six nipples) in male offspring. This approach was chosen in order to
avoid that one single chemical contributed disproportionately to the overall
mixture effect. The resulting mixture ratio of vinclozolin, flutamide, and
procymidone was 0.62:0.02:0.36, and the master mixture contained 22.026 mg
vinclozolin, 696.6 mg flutamide, and 12.675 mg procymidon in 600 ml corn oil.
The master mixture was diluted into five dilutions termed ‘Mix1’ to ‘Mix5’.
These five solutions gave rise to the following total doses of all three chemicals
combined: 7.9, 19.7, 39.3, 70.8, or 106.2 mg/kg/day (16 dams per dose group).
The Mix study also included a vehicle-dosed control group (16 dams) and a low
and high dose of the three single compounds: vinclozolin (24.5 and 95.9 mg/kg/
day), flutamide (0.77 and 3.9 mg/kg/day), and procymidone (14.1 and 68.1 mg/
kg/day). For vinclozolin, 16 dams per dose group and 8 dams per dose group for
the latter two compounds were included. It should be noted that the low doses
of all three chemicals were combined to give one of the doses in the Mix study
(‘Mix3’, 39.3 mg/kg/day).
Animals and dosing. Time-mated young adult nulliparous Wistar rats
(HanTac:WH, Taconic Europe, Denmark, body weight approximately 200g)
were supplied at day 3 of pregnancy (gestational day [GD] 3). The day after
arrival, at GD 4, the dams were randomly distributed into groups of 8 or 16
animals with similar body weight distribution. The animals were housed and
handled as previously described (Hass et al., 2007). Test compounds and
mixtures were administered by gavage from GD 7 to the day prior to expected
birth (GD 21) and from postnatal day (PND) 1 to PND 16. Dams were weighed
daily, and the health status of dams and offspring was monitored twice daily.
All studies were divided into four blocks (one week between blocks), and each
dose group was represented equally in all four blocks.
Autopsy of male pups PND 16. The body weights of male pups were
recorded, and an autopsy was performed at PND 16. Male external genitals
were investigated, various organs were excised and weighed, and used for either
histopathology or gene expression studies. Trunk blood was taken and pooled
within litters.
Investigation of external genitals. At PND 16, the external genitals were
inspected blinded to the observer in all males from all litters. The changes were
scored on a scale from 0 to 3 in order to investigate if male external genitals
were demasculinized. The scores were as follows:
Score 0 (no effect): normal genital tubercle, with the urethral opening found at
the tip of the genital tubercle and the preputial skin intact. In the perineal
area, thick fur extends caudally from the base of the genital tubercle and
half the distance to the anus. A furless area circumscribes the anus.
Score 1 (mild dysgenesis of the external genitals): a small cavity on the
inferior side of the genital tubercle or a minor cleft in the preputial opening
is observed, estimated 0.5–1.4 on an arbitrary scale. The size of the genital
tubercle may be decreased. The furless area around the anus expands
toward the base of the genital tubercle, but thick fur is still present at the
base of the genital tubercle.
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Score 2 (moderate dysgenesis of the external genitals): the preputial cleft is
larger, estimated 1.5–2.4 on an arbitrary scale. The urethral opening is
situated halfway down toward the base of the genital tubercle (hypospadia).
Partly furless e.g., thin fur is noted in the perineal area ranging from the
base of the genital tubercle and caudally to the furless area circumscribing
the anus.
Score 3 (severe dysgenesis of the external genitals): the preputial cleft is large,
estimated 2.5–3.5 on an arbitrary scale. The urethral opening is situated
further than halfway down the inferior side of the genital tubercle to the
base of the genital tubercle. At the base of the genital tubercle, a groove
extending laterally is observed (similar to control females at PND 16). The
rat is totally furless in the entire perineal area.
Dissection and histopathology of organs. From one male per litter at PND
16, the following organs were excised and weighed: testis, epididymides,
ventral prostate, seminal vesicles, levator ani/bulbocavernosus muscle (LABC),
bulbourethral glands, adrenals, kidney, and liver. From one or two males per
litter, right or left testis was alternately fixed in Bouin’s fixative. From males in
the Mix study, the thyroid glands were excised and weighed as well. The
remaining aforementioned organs, and one testis from litters with three or more
males, were fixed in formalin. All fixed organs were embedded in paraffin, stained
with hematoxylin and eosin, and used for the histopathological evaluation.
Gene expression levels. When at least two males were in a litter, one pub
was randomly selected and its ventral prostate was weighed and stored in
RNAlater (Qiagen, Ballerup, Denmark) for gene expression analyses. The
organs were homogenized, and total RNAwas isolated using RNeasy-mini kit
and RNase-Free DNase set (Qiagen). cDNAwas synthesized from 0.5 lg total
RNA using the Omniscript Reverse Transcription kit (Qiagen) with T16
oligonucleotides and a 18S rRNA primer. Samples were quantified on the
7900HT Fast Real-Time PCR System (Applied Biosystems, Naerum, Denmark)
by standard TaqMan technology.
Expression levels of prostate-binding protein subunit C3 (PBP C3),
ornithine decarboxylase (ODC), insulin-like growth factor I (IGF-I), com-
plement component 3 (Compl.C3), testosterone-repressed prostate message
2 (TRPM-2), and AR were quantified in the prostate. Expression levels of each
target gene were normalized to the expression level of the housekeeping gene
18S rRNA. For each sample, 2-ll cDNA (1.75 ng/ll) was amplified under
universal thermal cycling parameters (Applied Biosystems) using TaqMan Fast
Universal PCR Master Mix (Applied Biosystems) in a total reaction volume of
10 ll. Three separate amplifications were performed for each gene, and when
intraassay variation was above 15%, additional amplifications were performed.
All genes were quantified from standard curves. Primers and probes for PBP
C3,ODC, IGF-1, Compl.C3, TRPM-2, AR, and 18S rRNA have previously been
published by Laier et al. (2006). The number of prostates analyzed from the
control and the Mix1 to Mix5 group was 12, 11, 12, 11, 10, and 4, respectively.
The number of prostrates from the low and high dose groups of single
chemicals (Vin, Flu, and Pro) were 12, 10, 6, 4, 4, and 6, respectively. All
prostates were from males belonging to different litters.
Statistical data analyses. The weights of male and female pups were
analyzed for all offspring. Statistical analyses of organ weights and macro-
scopic lesions were performed for one to four males per litter, and testes were
analyzed from all offspring. The numbers of litters varied for the control and
mixture groups from 11 to 13 and for the single-compound experiments from
4 to 10, respectively.
Continuous data were confirmed for normal distribution and homogeneity
(Shapiro-Wilk’s and Bartlett’s tests). Dose-response effects different from
controls were estimated by multiple testing methods (global error rate a¼ 5%,
two sided). When organ weights were analyzed, body weight was included
as covariate, and statistical analyses were always adjusted using litter as
an independent, random, and nested factor. Statistical significance was then
assessed on the basis of contrast tests. All analyses were done using the SAS
procedure PROC GENMOD, PROC MIXED, and PROC MULTTEST (SAS
version 8, SAS Institute Inc., Cary, NC). Macroscopic and histological lesions
were analyzed using Fisher’s exact test with p values adjusted by permutation.
Statistical dose-response regression analyses for body weight data (seminal
vesicle, ventral prostate, and LABC) and gene expression data (PBP C3/18S)
were carried out by applying a best-fit approach (Scholze et al. 2001). Various
nonlinear regression models (logit, probit Weibull, generalized logit) were
fitted independently to the same data set, and the best fitting model was selected
on the basis of a statistical goodness-of-fit criterion (information criterion of
Schwarz). To control for litter effects, dose-response data were analyzed by
using a generalized nonlinear mixed modeling approach (Vonesh and
Chinchilli, 1996), with litter as a random effect modifier for individual organ
weights and carried out using the SAS procedure PROC NLMIXED.
Prior to regression analysis, we analyzed whether there was a linear
relationship between organ weights and body weight based on all control
pups. This was indeed the case, and the corresponding regression lines went
through the origin within their 95% confidence belts. Therefore, individual
organ weights were normalized as the ratio between organ and body weight.
Regression analyses were done for the single compounds on pooled effect data
from the initial dose-response studies (Table 1) and the repeated doses that were
run concurrently with the mixture study (Table 2).
Under assumption of additive combination effects, a dose-response re-
lationship for the mixture was predicted using the best-fit dose-response
regression curves of the individual compounds and compared to the observed
effects. Equation 1 allows calculation of any effect dose of a mixture under the
hypothesis of dose additivity, provided the dose-response functions of all
mixture components and the mixture ratio are known
EDxmixture ¼ p1
EDx1
þ p2
EDx2
þ p3
EDx3
 1
ð1Þ
EDx1, EDx2, and EDx3 are the effect doses of vinclozolin, flutamide, and
procymidone that on their own produce the same quantitative effect x as the
mixture, and p1, p2, and p3 are the relative proportions of the corresponding
individual doses present in the total mixture dose. The statistical uncertainty for
the predicted mixture effects was determined by using the bootstrap method
(Efron and Tibshirani, 1993) and expressed as 95% confidence limits for the
predicted mean estimate.
RESULTS
Pregnancy Data, Postnatal Growth, and General Toxicity
No clinical signs of general toxicity were observed. The
maternal body weight gain from GD 7 to PND 1, pregnancy
length, litter size, birth weight of male and female offspring,
sex ratio in the litters, and pup weight gain and survival were
unaltered in all groups when compared to controls.
Malformations of the External Male Genitals
In the Mix study, external male genitals were investigated for
malformations. For all low mixture doses (Mix1–Mix3),
between 30 and 70% of the pups were diagnosed with a mild
dysgenesis (score 1). At the higher doses, moderate (score 2)
and severe dysgenesis (score 3) dominated, with up to 100% of
the animals affected in the experiments with the two highest
doses (Fig. 1A). Overall, the incidence as well as the severity of
malformations increased with increasing mixture doses. For all
three single compounds, pups with a mild dysgenesis were
observed only at the low doses, while animals with a moderate
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TABLE 1
Dose-Response Studies of Vinclozolin, Procymidone, and Flutamide in Which Pregnant Rats Were Exposed from GD 7 to PND 16. Body and Organ Weights from Male
Rat Pups PND 16 are Shown
Body
weight (g)
Testis
right (mg)
Testis
left (mg)
Epididymides
(mg)
Ventral
prostate (mg)
Seminal
vesicle (mg)
LABC
(mg)
Bulbourethral
glands (mg)
Adrenals
(mg)
Kidneys
(mg)
Liver
(mg)
Vinclozolin (mg/kg/day)
Control 34.7 ± 1.1 66.0 ± 1.5 66.4 ± 1.2 27.0 ± 1.1 16.5 ± 0.6 12.0 ± 0.9 27.0 ± 1.8 2.2 ± 0.2 10.5 ± 0.3 347 ± 14.1 895 ± 31.2
5 33.5 ± 1.2 61.1 ± 1.1 62.0 ± 1.0* 25.5 ± 3.9 13.7 ± 0.7 9.2 ± 0.1 24.0 ± 2.6 1.9 ± 0.2 10.4 ± 0.6 328 ± 19.2 855 ± 35.3
10 34.3 ± 0.8 64.7 ± 1.1 65.5 ± 1.2 21.2 ± 1.8* 15.1 ± 0.5* 10.0 ± 0.5* 27.4 ± 1.7 2.0 ± 0.2 11.3 ± 0.5 340 ± 15.4 873 ± 34.8
20 34.8 ± 1.3 68.0 ± 1.5 67.7 ± 1.6 21.8 ± 0.5** 14.8 ± 0.7* 10.3 ± 0.6* 25.0 ± 0.5 1.7 ± 0.2 10.7 ± 0.5 360 ± 18.6 906 ± 43.4
40 34.3 ± 1.1 68.5 ± 1.2 68.7 ± 1.2 22.2 ± 1.6** 15.0 ± 0.6 9.7 ± 1.0* 22.7 ± 2.0 1.5 ± 0.2 10.8 ± 0.2 344 ± 14.4 876 ±4 0.9
80 34.9 ± 0.9 66.7 ± 1.7 67.9 ± 1.7 22.3 ± 1.8** 10.5 ± 0.6** 7.3 ± 0.7** 20.4 ± 2.2* 1.1 ± 0.3* 12.8 ± 0.8** 357 ± 14.8 961 ± 29.2
160 34.1 ± 1.6 55.2 ± 2.7* 54.9 ± 2.6** 17.1 ± 1.0** 5.1 ± 1.0** 3.1 ± 0.8** 12.1 ± 1.6** ND** 12.5 ± 0.5** 334 ± 24.1 920 ± 71.2*
Flutamide (mg/kg/day)
Control 34.7 ± 1.1 66.0 ± 1.5 66.4 ± 1.2 27.0 ± 1.1 16.5 ± 0.6 12.0 ± 0.9 27.0 ± 1.8 2.2 ± 0.2 10.5 ± 0.3 348 ± 14.1 895 ± 31.2
0.5 34.1 ± 1.3 66.3 ± 1.5 65.7 ± 1.5 23.9 ± 0.7 13.8 ± 0.8* 9.9 ± 0.3* 24.9 ± 2.0 1.7 ± 0.2 9.5 ± 0.7 335 ± 16.9 895 ± 39.9
1 32.7 ± 0.6 61.8 ± 1.1 62.6 ± 1.2 22.7 ± 1.5* 13.2 ± 0.6** 11.0 ± 0.7 24.8 ± 1.9 2.2 ± 0.6 11.1 ± 0.3 326 ± 11.9 843 ± 36.0
2 34.6 ± 1.1 67.4 ± 1.6 67.8 ± 1.7 26.7 ± 1.6 10.9 ± 0.7** 9.3 ± 0.6* 22.6 ± 1.1 1.6 ± 0.1 9.9 ± 0.5 345 ± 9.8 884 ± 34.3
4 36.4 ± 0.6 69.4 ± 1.4 68.2 ± 1.4 24.1 ± 1.8 8.6 ± 0.5** 6.8 ± 1.2** 20.5 ± 2.5 1.5 ± 0.4 9.9 ± 0.5 375 ± 14.9 948 ± 42.1
8 35.6 ± 1.3 64.8 ± 1.3 64.6 ± 1.3 20.5 ± 1.2** 3.3 ± 0.4** 3.8 ± 1.0** 14.9 ± 3.6* 1.5 ± 0.1 11.9 ± 0.9 354 ± 19.6 935 ± 42.7
16 34.8 ± 1.1 56.0 ± 2.0** 56.1 ± 1.6** 17.4 ± 0.3** 2.3 ± 0.4** 2.0 ± 0.2** 11.1 ± 2.8** ND** 10.5 ± 0.9 352 ± 15.1 914 ± 28.1
Procymidone (mg/kg/day)
Control 38.5 ± 1.2 68.7 ± 1.7 68.9 ± 1.8 25.3 ± 1.2 16.6 ± 0.8 13.4 ± 1.2 24.8 ± 1.4 1.9 ± 0.1 10.9 ± 0.4 399 ± 14.3 1032 ± 27.9
5 39.3 ± 1.5 69.5 ± 1.2 69.7 ± 1.2 25.9 ± 1.5 14.7 ± 0.8 10.2 ± 0.8* 22.1 ± 2.1 1.7 ± 0.1 10.8 ± 0.7 405 ± 17.6 1031 ± 54.5
10 36.1 ± 1.4 70.0 ± 1.3* 69.8 ± 1.2* 24.6 ± 1.6 13.0 ± 0.6* 11.9 ± 0.9 20.3 ± 1.3* 1.5 ± 0.0* 9.9 ± 0.7 383 ± 23.3 923 ± 40.4
25 35.9 ± 2.5 67.0 ± 2.9 67.0 ± 3.5 20.0 ± 1.3* 10.1 ± 1.0** 8.5 ± 1.0** 23.0 ± 3.8 1.3 ± 0.2** 11.1 ± 0.8 373 ± 31.5 962 ± 83.0
50 36.8 ± 1.9 68.1 ± 2.0 68.6 ± 1.9 22.0 ± 1.6 9.1 ± 0.8** 8.4 ± 0.9** 17.4 ± 1.1** 0.9 ± 0.2** 10.9 ± 0.6 385 ± 22.8 994 ± 55.3
100 32.0 ± 1.8 61.0 ± 1.5 60.7 ± 1.6 18.4 ± 2.0** 6.2 ± 1.0** 6.6 ± 1.1** 19.7 ± 2.0 0.7 ± 0.5** 10.8 ± 0.7 333 ± 9.5 916 ± 32.6
150 36.0 ± 1.5 54.0 ± 1.6** 54.1 ± 1.8** 16.8 ± 1.6** 2.3 ± 0.4** 4.5 ± 0.9** 9.4 ± 1.9** 1.2 ± 0.4* 13.0 ± 1.2* 378 ± 22.0 1123 ± 111.8
Note. Data represent least squares means ± SEM. ND, not detectable, tissue weights were too low to measure.
The columns 2, 3, 4, 5, 9, 10, and 11 of ‘‘Vinclozolin (mg/kg/day)’’ and ‘‘Flutamide (mg/kg/day)’’ and the columns 2, 3, 5, 9, and 10 of ‘‘Procymidone (mg/kg/day)’’ represent statistical significant
effect of the covariate, body weight (p < 0.05).
Statistical significant different compared to controls (*p < 0.05) and (**p < 0.01), respectively. All statistically significant numbers are shown in bold.
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TABLE 2
Mixture Study: Five Mixtures of Vinclozolin (Vin), Procymidone (Pro), and Flutamide (Flu) Were Administered to Pregnant Rats from GD 7 to PND 16. Body and Organ
Weights from Male Rat Pups PND 16 are Shown. In Addition a Low and a High Dose of Each Single Compound Were Included in the Experiment
Group (dose
in mg/kg/day)
Body
weight (g)
Right
testis (mg)a
Left
testis (mg)a
Epididymides
(mg)a
Ventral
prostate (mg)
Seminal
vesicle (mg)a
LABC
(mg)a
Bulbourethral
glands (mg)a
Adrenals
(mg)a
Kidneys
(mg)a
Liver
(mg)a
Thyroid
gland (mg)a
Control 33.7 ± 0.9 64.4 ± 2.2 65.1 ± 2.3 25.3 ± 0.8 17.1 ± 0.9 11.0 ± 0.9 31.1 ± 1.8 2.5 ± 0.3 10.1 ± 0.3 350 ± 8.6 872 ± 29.1 4.2 ± 0.3
Mix1 (7.9) 33.7 ± 1.1 62.7 ± 2.0 63.8 ± 1.8 22.1 ± 0.8** 15.4 ± 1.4 10.2 ± 0.9 29.6 ± 1.8 1.9 ± 0.2 10.5 ± 0.5 349 ± 14.1 847 ± 30.2 4.0 ± 0.2
Mix2 (19.7) 33.9 ± 1.4 65.9 ± 1.9 66.8 ± 1.9 21.9 ± 0.7** 12.4 ± 0.5** 8.5 ± 0.7 26.7 ± 1.4 1.4 ± 0.1* 10.5 ± 0.4 357 ± 13.9 860 ± 48.5 3.6 ± 0.2
Mix3 (39.3) 32.2 ± 1.3 62.7 ± 3.2 63.7 ± 3.4 18.8 ± 0.9** 9.4 ± 0.6** 6.4 ± 0.7* 17.6 ± 1.9* 0.7 ± 0.1** 10.5 ± 0.7 330 ± 15.2 830 ± 42.8 4.0 ± 0.1
Mix4 (70.8) 30.6 ± 1.1 55.6 ± 1.8* 57.0 ± 1.9 15.9 ± 0.9** 4.8 ± 0.8** 3.8 ± 0.8** 13.7 ± 0.6** 1.2 ± ** 11.2 ± 0.3* 322 ± 16.9 843 ± 44.0* 3.6 ± 3.2
Mix5 (106.2) 32.0 ± 1.7 50.4 ± 2.7* 51.6 ± 2.4* 11.6 ± 0.8** 2.0 ± 0.6** 2.1 ± 0.5** 8.2 ± 0.9** 0.3 ± ** 11.5 ± 0.7** 321 ± 22.8 845 ± 52.5* 3.4 ± 0.2
Vin (24.5) 34.1 ± 1.9 64.7 ± 3.0 65.4 ± 3.1 21.8 ± 0.7** 13.8 ± 0.6** 9.4 ± 0.7 25.1 ± 1.4* 1.6 ± 0.2* 10.7 ± 0.6 351 ± 19.2 867 ± 57.3 3.5 ± 0.2*
Vin (95.9) 32.7 ± 1.2 60.1 ± 2.1 61.0 ± 2.1 17.2 ± 0.7** 7.9 ± 0.6** 4.9 ± 0.8** 18.7 ± 1.7** 0.6 ± 0.2** 11.5 ± 0.4* 343 ± 16.5 855 ± 38.7* 3.8 ± 0.2*
Flu (0.77) 36.4 ± 2.0 68.3 ± 3.2 68.4 ± 3.4 22.4 ± 1.1* 15.5 ± 0.5 8.3 ± 1.0 27.2 ± 2.0 2.0 ± 0.3 10.3 ± 0.7 376 ± 26.6 920 ± 58.3 4.5 ± 0.7
Flu (3.86) 37.5 ± 3.7 70.3 ± 7.3 69.6 ± 7.2 20.8 ± 2.7* 11.9 ± 1.3** 6.6 ± 1.5* 21.4 ± 2.1* 1.0 ±  10.7 ± 1.4 416 ± 55.5 1020 ± 123.6 4.5 ± 0.6
Pro (14.1) 37.1 ± 1.8 72.7 ± 3.7 72.2 ± 3.1 21.8 ± 1.0* 14.8 ± 1.4* 8.9 ± 0.9 28.1 ± 0.8 1.8 ± 0.2 10.6 ± 0.4 357 ± 22.9 959 ± 30.1 4.6 ± 0.5
Pro (68.1) 31.6 ± 1.5 57.7 ± 4.2 58.6 ± 4.2 16.1 ± 1.3** 8.8 ± 0.6* 5.9 ± 1.4* 16.8 ± 1.2** 0.1 ±  10.5 ± 0.4 338 ± 23.7 884 ± 38.5* 3.6 ± 0.4
Note. Data represent least squares means ± SEM. ‘’ Denotes that SEM is close to 0.
aStatistical significant effect of the covariate, body weight (p < 0.05).
Statistical significant different compared to controls (*p < 0.05) and (**p < 0.01), respectively. All statistically significant numbers are shown in bold.
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Mix3, a combination of 24.5 mg/kg vinclozolin, 0.77 mg/kg
flutamide, and 14.1 mg/kg procymidone, yielded a clear
increase in malformations. This response was considerably
higher than any effect observed with the individual chemicals
at the doses present in the combination.
Organ Weights
In the dose-response studies with the individual compounds,
all reproductive organ weights showed a downward trend with
increasing doses (Table 1). For vinclozolin, prostate, seminal
vesicle, and epididymides weights were significantly reduced
at 10 mg/kg and the remaining investigated organs, except
kidneys, only at the higher doses (80 and 160 mg/kg). For
prostate and seminal vesicle weights, these differences can be
explained in terms of lower data variations with consequent
lower statistical detection limits. A similar pattern became
apparent for flutamide, although for all administered doses, the
weights of the bulbourethral glands, adrenals, kidneys, and
livers could not be detected as statistically different from the
controls. For procymidone, seminal vesicle weights were af-
fected at the lowest dose (5 mg/kg), weights of prostate, LABC,
and bulbourethral glands were affected at 10 mg/kg, and
epididymides weights were reduced at 25 mg/kg. Changes in
the weight of the kidney and liver could not be identified.
In the Mix study, increasing doses both for the mixtures as
well as for the single compounds decreased the reproductive
organ weights (Table 2). A mixture dose of 19.7 mg/kg (Mix2)
reduced weights of epididymides, prostates, and bulbourethral
glands. The weight of the epididymides was the most sensitive
parameter among all analyzed reproductive organs. At the
Mix3, dose weights of all reproductive organs except for testes
were reduced. In general, all high doses of single compounds
affected reproductive organ weights, whereas low doses only
affected prostate and LABC weights in a few cases (Table 2).
Histopathological Effects
Histopathological effects in the ventral prostate, seminal
vesicles, epididymides, and in the testes were investigated in
the Mix study. The ventral prostates from 16-day-old male rats
are shown in the upper three Figures (2A for vehicle controls,
2B for mixture dose Mix4, 2C for mixture dose Mix5).
Compared to controls (Fig. 2A), the three highest mixture
doses and all high doses of the single compounds induced
a dose-dependent hypoplasia of the ventral prostate, with
a severe dysgenesis at the two highest mixture doses (Mix4
andMix5). The acini were small, and the tall cuboidal epithelial
cells lining the acini were flattened in some areas (Fig. 2B). The
interstititial tissue was enlarged, and the acini were devoid of
secretion (Fig. 2C).
A general hypoplasia was also seen in the seminal vesicle at
the two highest mixture doses (Figs. 2E and 2F). In contrast to
controls (Fig. 2D), exposed males with hypoplastic seminal
vesicles lacked large ducts with papillary and villous projec-
tions (Fig. 2E). The epithelial cells lining the duct were
flattened, sometimes more cuboidal than columnar, sometimes
even almost squamous. In Mix5, the duct was primitively
developed and was surrounded by extensive interstitial con-
nective tissue (Fig. 2F). In the epididymides, the epithelial cells
lining the tubule were occasionally small with pyknotic nuclei.
Furthermore, the cells were disarranged and the tubule had no
lumen (data not shown).
The incidence of male pups with histological alterations in
the prostates, seminal vesicles, and epididymides are summa-
rized in Figure 3, demonstrating that these three organs were all
affected at higher mixture doses (Mix4, Mix5). For epididymi-
des, data indicate a low incidence even at the lowest adminis-
tered mixture doses but no effect of the single compounds.
No changes were observed in any of the single-compound low-
dose groups for any of the three organs, and there were no
histopathological alterations in the testes in any of the groups in
the Mix study (data not shown).
Gene Expression
The mRNA levels of the five androgen-regulated genes PBP
C3, ODC, IGF-1, Compl.C3, and TRPM-2 as well as those for
the AR were investigated in ventral prostates by real-time RT-
PCR in the two dose-response studies. With the aim of
screening for altered gene expression to select biomarkers for
the Mix study, only controls and the highest doses were
examined. The experiments revealed that PBP C3 and ODC
mRNA were significantly down-regulated for vinclozolin and
procymidone, and a tendency toward down-regulation was seen
for flutamide as well. Furthermore, Compl.C3 mRNA was
significantly elevated in the prostates of rats that received
flutamide and procymidone (data not shown). In the Mix study,
all five androgen-regulated genes were investigated in the
ventral prostate for all dose levels (Fig. 4). As expected, PBP
C3, ODC, and Compl.C3mRNAwere markedly affected in the
mixture experiment. A significant down-regulation of PBP C3
mRNAwas found forMix2 doses and higher, a down-regulation
of ODC mRNA was evident at the Mix4 dose and higher, and
finally an up-regulation of Compl.C3 from the Mix2 dose. For
the single compounds, PBP C3 and Compl.C3 were affected
with the highest vinclozolin dose, PBP C3 was down-regulated
by procymidone, whereas flutamide showed no effects.
Observed versus Predicted Effect of Organ Weights and
PBP C3 Expression
Dose-response relationships for organ weights (LABC,
seminal vesicles, and prostate) and PBP C3 expression in
prostates were constructed for each of the three compounds,
vinclozolin, flutamide, and procymidone (Fig. 5, left column).
These data enabled us to calculate response curves for the
mixture of the three compounds, under the assumption of dose
addition. The anticipated (additive) responses were then
compared with the experimentally observed mixture effects
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(Fig. 5, right column). For all end points, the means of the
observed mixture effects fell within the 95% confidence inter-
val of the prediction curves, thus demonstrating good agree-
ment with the expected additive effects of the compounds. It is
safe to conclude that the overall combination effects were dose
additive in all cases.
For each of the three AR antagonists and their mixture, the
investigated end points showed comparable sensitivity. Thus,
flutamide was most effective in the dose range between 1 and
10 mg/kg and procymidone and vinclozolin between 10 and
100 mg/kg, no matter whether reproductive organ weights or
PBP C3 expression was considered. Similarly, the investigated
FIG. 2. Hematoxylin staining of reproductive organs from PND 16 male rats exposed to a mixture of the three AR antagonists vinclozolin, flutamide, and
procymidone. Ventral prostates are shown from pups of the vehicle controls (A), Mix 4 group (70.8 mg/kg) (B), and Mix 5 group (106.2 mg/kg) (C). Seminal
vesicles are shown from pups of the vehicle controls (D), Mix 4 group (E), and Mix 5 group (F). (A) In prostate from controls, large cubic to columnar epithelial
cells with large amounts of cytoplasm line the acini of various sizes. Large, distended acini lined with tall cubic epithelial cells are arranged in the center of the
gland, while the smaller and less distended acini lined with columnar epithelial cells are situated in the periphery. The acini are regular in shape and almost all acini
contain secretion. The stroma is relatively scarce. (B) In general, the gland is hypoplastic, and the acini are small. In several areas, the epithelial cells are flattened
(thin arrow). (C) In general, the gland is hypoplastic. The acini are quite small and irregular and only a few acini contain secretion. The epithelial cells are
hypotrophic. The interstitial stroma is extended. (D) Seminal vesicles of a PND 16 control male rat. Note the papillary and villous infolding of the columnar
epithelium (thick white arrow). (E) Seminal vesicles from a PND 16 male rat in Mix 4 group. The gland is hypoplastic. No papillary and villous infolding is seen.
Epithelial cells are more cubic than columnar. A large amount of stroma is present compared to the seminal vesicles in control males. (F) Seminal vesicles from
a PND 16 male rat in the Mix 5 group. The gland is hypoplastic, and only a primitive duct is visible. The epithelium lining the duct is exceedingly flattened (thick
black arrow). A large amount of interstitial stroma cells is present.
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mixture was active between 10 and 100 mg/kg for all end
points. Our previously published data show that AGD and NR
exhibited comparable sensitivity to these three chemicals (Hass
et al. 2007). Thus, all five end points of antiandrogen action,
representative of differing levels of biological complexity
(from the molecular to the organ level), appear to be equally
well suited for assessments of mixture effects.
Finally, we tested whether doses of vinclozolin, flutamide,
and procymidone that on their own were not effective or
showed only small effects could induce significant responses in
combination (Fig. 6). Administered on their own, vinclozolin
(24.5 mg/kg), flutamide (0.77 mg/kg), and procymidone (14.1
mg/kg) did generally not induce effects statistically signifi-
cantly different from vehicle-treated controls, the only ex-
ceptions being vinclozolin with respect to LABC weights (Fig.
6a) and ventral prostate weights and procymidone relative to
ventral prostate weights (Fig. 6b). However, in all cases, the
observed mixture effects were severe and statistically signif-
icant. Moreover, they were always higher than observed for the
low doses of the individual compounds and were reasonably
well predictable by dose addition.
DISCUSSION
Early work with antiandrogens focused mainly on events
surrounding AR binding and activation and has shown that
combinations of these chemicals are able to act together in an
additive fashion (Birkhoj et al., 2004; Nellemann et al., 2003).
These early studies were expanded upon by a recent paper
addressing the question as to whether there are also joint effects
with responses further removed from AR binding and activa-
tion, such as those related to male sexual differentiation (Hass
et al., 2007). In this study, a fixed mixture ratio approach was
applied for assessing combination effects on the disruption of
male sexual development as determined by alterations of AGD
and NR in newborn rat males. Using these morphological end
points as a sign of demasculinization of the males, we have
shown that vinclozolin, flutamide, and procymidone exhibited
dose additivity (Hass et al., 2007). By making use of material
from this study, we have investigated a wider range of end
points indicative of antiandrogen action in 16-day-old male
pups. The selected end points were morphological changes as
determined by reproductive organ weights, dysgenesis of male
external genitals, histological changes in the reproductive
system, and changes at the molecular level as determined by
gene expression levels in the prostate. It was our hypothesis
that the joint action of vinclozolin, flutamide, and procymidone
should also be dose additive in relation to these end points.
The results in our study show clearly that antiandrogens with
a similar mode of action (AR antagonism) work together in an
additive way for a broad spectrum of end points, ranging from
reproductive organ weights to PBP C3 gene expression in the
prostate. Our findings are consistent with the previously
reported additivity of antiandrogens on other end points such
as AR receptor activation in vitro and in vivo (Birkhoj et al.,
2004; Nellemann et al., 2003) and demasculinization of
newborn males exposed during gestation and lactation (Hass
et al., 2007). Thus, the accumulated evidence points to the fact
that receptor-mediated antiandrogenic effects follow the dose-
addition principle for various end points of differing biological
complexity, ranging from changes at the morphological level,
FIG. 3. The percentage incidence of histological alterations in ventral prostates, seminal vesicles, or epididymides in male rats pups (PND 16) is shown. The
male pups were exposed to either vehicle, five doses of the mixture of vinclozolin (Vin), flutamide (Flu), and procymidone (Pro), or to low (L) or high (H) doses of
the individual compounds. The numbers above the bars indicate the number of animals investigated in each group. The control group was set to 100%.
*Statistically significant effects compared to controls (p < 0.05).
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tissue architecture, receptor level, to changes at the gene
expression level. This is surprising, considering that the
features of the dose-addition concept lend themselves partic-
ularly to the modeling of events close to receptor binding and
molecular activation processes. At this level of biological
complexity, the basic premise of dose addition, i.e., that one
compound can be replaced by a fraction of an equieffective
dose of another chemical, is readily interpreted in terms of
molecular interactions. Our results indicate that antiandrogen
action involves effector chains that feed through to higher
levels of biological complexity without violating the principles
of dose addition. This insight may be of relevance for human
and clinical studies and has the potential to be exploited in
future biomonitoring studies.
Although the primary aim of our work was to assess the
predictability of mixture effects of antiandrogens, the results of
our study also allow assessments of the question as to whether
there are joint effects when all mixture components are present
at doses that individually do not induce detectable effects. This
phenomenon, termed ‘‘something from ‘nothing’’’ (Silva et al.,
2002), has been observed with multicomponent mixtures of
estrogenic agents in reporter-based assays (Rajapakse et al.,
2002; Silva et al., 2002), the uterotrophic assay (Tinwell and
Ashby, 2004), and vitellogenin induction in fish (Brian et al.,
FIG. 4. The expression of PBP C3, ODC, Compl.C3, or TRPM-2 mRNA in ventral prostates from male pups PND 16 is shown. Male pups were perinatally
exposed to either vehicle, five doses of the mixture of vinclozolin (Vin), flutamide (Flu) and procymidone (Pro), or to low (L) or high (H) doses of the individual
compounds. The mRNA expression was determined by real-time RT-PCR and calculated relative to the expression of the housekeeping gene 18S rRNA. Controls
were set to 100% and data represent means ± SEM. ‘a’ denotes a statistically significant difference compared to controls with p < 0.05 and ‘b’ denotes
a significance with p < 0.01.
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FIG. 5. Dose-response curves for the effects of low doses of vinclozolin, procymidone, and flutamide on weights of muscle LABC, seminal vesicles, and
prostate and PBP C3 gene expression in prostates (left column) in male pups PND 16. On the right side, the observed (data points) and predicted (solid line, with
95% confidence interval represented by broken lines) responses of the mixture assuming dose additivity are shown. All data were normalized to the mean control
value (equaling 1).
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2005). The basis of this phenomenon derives from the
theoretical assumptions that underlie the concept of dose
addition: every agent at any dose contributes, in proportion to
its toxic unit, to the overall effect of a mixture. Because every
mixture component can be replaced totally or in part by an
equal fraction of an equieffective dose of another, it does not
matter whether the individual doses are also effective on their
own. ‘‘Something from ‘nothing’’’ effects should occur even
when individual toxicants are present at doses below effect
thresholds, provided sufficiently large numbers of components
sum up to a suitably high total effect dose. The results shown in
Figure 6 support the idea that the ‘‘something from ‘nothing’’’
phenomenon also applies to the end points investigated in
this study. A combination of the low doses of vinclozolin,
flutamide, and procymidone induced an approximately 30 and
35% reduction of seminal vesicles weights and PBP C3
expression, respectively. The effects induced by each chemical
on its own did not reach statistical significance when compared
with untreated controls, and thus these data support the
‘‘something from ‘nothing’’’ phenomenon. For the other end
points, the Mix3 dose caused a more pronounced effect than
that observed with the single chemicals. Generally, these
FIG. 6. Comparison of the observed effects at the low doses of the single compounds (vinclozolin 24.5 mg/kg, flutamide 0.77 mg/kg, procymidone 14.1 mg/
kg) on the weights of muscle LABC (A), seminal vesicles (B), prostates (C), and PBP C3 gene expression (D) with the effects of Mix 3, the mixture that combines
the three chemicals at these low doses. The predicted effects of Mix 3 (dark bars) assuming additivity are shown as well. All data were normalized to the mean
control value (equaling 1).
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results show that lack of statistical significance cannot be
equated with an absence of biological effects.
In conclusion, our results show that combinations of similarly
acting antiandrogens are able to affect themale offspring of rats.
These effects can be predicted fairly accurately on the basis of
information about the potency of the individual mixture
components by using the dose-addition concept. These data
lend further support to the idea that antiandrogens act together
to produce marked joint effects when combined at doses that
individually produce small, statistically insignificant responses.
The significance of these findings for human and environmental
risk assessment must be emphasized; doses of endocrine active
chemicals, which appear to exert only small effects when
judged on their own, may induce marked responses when they
act in concert with numerous, possibly unrecognized, similarly
acting agents.
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ORIGINAL ARTICLE
Combined exposure to anti-androgens causes markedly
increased frequencies of hypospadias in the rat
S. Christiansen,* M. Scholze, M. Axelstad,* J. Boberg,* A. Kortenkamp and U. Hass*
*Department of Toxicology and Risk Assessment, National Food Institute, Technical University of Denmark, Søborg, Denmark, and The School of
Pharmacy, University of London, London, UK
Introduction
Studies have indicated that incidences of disorders in the
male reproductive system, including hypospadias in new-
born boys, have risen during the last 50 years (Toppari
et al., 2001), but the impact of human exposure to endo-
crine disrupting chemicals remains largely unknown at
present. Animal studies have shown a clear connection
between in utero exposure to endocrine disrupting chemi-
cals and adverse effects on male reproduction (Foster,
2006; Gray et al., 2006). Chemicals risk assessment is cur-
rently based on the no-observed-adverse-effect-levels for
effects of single compounds. Using this approach, single
endocrine disrupting chemicals alone may appear to be
present in human tissues at levels too low to cause con-
cern for adverse reproductive effects. However, as several
anti-androgenic chemicals have been found as mixtures
(MIX) in humans (Blount et al., 2000; Swan et al., 2005)
including children (Brock et al., 2002; Main et al., 2006),
it is crucial to elucidate the consequences of combined
exposures to anti-androgens to assess human health risks.
We have studied the effects of a MIX of three androgen
receptor (AR) antagonists, vinclozolin, flutamide (FLU),
and procymidone, on male sexual differentiation in rats
after exposure in utero and post-natally. Vinclozolin
metabolites, procymidone and FLU compete with andro-
gens for AR binding and suppress androgen-dependent
gene transcription (Simard et al., 1986; Kelce et al., 1994,
1997; Ostby et al., 1999). Common developmental effects
of all three chemicals after exposure of male rats during
development include reduced anogenital distance (AGD),
nipple retention (NR), diminished prostate, testis and
epididymal weights, and hypospadias (Gray et al., 1994;
Hib & Ponzio, 1995; Ostby et al., 1999; Hellwig et al.,
2000; McIntyre et al., 2001; Foster & McIntyre, 2002;
Miyata et al., 2002; Shimamura et al., 2002).
The joint effects observed in the male offspring before
weaning have been reported by Hass et al. (2007) and
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Summary
The incidence of hypospadias is increasing in young boys, but it remains
unclear whether human exposure to endocrine disrupting chemicals plays
a role. Risk assessment is based on estimation of no-observed-adverse-effect
levels for single compounds, although humans are exposed to combinations of
several anti-androgenic chemicals. In a mixture (MIX) study with three andro-
gen receptor antagonists, vinclozolin, flutamide and procymidone, rats were
gavaged during gestation and lactation with several doses of a MIX of the three
chemicals or the chemicals alone. External malformations of the male repro-
ductive organs were assessed on PND 47 using a score from 0 to 3 (normal to
marked) for hypospadias. Markedly increased frequencies were observed after
exposure to a MIX of the three chemicals compared to administration of the
three chemicals alone. Anogenital distance at PND 1, nipple retention at PND
13, and dysgenesis score at PND 16 were highly correlated with the occurrence
of hypospadias, and MIX effects were seen at doses where each of the individ-
ual chemicals caused no observable effects. Therefore, the results indicate that
doses of anti-androgens, which appear to induce no hypospadias when judged
on their own, may induce a very high frequency of hypospadias when they
interact in concert with other anti-androgens.
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Metzdorff et al. (2007) and were essentially dose-additive
(Table 1). A combination of doses of each chemical that
on its own did not produce significant effects, induced
marked MIX effects on AGD, NR, seminal vesicles weight
and histopathology, and PBP C3 gene expression in the
prostate, and caused marked dysgenesis of external repro-
ductive organs on PND 16.
In this paper, we broaden the range of endpoints rele-
vant to anti-androgenic action with additional results
from sexually mature male offspring. Dysgenesis of exter-
nal reproductive organs was clearly seen at PND 16, but
major events in the development of male external sex
organs occur after this time during the pubertal period.
Consequently, the aim was to assess the frequencies of
hypospadias and other external sexual malformations in
the young adult male rats. An additional aim was to
examine if the anti-androgenic effects observed in the
male pups were predictive biomarkers of external malfor-
mations observed in the young adult male rats later in
life.
Materials and methods
Animals and exposure
Time-mated nulliparous, young adult Wistar rats
(HanTac: WH; Taconic Europe, Ejby, Denmark) were
supplied at day 3 (GD 3) of pregnancy.
Table 1 Summary of effects in male rat pups exposed to flutamide (FLU), vinclozolin (VIN), procymidone (PRO), or a mixture of FLU, vinclozolin,
and procymidone (MIX) from GD 7 to PND 16. Based on Hass et al. (2007) and Metzdorff et al. (2007). Values are expressed as percent of control
values for AGD and organ weights and as increase in number for nipple retention (NR) (control value = 0.0). Values for dysgenesis of external
reproductive organs are shown as the increase in mean score (scores 0–3; control = 0) and the percentage of litters with a score larger than 1.
Statistically significant effects compared to controls are shown in bold
Endpoint
FLU
0.77 mg ⁄ kg
VIN
24.5 mg ⁄ kg
PRO
14.1 mg ⁄ kg
MIX
39.3 mg ⁄ kg Dose-additivity?
Joint effect compared to
effect of single chemicals
AGD index, PND 1, %
of control
95 97 99 77 Yes Marked joint effect; no
significant effect of single
chemicals
NR, PND 13, number 2.8 1.3 2.6 9.2 Yes (slight synergy
at high doses)
Marked joint effect; small
significant effect of single
chemicals
Right testis, PND 16,
% of control
106 100 113 97 n.a No joint effect; no significant
effect of single chemicals
Epididymides, PND 16,
% of control
89 86 86 74 n.a Marked joint effect;
significant effect of single
chemicals
Ventral prostate, PND 16,
% of control
91 81 87 55 Yes Marked joint effect; no or
small significant effect of
single chemicals
Seminal vesicles, PND 16,
% of control
75 85 81 58 Yes Marked joint effect; no
significant effect of single
chemicals
LABC#, PND 16, % of control 87 81 90 57 Yes Marked joint effect; no or
small significant effect of
single chemicals
Bulbourethral glands, PND 16,
% of control
80 64 72 28 n.a Marked joint effect; no
significant effects of FLU
and PRO, but clear
significant effect of VIN
PBP C3 expression in prostate,
PND 16, % of control
81 96 83 65 Yes Marked joint effect; no
significant effect of single
chemicals
Dysgenesis of external reproductive
organs, PND 16, mean score
0.6 0.5 0.5 1.8 n.a Marked joint effect; small
significant effect of single
chemicals
Dysgenesis of external reproductive
organs, PND 16, % with score > 1
0 0 0 54 n.a Marked joint effect; no
significant effect of single
chemicals
#Levator ani ⁄ bulbocavernosus muscles; n.a: not analysed.
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The substances used were corn oil (vehicle), vinclozolin
(VIN) and procymidone (PRO) (all from Bie & Berntsen,
Herlev, Denmark), and FLU (Sigma Aldrich, Brøndby,
Denmark).
Two selected doses of the three chemicals were applied
in parallel with the MIX experiment. The composition of
the MIX was chosen according to the equi-effective doses
of each individual component that produced a half-maxi-
mal NR (MIX ratio 31 : 1 : 18, VIN: FLU: PRO). This
step was taken to avoid that one single chemical contrib-
uted disproportionately to the overall MIX effect. The
animals were dosed by gavage from GD 7–21 and from
PND 1–16. On GD 4, the dams were distributed into
groups of animals with similar body weight distributions
(16 animals per group in control, MIX-doses of 7.9, 19.7,
39.3 and 70.8 mg ⁄kg, VIN-doses of 24.5 and 95.9 mg ⁄ kg;
8 animals per group in MIX-dose of 106.2 mg ⁄ kg, FLU-
doses of 0.8 and 3.9 mg ⁄ kg, PRO-doses of 14.1 and
61.8 mg ⁄ kg). The smaller group size for the highest MIX
group, FLU and PRO was selected, because the animals in
these groups were only to be used for the assessment of
endpoints during lactation, while those with group size
16 were designated for assessment of effects in adult off-
spring too. One randomly chosen male pup per litter was
kept after weaning from these litters.
To compensate for lack of single compounds data from
PRO and FLU in this study, results from groups of 10–12
litters exposed to PRO (25, 50 and 100 mg ⁄ kg) were
included from another study in our lab (data not pub-
lished). The animals were exposed at GD 7-PND 16 and
malformations were scored at 8 month of age. Results
from groups of 10–12 male rats (representing about 5 lit-
ters) exposed to FLU (2.5, 10 and 100 mg ⁄ kg) were
included from the literature (Miyata et al., 2002). In that
study, rats (Sprague–Dawley) were exposed from GD 14
to PND 3 and malformations in male rats were scored at
PND 60.
The animals were treated humanely and with regard
for alleviation of suffering. The animal studies were per-
formed under conditions approved by the Danish Agency
for Protection of Experimental Animals and by the in-
house Animal Welfare Committee.
Malformation score on PND 47
Malformations and variations in the external male repro-
ductive organs including cleft phallus ⁄hypospadias and
blind vaginal opening were scored on PND 47 by the
same technician who was blinded with respect to expo-
sure group.
The changes were scored on a scale from 0 to 3 using
the following criteria:
Score 0: Normal external reproductive organs.
Score 1: Slight cleft or variations of preputium, but no
hypospadias or vaginal opening.
Score 2: Clear hypospadias, but no vaginal opening.
Score 3: Marked hypospadias with exposure of the os
penis and vaginal opening.
When scoring the PRO exposed rats at 8 month of age,
the number of rats with hypospadias was counted,
whereas FLU exposed rats in Miyata et al. (2002) was
presented as percentage hypospadias (Miyata et al., 2002).
Statistics
The statistical means for AGD and NR (group mean)
were estimated by using a generalized non-linear mixed
modelling approach (Vonesh & Chinchilli, 1996), with lit-
ter as a random effect modifier for individual effect data
(see Hass et al., 2007 for more details). Scores of external
genitalia on PND 16 and PND 47 are responses that can
take values from a number of categories (multinomial
data). They were assumed to follow a multinomial distri-
bution and analysed by using a cumulative logit model
(McCullagh & Nelder, 1989): the most likely occurrence
of each score is estimated in dependence of the dose
(likelihood). For malformation data on PND 47 all four
scores were used (Fig. 2), and to maintain comparability
with external data (Fig. 1), additionally they were catego-
rized into a binary variable, with scores 0 and 1 (no hy-
pospadias) vs. scores 2 and 3 (clear and marked
hypospadias). In cases where only one score was observed
in the sample, the missing data variation prevented the
calculation of confidence intervals. All analyses were car-
ried out using the sas procedure PROC GENMOD (sas
version 8; SAS Institute Inc, Cary, NC, USA).
Results
Table 1 shows the effects of a MIX of VIN, PRO and
FLU, and of all three chemicals individually, on sexual
differentiation in male rat offspring from PND 1 to PND
16 as reported in Hass et al. (2007) and Metzdorff et al.
(2007). The MIX showed dose additivity when evaluated
in terms of AGD index, NR, accessory sex organ weights
(ventral prostate, seminal vesicles, and LABC), as well as
PBP C3 gene expression in the prostate at PND 16. Here,
we describe effects that were observed later in male off-
spring.
Malformations in adult male rats
The two highest MIX doses (39.3 and 70.8 mg ⁄ kg) and
VIN on its own (95.9 mg ⁄ kg) produced significant
increases in malformations at PND 47. More than 50% of
the animals showed clear signs of hypospadias; at the
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MIX dose of 39.3 mg ⁄ kg, around 56% (range 30–80%) of
them can be expected to have this malformation with
a statistical 95% certainty (Fig. 1). This MIX dose con-
tained 24.5 mg ⁄ kg VIN. However, when VIN was tested
on its own at this dose, none of the animals exhibited
signs of malformations (score of 0). The 39.3 mg ⁄ kg MIX
dose also contained 14.1 mg ⁄ kg PRO and 0.77 mg ⁄ kg
FLU. In a previous study, we tested PRO on its own, but
signs of malformations were not detected at a dose of
25 mg ⁄ kg. Although FLU-induced malformations at PND
47 were not tested in our lab, results communicated by
Miyata et al. (2002) showed that FLU was without obser-
vable effects in Sprague–Dawley rats at the higher dose of
2.5 mg ⁄ kg. Thus, when tested individually at doses pres-
ent in the MIX, none of the compounds showed any
signs of malformations. Yet, when combined (MIX dose
of 39.3 mg ⁄ kg), the malformation frequency (clear or
marked hypospadias) was significantly increased to 60%
(p < 0.01).
Correlations between malformation scores at PND 47,
and AGD, NR and dysgenesis score at PND 16
To assess whether early biomarkers of disruption of sex-
ual differentiation can be used to predict the occurrence
of hypospadias in later life (PND 47), we correlated anti-
androgenic endpoints in the pups, i.e. AGD, NR and the
dysgenesis score at PND 16, to the mean likelihood for
malformations at PND 47 (Fig. 2a–c). The data (Fig. 2)
are based on group means, i.e. the mean responses were
estimated for all doses and controls and then compared.
Figure 2a shows that if the male rats show an average
50% reduction of the AGD-index at PND 1, it is most
likely that after 6 weeks, a majority of them (72%) will
have at least a slight malformation at PND 47, and 25%
will even reveal marked hypospadias. If they exhibit on
average six nipples at PND 13, more than 20% of them
will present with slight malformations at PND 47, with
10% having a clear hypospadias (Fig. 2b). Comparison of
the scores for dysgenesis at PND 16 with those for mal-
formations at PND 47 (Fig. 2c) revealed a clear correla-
tion between the corresponding likelihoods. Severe signs
of dysgenesis at PND 16 in 50% of the male rats are
strongly predictive of marked hypospadias at PND 47 in
nearly all of these animals. However, signs of weak dys-
genesis at PND 16 (score 1) do not seem to be a good
early biomarker for later hypospadias, at least when the
number of affected rats is small.
Discussion
Our study has shown clearly that anti-androgens with
a similar mode of action (AR antagonism) act together in
an additive way for a broad spectrum of endpoints
assessed in rat pups before weaning (Table 1, Hass et al.,
2007; Metzdorff et al., 2007). These findings are consis-
tent with the previously reported additivity of anti-andro-
gens on other endpoints such as AR activation in vitro
and in vivo (Nellemann et al., 2003; Birkhøj et al., 2004)
and with the cumulative effects of DBP and DEHP and
of linuron and butyl benzyl phthalate reported by
(Howdeshell et al., 2007; Hotchkiss et al., 2004).
Figure 1 Malformations in male rats exposed
to a mixture of three anti-androgens. The
observed mixture effects for malformation in
adult male rats, characterized by their likeli-
hood (black dots), 95% confidence belt
(shown as error lines) and regression fit (black
line), are compared with the expected dose
response curves of the individual compounds
(symbols with corresponding curves), at the
doses present in the mixture. To enable com-
parisons with the effects of the combination,
the curves of the individual chemicals were
scaled to the levels present in the mixture.
Data for procymidone are from eight month
old male rats, data for flutamide are from
(Miyata et al., 2002). The likelihood for
malformations presented here are for clear
and marked malformations (scores 2 and 3).
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There is good evidence that combined administration
of anti-androgens may lead to marked effects on AGD,
NR, reproductive organ weights, PBP C3 gene expression
in the prostate and pronounced dysgenesis of external
reproductive organs at PND 16, even when the compo-
nents are present at levels below doses associated with
observable effects (Hass et al., 2007; Metzdorff et al.,
2007). This phenomenon has also been observed with
multi-component MIXs of estrogenic agents in reporter-
based assays (Rajapakse et al., 2002; Silva et al., 2002), the
uterotrophic assay (Tinwell & Ashby, 2004), and vitelloge-
nin induction in fish (Brian et al., 2005).
The results in Fig. 1 indicate that similar low dose MIX
effects also apply to malformations (hypospadias) in
adults that are the consequence of disruption of male sex-
ual differentiation during development. A combination of
24.5 mg ⁄ kg ⁄day VIN, 0.77 mg ⁄ kg ⁄day FLU and
14.1 mg ⁄ kg ⁄day PRO induced hypospadias in 56% of the
male offspring, whereas the frequency after exposure to
24.5 mg ⁄ kg VIN alone was similar to the untreated con-
trols (0%).
Unfortunately, the frequencies of hypospadias on PND
47 induced by FLU and PRO individually at the dose lev-
els present in the 39.3 mg ⁄ kg MIX exposure were not
investigated directly in the same study, because animals
from these dose groups were not kept after weaning. We
have bridged this gap by making comparisons with his-
torical data on PRO from our own lab, and with litera-
ture reports about FLU (Miyata et al., 2002). Even at
a dose considerably higher (25 mg ⁄ kg) than present in
the MIX (14.1 mg ⁄kg), PRO did not produce observable
malformations at PND 47. Similarly, FLU lacked the abil-
ity to cause such effects at 2.5 mg ⁄ kg (Miyata et al.,
2002), a dose approximately three times higher than that
administered in the MIX (0.77 mg ⁄ kg). Thus, we have
good reason to believe that the frequencies of hypospadias
produced by PRO and FLU individually at the levels pres-
ent in the MIX would have been 0% at the doses applied
in the MIX. This line of argumentation is further sup-
ported by considering the similarities in the mode of
action of three anti-androgens, which led to quite similar
anti-androgenic effects in the pups (Table 1, Hass et al.,
2007; Metzdorff et al., 2007). The MIX effects seen here
Figure 2 (a–c). Relationships between early anti-androgenic effects
and malformations in male rats at PND 47. Shown are combination
effects of vinclozolin, flutamide and procymidone, characterized by
their likelihoods for three malformation scores, in relation to a %
reduction in AGD-index (a) (control male = 0%, female = 100%), an
average nipple retention at PND 13 (b) and the likelihood for dysgene-
sis at PND 16 (c). Group means are derived from this study with four
mixture doses of three anti-androgens and two doses of vinclozolin.
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clearly exceed predictions of independent action, because
56% is much higher than the sum of 0% + 0% + 0%.
In studies with single chemicals (finasteride and linuri-
on), it has been shown earlier that changes in AGD
(Bowman et al., 2003) and NR (McIntyre et al., 2002) are
highly predictive of permanent malformations of the male
reproductive system. Here, we demonstrate that early
effects in pups that arose from exposure to MIXs of anti-
androgens are also good predictors of the malformations
observable later in adult and sexually mature male rats
(Fig. 2a–c).
In conclusion, our results show that doses of anti-
androgens, which induced no hypospadias when judged
on their own, may cause a very high frequency of hypo-
spadias when they interact in concert with other similarly
acting anti-androgens. The significance of these findings
for human and environmental risk assessment must be
emphasized, because they clearly indicate that risk assess-
ment based on NOAELs for single anti-androgens alone
underestimates the risk for hypospadias and other adverse
anti-androgenic effects.
In addition, changes in the early biomarkers; AGD,
NR and dysgenesis PND 16 could predict malformations
in the adult male rat. This should be taken into account
in future risk assessments of individual chemicals and
MIXs.
Acknowledgements
Majken Dalgaard, Dorte Hansen, Lillian Sztuk, Heidi Let-
ting, Birgitte Møller Plesning, Ulla El-Baroudy and Trine
Gejsing are thanked for their excellent technical assis-
tance. This work was supported by the European Com-
mission, and financially supported by the European
Union as part of the EDEN-project ‘Endocrine Disrupt-
ers: Exploring Novel Endpoints, Exposure, Low Dose-
and Mixture-Effects in Humans, Aquatic Wildlife and
Laboratory Animal’ (QLK4-CT-2002-00603), and by the
Danish Research Council grant no. 2107-04-0006.
References
Birkhøj, M., Nellemann, C., Jarfelt, K., Jacobsen, H., Andersen,
H. R., Dalgaard, M. & Vinggaard, A. M. (2004) The
combined antiandrogenic effects of five commonly used
pesticides. Toxicology and Applied Pharmacology 201, 10–20.
Blount, B. C., Silva, M. J., Caudill, S. P., Needham, L. L.,
Pirkle, J. L., Sampson, E. J., Lucier, G. W., Jackson, R. J. &
Brock, J. W. (2000) Levels of seven urinary phthalate metab-
olites in a human reference population. Environmental
Health Perspectives 108, 979–982.
Bowman, C. J., Barlow, N. J., Turner, K. J., Wallace, D. G. &
Foster, P. M. D. (2003) Effects of in utero exposure to
finasteride on androgen-dependent reproductive development
in the male rat. Toxicol Sci 74, 393–406.
Brian, J. V., Harris, C. A., Scholze, M., Backhaus, T., Booy, P.,
Lamoree, M. et al. (2005) Accurate prediction of the
response of freshwater fish to a mixture of estrogenic chemi-
cals. Environmental Health Perspectives 113, 721–728.
Brock, J. W., Caudill, S. P., Silva, M. J., Needham, L. L. &
Hilborn, E. D. (2002) Phthalate monoesters levels in the
urine of young children. Bulletin of Environmental
Contamination and Toxicology 68, 309–314.
Foster, P. M. D. (2006) Disruption of reproductive develop-
ment in male rat offspring following in utero exposure to
phthalate esters. International Journal of Andrology 29,
140–147.
Foster, P. M. & McIntyre, B. S. (2002) Endocrine active agents:
implications of adverse and non-adverse changes. Toxicologic
Pathology 30, 59–65.
Gray, L., Ostby, J. S. & Kelce, W. R. (1994) Developmental
effects of an environmental antiandrogen: the fungicide
vinclozolin alters sex differentiation of the male rat. Toxicol-
ogy and Applied Pharmacology 129, 46–52.
Gray, L., Wilson, V., Stoker, T., Lambright, C., Furr, J.,
Noriega, N., Howdeshell, K., Ankley, G. T. & Guillette, L.
(2006) Adverse effects of environmental antiandrogens and
androgens on reproductive development in mammals.
International Journal of Andrology 29, 96–104.
Hass, U., Scholze, M., Christiansen, S., Dalgaard, M., Vingg-
aard, A. M., Axelstad, M., Metzdorff, S. B. & Kortenkamp,
A. (2007) Combined exposure to anti-androgens exacerbates
disruption of sexual differentiation in the rat. Environmental
Health Perspectives 115 (Suppl. 1), 122–128.
Hellwig, J., van Ravenzwaay, B., Mayer, M. & Gembardt, C.
(2000) Pre- and postnatal oral toxicity of vinclozolin in
Wistar and Long-Evans rats. Regulatory Toxicology and
Pharmacology 32, 42–50.
Hib, J. & Ponzio, R. (1995) The abnormal development of
male sex organs in the rat using a pure antiandrogen and
a 5 alpha-reductase inhibitor during gestation. Acta Physio-
logica, Pharmacologica Et Therapeutica Latinoamericana 45,
27–33.
Hotchkiss, A. K., Parks-Saldutti, L. G., Ostby, J. S., Lambright,
C., Furr, J., Vandenbergh, J. G. & Gray, L. E., Jr. (2004)
A mixture of the ‘‘antiandrogens’’ linuron and butyl benzyl
phthalate alters sexual differentiation of the male rat in
a cumulative fashion. Biology of Reproduction 71, 1852–
1861.
Howdeshell, K. L., Furr, J., Lambright, C. R., Rider, C. V.,
Wilson, V. S. & Gray, L. E., Jr. (2007) Cumulative effects of
dibutyl phthalate and diethylhexyl phthalate on male rat
reproductive tract development: altered fetal steroid
hormones and genes. Toxicological Sciences 99, 190–202.
Kelce, W. R., Monosson, E., Gamcsik, M. P., Laws, S. C. &
Gray, L. E. (1994) Environmental hormone disruptors:
evidence that vinclozolin developmental toxicity is mediated
Hypospadias in rats exposed to anti-androgen mixture S. Christiansen et al.
6
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Publishing Ltd • International Journal of Andrology 31, 1–7
by antiandrogenic metabolites. Toxicology and Applied
Pharmacology 126, 276–285.
Kelce, W. R., Lambright, C. R., Gray, L. E. & Roberts, K. P.
(1997) Vinclozolin and p,p’-DDE alter androgen-dependent
gene expression: in vivo confirmation of an androgen recep-
tor-mediated mechanism. Toxicology and Applied Pharmacol-
ogy 142, 192–200.
Main, K., Mortensen, G. K., Kaleva, M. M., Boisen, K. A.,
Damgaard, I. N., Chellakooty, M. et al. (2006) Human
breast milk contamination with phthalates and alterations of
endogenous reproductive hormones in infants three months
of age. Environmental Health Perspectives 114, 270–276.
McCullagh, P. & Nelder, J. A. (1989) Generalized linear mod-
els, 2nd edn. Chapman and Hall, London.
McIntyre, B. S., Barlow, N. J. & Foster, P. M. D. (2001)
Androgen-mediated development in male rat offspring
exposed to flutamide in utero: permanence and correlation
of early postnatal changes in anogenital distance and nipple
retention with malformations in androgen-dependent
tissues. Toxicological Sciences 62, 236–249.
McIntyre, B. S., Barlow, N. J. & Foster, P. M. (2002) Male rats
exposed to linuron in utero exhibit permanent changes in
anogenital distance, nipple retention, and epididymal
malformations that result in subsequent testicular atrophy.
Toxicological Science 65, 62–70.
Metzdorff, S. B., Dalgaard, M., Christiansen, S., Axelstad, M.,
Hass, U., Kiersgaard, M. K., Scholze, M., Kortenkamp, A. &
Vinggaard, A. M. (2007) Dysgenesis and histological changes
of genitals and perturbations of gene expression in male rats
after in utero exposure to antiandrogen mixtures. Toxicologi-
cal Sciences 98, 87–98.
Miyata, K., Yabushita, S., Sukata, T., Sano, M., Yoshino, H.,
Nakanishi, T., Okuno, Y. & Matsuo, M. (2002) Effects of
perinatal exposure to flutamide on sex hormones and
androgen-dependent organs in F1 male rats. The Journal of
Toxicological Sciences 27, 19–33.
Nellemann, C., Dalgaard, M., Lam, H. R. & Vinggaard, A. M.
(2003) The combined effects of vinclozolin and procymi-
done do not deviate from expected additivity in vitro and in
vivo. Toxicological Sciences 71, 251–262.
Ostby, J., Kelce, W. R., Lambright, C., Wolf, C. J., Mann, P. &
Gray, L. E. Jr. (1999) The fungicide procymidone alters
sexual differentiation in the male rat by acting as an andro-
gen-receptor antagonist in vivo and in vitro. Toxicology and
Industrial Health 15, 80–93.
Rajapakse, N., Silva, E. & Kortenkamp, A. (2002) Combining
xenoestrogens at levels below individual no-observed effect
concentrations dramatically enhances steroid hormone
action. Environmental Health Perspectives 110, 917–921.
Shimamura, M., Kodaira, K., Kenichi, H., Ishimoto, Y., Tam-
ura, H. & Iguchi, T. (2002) Comparison of antiandrogenic
activities of vinclozolin and -camphorquinone in androgen
receptor gene transcription assay in vitro and mouse in
utero exposure assay in vivo. Toxicology 174, 97–107.
Silva, E., Rajapakse, N. & Kortenkamp, A. (2002) Something
from ‘‘nothing’’ – eight weak estrogenic chemicals combined
at concentrations below NOECs produce significant mixture
effects. Environmental Science and Technology 36, 1751–1756.
Simard, J., Luthy, I., Guay, J., Belanger, A. & Labrie, F. (1986)
Characteristics of interaction of the antiandrogen flutamide
with the androgen receptor in various target tissues.
Molecular and Cellular Endocrinology 44, 261–270.
Swan, S. H., Main, K. M., Liu, F., Steward, S. L., Kruse, R. L.,
Calafat, A. M. et al. (2005) Decrease in anogenital distance
among male infants with prenatal phthalate exposure.
Environmental Health Perspectives 113, 1056–1061.
Tinwell, H. & Ashby, J. (2004) Sensitivity of the immature rat
uterotrophic assay to mixtures of estrogens. Environmental
Health Perspectives 112, 575–582.
Toppari, J., Kaleva, M. & Virtanen, H. E. (2001) Trends in the
incidence of cryptorchidism and hypospadias, and methodo-
logical limitations of registry-based data. Human Reproduc-
tion Update 7, 282–286.
Vonesh, E. & Chinchilli, V. M. (1996) Linear and Nonlinear
Models for the Analysis of Repeated Measurements. Marcel
Dekker, New York.
S. Christiansen et al. Hypospadias in rats exposed to anti-androgen mixture
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Publishing Ltd • International Journal of Andrology 31, 1–7 7
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Paper V 
 
Christiansen S, Scholze M, Dalgaard M, Vinggaard AM, Axelstad M, Kortenkamp A & Hass U. 
Synergistic disruption of external male sex organ development by a mixture of four anti-androgens. 
Submitted to Environmental Health Perspectives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Synergistic disruption of external male sex organ 
development by a mixture of four anti-androgens 
 
 
Sofie Christiansen1^), Martin Scholze2^), Majken Dalgaard 1), Anne Marie Vinggaard1), 
Marta Axelstad 1), Andreas Kortenkamp 2*), and Ulla Hass 1*) 
 
1) National Food Institute, Technical University of Denmark 
Dept. of Toxicology and Risk Assessment 
Mørkhøj Bygade 19 
DK-2860 Søborg 
Denmark 
Tel.: +45 72 34 75 44 
 
2) The School of Pharmacy 
University of London 
29-39 Brunswick Square 
London WC1N 1AX 
United Kingdom 
Tel.: +44 20 7753 5908 
 
*) Correspondence regarding reproductive toxicity should be addressed to Ulla Hass, fax 
number +45 72347699, email address ulha@food.dtu.dk, communications regarding 
mixture effect assessments to Andreas Kortenkamp, fax number +44 20 77535811, email 
address andreas.kortenkamp@pharmacy.ac.uk 
 
^ Both authors contributed equally. 
 1
Acknowledgements 
Dorte Hansen and Ulla El-Baroudy are thanked for laboratory technical assistance and Eva 
Ferdinandsen and Elise Navntoft for the dosing of animals. This work was financially 
supported by the EU (EDEN-project “Endocrine Disrupters: Exploring Novel Endpoints, 
Exposure, Low Dose- and Mixture-Effects in Humans, Aquatic Wildlife and Laboratory 
Animal”, QLK4-CT-2002-00603) and the Danish Environmental Protection Agency.  
 
Disclaimers, competing interests 
There are no competing interests to declare. 
 
Short running head 
Synergisms with a mixture of four antiandrogens 
 
Key words 
Cumulative effects, combination effects, mixtures, dose addition, independent action, anti-
androgens, male sexual differentiation, phthalates, azole fungicides, DEHP, vinclozolin, 
finasteride, prochloraz 
 
 
 2
 Abbreviations 
AGD   Anogenital distance 
AR   Androgen receptor 
DEHP   di(2-ethylhexyl) phthalate 
DHT   Dihydrotestosterone 
ECHA   European Chemicals Agency 
FIN   Finasteride 
GD   Gestational day 
LABC   levator ani/bulbocavernosus muscles  
NOAEL   No-observed-adverse-effect-level 
NR   Nipple retention 
NR NOAEL  No-observed-adverse-effect-level based on nipple retention 
PND   Postnatal day 
PZ   Prochloraz 
U.S EPA   United States Environmental Protection Agency  
VZ   Vinclozolin 
 3
Outline manuscript section headers 
Abstract 
Introduction 
Results 
Discussion 
Conclusions 
References 
Tables 
Figure legends 
Figures 
Supplementary material 
 4
Abstract 
Background: By disrupting the action of androgens during gestation, certain chemicals 
present in food, consumer products and the environment can induce irreversible 
demasculinisation and malformations of sex organs among male offspring. However, the 
consequences of simultaneous exposure to such chemicals are not well described, 
especially when they exert their actions by differing molecular mechanisms. 
Objectives: To fill this gap, we investigated the effects of mixtures of a widely used 
plasticizer, di(2-ethylhexyl) phthalate (DEHP), two fungicides present in food, 
vinclozolin and prochloraz, and a pharmaceutical, finasteride, on landmarks of male 
sexual development in the rat, including changes in anogenital distance, retained nipples, 
sex organ weights and malformations of genitalia. These chemicals were chosen because 
they disrupt androgen action according to differing mechanisms of action. 
Results: Strikingly, the effect of combined exposure to the selected chemicals on 
malformations of external sex organs was synergistic, and the observed responses were 
greater than would be predicted from the toxicities of the individual chemicals. In relation 
to other hallmarks of disrupted male sexual development, including changes in anogenital 
distance, retained nipples, and sex organ weights, the combined effects were dose 
additive. When the four chemicals were combined at doses equal to no-observed-adverse-
effect levels estimated for nipple retention, significant reductions in anogenital distance 
were observed in male offspring. 
Conclusions: Since unhindered androgen action is essential for human male development 
in foetal life, these findings are highly relevant to human risk assessment. Evaluations 
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that ignore the possibility of combination effects may lead to considerable 
underestimations of risks associated with exposures to chemicals that disrupt male sexual 
differentiation.
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Introduction 
Certain chemicals present in consumer products and food can disrupt the action of 
steroidal androgens in foetal life, with irreversible consequences for later life stages. In 
the male rat, exposure to such chemicals during development leads to incomplete 
masculinisation and severe malformations of the reproductive organs (Christiansen et al. 
2008; Welsh et al. 2008; Wilson et al. 2008). Because of their relevance to humans, the 
effects seen in laboratory animals have led to considerable concerns. Substances of 
interest, so-called anti-androgens, include certain phthalates, widely used as plasticizers, 
a few pharmaceutical agents and some fungicides. Phthalates have attracted significant 
recent interest, with several regulatory bodies currently engaged in risk assessments 
(U.S.EPA, ECHA). As yet, these regulatory efforts have taken little account of realistic 
human exposures which is to several phthalates and other anti-androgens simultaneously 
(Blount et al. 2000; Brock et al. 2002; Swan et al. 2005; Main et al. 2006; Marsee et al. 
2006). With the aim of exploring the effects of combined exposure to anti-androgens 
during gestation, we have conducted large developmental toxicity mixture experiments in 
the rat with the widely used phthalate di(2-ethylhexyl) phthalate (DEHP), the fungicides 
vinclozolin and prochloraz, present in certain food items, and the pharmaceutical 
finasteride. 
These anti-androgens were selected because they can disrupt male sexual differentiation 
in different ways, by a variety of mechanisms. In foetal life, testosterone is a key driver 
of the differentiation of the Wolffian duct system into the vas deferens, epididymis, 
seminal vesicles and external genitalia. Phthalates with a certain ester side-chain length, 
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such as DEHP, can lower testosterone levels by interfering with the uptake of cholesterol 
precursors into foetal Leydig cells, where testicular androgen production takes place 
(Foster et al. 1980). In the rat, malformations of internal reproductive organs (epididymis, 
testes) are the consequence. Because dihydrotestosterone (DHT) is derived from 
testosterone through enzymatic conversion by 5α-reductase, lower testosterone 
concentrations also affect the development of tissues that rely on DHT (prostate and 
external genitalia). DHT is further required for the regression of nipple anlagen in male 
rats and for the growth of the perineum to produce the normal male anogenital distance 
(AGD) which is longer than in females (Imperato-McGinley et al. 1985; Imperato-
McGinley et al. 1986). Due to reduced DHT levels in the wake of suppressed testosterone 
synthesis, retained nipples and feminised AGDs are also seen in male rats exposed to 
phthalates in foetal life (Carruthers and Foster 2005; Jarfelt et al. 2005; Foster 2006). 
Vinclozolin metabolites impact more directly on the development of DHT-dependent 
tissues by antagonising the androgen receptor (AR)  (Gray et al. 1999b; Wolf et al. 2000; 
Hass et al. 2007). In disrupting the enzymatic conversion of testosterone to DHT through 
inhibition of 5α-reductase  (Clark et al. 1990; Bowman et al. 2003), the pharmaceutical 
finasteride induces an effect spectrum similar to AR antagonists. Finally, the fungicide 
prochloraz disrupts androgen action by inhibiting the conversion of progesterone to 
testosterone and by antagonising the AR (Vinggaard et al. 2002; Noriega et al. 2005; 
Vinggaard et al. 2005; Laier et al. 2006; Blystone et al. 2007).  
One goal of mixture toxicology is to anticipate the toxicities of untested mixtures of 
chemicals when only the effects of individual components are known (Könemann 1980; 
Könemann 1981; Hermens et al. 1984; Hermens et al. 1985). A second issue of relevance 
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to regulatory toxicology concerns the question of mixture effects at low doses. A view 
that has persisted over the last 30 years is that combination effects do not occur when 
each chemical is present at doses equal to their no-observed-adverse-effect-levels 
(NOAELs), or lower (COT 2002; VKM 2008). This is thought to be the case with 
chemicals that act through different mechanisms, but not with agents that target similar 
molecular structures. The NOAEL is the highest tested dose at which no statistically or 
biologically adverse effects can be identified and is used in regulatory toxicology as a 
point of departure for establishing “acceptable” exposures for humans. 
In experiments with rats, the combined effects of anti-androgens that act through similar 
mechanisms, such as several phthalates that suppress testosterone synthesis (Howdeshell 
et al. 2008) or some AR antagonists (Hass et al. 2007; Metzdorff et al. 2007; Christiansen 
et al. 2008) were additive and could be predicted well from the effects of the individual 
mixture components. In addition, combination effects were observed at NOAELs for the 
individual chemicals. Less obvious is how combinations of anti-androgens behave that 
disrupts androgen action via different mechanisms. Here, we have investigated the 
predictability of the combined effects of mixtures composed of dissimilarly acting anti-
androgens. In pursuing this aim, we decided to combine all chemicals in the mixture in 
proportion to their NOAELs for effects on male sexual development. This was done in 
order to investigate whether combination effects occur at individual doses of the 
compounds that are of regulatory relevance, and in order to avoid the testing situation 
that one or two chemicals contributed disproportionately to an overall combination effect. 
Our motivation was not to model environmental intakes. A second goal was to test 
whether combination effects occur at doses around the NOAELs for the single chemicals, 
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and this also forced us to combine the antiandrogens in proportion to their relative 
potency, rather than their environmental exposures.  
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Materials and Methods 
Chemicals 
VZ (vinclozolin), CAS No. 50471-44-8, purity 99%, FIN (finasteride), CAS No.98319-
26-7, purity 99.8%, DEHP (di-(2-ethylhexyl)phthalate), CAS No. 117-81-7, purity 99% 
and PZ (prochloraz), CAS No. 67747, purity 99.6%, were obtained from VWR - Bie & 
Berntsen (Herlev, Denmark). The chemicals were dissolved in corn oil (used as vehicle) 
from VWR - Bie & Berntsen. 
Animals and dosing 
Time-mated nulliparous, young adult Wistar rats (HanTac:WH, Taconic Europe, Ejby, 
Denmark, body weight approximately 200 g) were supplied at day 3 of pregnancy. The 
day following mating was designated gestational day (GD) 1, and postnatal day (PND) 0 
was the day of birth. On the day after arrival at our facilities (GD 4), the dams were 
randomly distributed into groups of 16 or 8 animals with similar body weight (bw) 
distributions. A complete rodent diet for growing animals ALTROMIN 1314 (Soy- and 
alfalfa-free ALTROMIN GmbH, Lage, Germany) and acidified tap water (to prevent 
microbial growth) was provided ad libitum.  
Test chemicals and mixtures were administered by gavage from GD 7 to the day before 
expected birth (GD 21), and from PND 1 until PND 16 to the dams (see also Fig. 1), in a 
dosing volume of 2 ml/kg bw. The dose levels and group sizes are shown in Table 1. The 
studies were performed using 4 blocks (with one week in between), and all dose groups 
were equally represented in the blocks. 
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Studies and dose levels 
Before the mixture experiment was conducted, dose-response studies for each individual 
chemical were carried out. The dose ranges were chosen with the aim to cover the entire 
range of responses, from no apparent effects to complete feminisation, as determined by 
measurements of AGD and NR. The same approach was used in our first mixture study 
described in Hass et al 2007 (Hass et al. 2007). The dose levels selected for the dose-
response studies were based on the reductions of AGD and increases of NR reported for 
vinclozolin  (Gray et al. 1999b; Gray et al. 1994; Hellwig et al. 2000; Shimamura et al. 
2002; Hotchkiss et al. 2002), finasteride (Clark et al. 1990; Hib and Ponzio 1995; 
Bowman et al. 2003), DEHP (Gray et al. 1999a; Gray et al. 2000; Jarfelt et al. 2005) and 
prochloraz (Laier et al. 2006). In order to gain information about the variability of effects 
between studies as well as to facilitate a direct comparison within the mixture study, 
selected doses of vinclozolin, finasteride, DEHP and prochloraz were run in parallel with 
the mixture experiment. 
Two or three selected doses of the four chemicals were administered in parallel with the 
mixture doses. For the mixture experiment, a master mixture was prepared by combining 
doses of the four chemicals at a fixed ratio of 500:1:300:500 (vinclozolin: finasteride: 
DEHP: prochloraz). Thus, the master mixture contained 15,000 mg vinclozolin, 30.0 mg 
finasteride, 9,000 mg DEHP, and 15,000 mg prochloraz in 600 ml corn oil. The master 
mixture was administered undiluted in a dosing volume of 2 ml/kg bw to achieve the 
highest mixture dose of 130.1 mg/kg/day. Dilutions of 1 : 1 and 1 : 9 in corn oil were 
prepared for the two remaining dose groups of 65.05 mg/kg/day and 13.01 mg/kg/day, 
respectively. The lowest mixture (mix1) dose was equivalent to the sum of the chemicals’ 
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individual NOAELs for retained nipples (NR NOAEL), the middle dose (mix2) was 5-
fold higher, and the highest dose (mix3) 10-fold this values. The animals were treated 
humanely and with regard for alleviation of suffering. The animal studies were performed 
under conditions approved by the Danish Agency for Protection of Experimental Animals 
and by the in-house Animal Welfare Committee. 
Determination of changes in male sexual differentiation 
Anogenital distance and nipple retention 
In all studies, AGD and NR were recorded by the same technician who was blinded with 
respect to exposure groups. After birth, all live pups in the litter were weighted, sexed 
and AGD measured using a stereomicroscope. The crude AGD measurements were 
transformed to the AGD-index, by dividing AGD by the cube root of body weight. The 
cube root was used, because this converts a three-dimensional endpoint (weight) into a 
one-dimensional such as the AGD  (Gallavan et al. 1999; Gray et al. 1999a). This ratio 
assumes that the relationship between AGD and transformed body weight is directly 
proportional and linear. In order to assess the validity of this assumption, we explored the 
influence of using the transformed body weight as a co-variable in statistical analyses. 
However, relevant differences between these two approaches were not detected. In the 
interest of keeping the model parameters as simple as possible (to avoid over-
parameterisation), we decided to base all statistical analyses on the AGD-index.  
The body weights of all pups were recorded on PND 13, together with the number of 
nipples/areolas, defined as a dark focal area (with or without a nipple bud) located where 
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nipples are normally present in female offspring. Females normally have 12 nipples, but 
may in a few cases show up to 14.  
Organ weights and assessment of malformations in external genitalia 
On PND 16, 2-6 male pups per litter were weighed and their external genitalia were 
inspected. From one male per litter, the following organs were excised and weighed: 
testis, epididymis, ventral prostate, seminal vesicles, levator ani/bulbocavernosus muscles 
(LABC), bulbourethral glands, adrenals, kidney, and liver. In all examined males the 
level of demasculinisation was scored on a scale from 0 to 3, with the observer being 
blinded with respect to dose group. The scores were as follows: 
Score 0 (no effect): Normal genital tubercle, with the urethral opening found at the tip of 
the genital tubercle and the preputial skin intact. In the perineal area, thick fur extended 
caudally from the base of the genital tubercle and half the distance to the anus. A furless 
area circumscribed the anus. 
Score 1 (mild dysgenesis of the external genitals): A small cavity on the inferior side of 
the genital tubercle or a minor cleft in the preputial opening was observed, estimated 0.5-
1.4 on an arbitrary scale. The size of the genital tubercle was decreased. The furless area 
around the anus expanded towards the base of the genital tubercle, but thick fur was still 
present at the base of the genital tubercle. 
Score 2 (moderate dysgenesis of the external genitals): The preputial cleft was larger, 
estimated 1.5-2.4 on an arbitrary scale. The urethral opening was situated half-way down 
towards the base of the genital tubercle (hypospadia). Partly furless areas or thin fur was 
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noted in the perineal area extending from the base of the genital tubercle and caudally to 
the furless area circumscribing the anus. 
Score 3 (severe dysgenesis of the external genitals): The preputial cleft was large, 
estimated 2.5-3.5 on an arbitrary scale. The urethral opening was situated further than 
half-way down the inferior side of the genital tubercle to the base of the genital tubercle 
(hypospadia). At the base of the genital tubercle a groove extending laterally was 
observed (similar to control females at PND 16). The male rat was totally furless in the 
entire perineal area. 
For data analysis, we simplified the scoring into a binary variable, with scores 0 and 1 (no 
cleft phallus) vs. scores 2 and 3 (clear and marked cleft phallus). 
One male per litter was kept after weaning in order to examine the external reproductive 
organs after sexual maturation. On PND 47 malformations and changes of the external 
male reproductive organs including cleft phallus/hypospadia and blind vaginal opening 
were scored by the same technician, again blinded with respect to exposure groups. The 
changes were scored on a scale from 0 to 3 using the following criteria: 
Score 0: Normal external reproductive organs.  
Score 1: Slight cleft or variations of preputium, but no hypospadia or blind vaginal 
opening.  
Score 2: Clear hypospadia, but no blind vaginal opening. 
Score 3: Marked hypospadia with visible os penis and blind vaginal opening. 
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For data analysis, we transformed the scoring into a binary variable, with scores 0 and 1 
(no hypospadias) vs. scores 2 and 3 (clear and marked hypospadias). 
Data normalisations 
To enable pooling of the data from our studies, which in some cases stretched over a 
period of three years, all regression analyses had to be based on normalised values. For 
organ weight data from PND 16, a linear relationship between organ weights and body 
weight was found, based on all control pups, with the corresponding regression lines 
going through the origin within their 95% confidence belts. Therefore, individual organ 
weights were normalized to the ratio between that organ and body weight. Furthermore, 
slight differences in control values between studies were controlled for by standardizing 
these ratios to 1 by dividing them through the mean normalised organ weight from 
unexposed male pups. In a similar way, we standardized the absolute AGD indices to 
relative values between 1 (no effect on male AGD index) and zero (complete 
feminisation). The mean AGD indices from unexposed male and female pups were used 
to define the minimum and maximum responses, respectively. Assessment of nipple 
retention yielded count values which were used without further normalisation. Data 
normalisations were also not necessary in the case of the binary malformation scores. 
Dose-response analyses 
By using Shapiro-Wilk’s and Bartlett’s tests, we confirmed that all continuous effect 
measurements were normally distributed and homogeneous. Responses different from 
controls were assessed for statistical significance by multiple testing methods (global 
error rate α= 5%, two-sided). Statistical analyses were always adjusted for litter effects, 
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by using litter as an independent, random and nested factor, and statistical significance 
was then assessed on the basis of multiple contrast tests (see  (Hass et al. 2007) for more 
details). When organ weights were analysed, body weight was included as covariate. 
Statistical dose response regression analyses were conducted in the same way for the 
mixture and the single compounds, with analyses for the single compounds based on 
pooled effect data from initial dose-response studies and the repeated doses that were run 
concurrently with the mixture study (Supplementary Table 1a, b). A best-fit approach  
(Scholze et al. 2001) was used, where various non-linear regression models (logit, probit 
Weibull, generalized logit) were fitted independently to the same data set. The best fitting 
model was selected on the basis of a statistical goodness-of-fit criterion (information 
criterion of Schwarz). To control for litter effects, dose-response data were analysed by 
using a generalized non-linear mixed modelling approach (Vonesh and Chinchilli 1996), 
with litter as a random effect modifier for individual effect data. The dose-response 
functions in Scholze et al.  (Scholze et al. 2001) assume monotonic increasing 
relationships, but some endpoints studied here yielded monotonic decreasing forms. To 
maintain compatibility with the dose-response functions described by Scholze et al., the 
upper and lower asymptotes in the regression models were exchanged, i.e. the θmax in the 
corresponding functions of Table 2 were used as θmin and vice versa. 
All analyses were carried out using the SAS procedure PROC GENMOD, PROC 
MIXED and PROC MULTTEST (SAS version 8, SAS Institute Inc, Cary, NC, USA). 
More details can be found in (Hass et al. 2007; Metzdorff et al. 2007; Christiansen et al. 
2008). 
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 Calculation of mixture effect predictions 
In making predictions for the combined effects of DEHP, vinclozolin, prochloraz and 
finasteride, we assumed that each chemical in the mixture did not exacerbate or diminish 
the effects of the other components. Mixture effects according to such “no interaction” or 
“additivity” assumptions can be calculated by using two alternative concepts, dose 
addition and independent action. Dose addition looks at mixture effects in terms of a 
“dilution principle”. It assumes that one chemical can be replaced totally or in part by an 
equal fraction of an equi-effective dose of another, without diminishing the overall 
combined effect (Loewe and Muischnek 1926). Dose addition is often used for mixtures 
composed of chemicals that act through a similar or common mode of action (U.S.EPA 
1986; U.S.EPA 2000; COT 2002; U.S.EPA 2002). Its application to the present mixture 
of four anti-androgens appeared justified because all chemicals affect the biological 
action of testosterone and DHT during development, and produce common effect 
outcomes. However, it can be argued with equal justification that the similarity 
assumption characteristic for dose addition is not applicable to the chosen mixture 
because its component chemicals produce their effects by a diversity of molecular 
mechanisms. For this reason, we also employed the alternative concept of independent 
action to construct additivity expectations. Independent action assumes that the joint 
effects of a combination of agents can be calculated by adopting the statistical concept of 
independent events (Bliss 1939). It is viewed as appropriate for mixtures of chemicals 
with diverse modes of action (COT 2002), however, dose addition and independent 
action can yield very similar additive mixture effect predictions at low doses. 
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Under the assumption of dose additive combination effects, or those conforming with 
independent action, dose-response relationships for the mixture with defined mixture 
ratio (“fixed mixture ratio design (Faust et al. 2001)) were predicted using the best-fit 
dose-response regression curves of the individual compounds (Supplementary Table 1a-
c) and compared to the observed mixture effects (Table 3). Equation 1 allows the 
calculation of any effect dose of a mixture under the hypothesis of dose additivity. For 
this, the dose response functions of all mixture components and the mixture ratios have to 
be known: 
    
1
31 2 4
mixture
1 2 3 4
pp p pEDx
EDx EDx EDx EDx
     
. (1). 
Here, EDx1, EDx2, EDx3 and EDx4 are the effect doses of vinclozolin, finasteride, DEHP 
and prochloraz that on their own produce the same quantitative effect x as the mixture, 
and p1, p2, p3 and p4 are the relative proportions of the corresponding individual doses 
present in the total mixture dose. The individual effect doses were derived from the dose 
response functions for the compounds by using their inverse functional form. If no effects 
were observed in the tested dose ranges for the ith compound, we replaced the missing 
information about the effect doses in equation 1 (EDxi) by assuming either a maximal 
effect (realised mathematically by approximating a “Yes/No” step function through a 
dose-response logit function with model steepness parameter θ2=40) or no effect at all 
(i.e. setting the ratio pi/EDxi in equation 1 to zero) for doses exceeding those that were 
actually tested. This procedure had to be adopted in order to calculate mixture effect 
predictions for genital malformations, because two of the mixture components, DEHP 
and prochloraz, were without observable effects on their own (see Supplementary Tables 
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1a and 1c. These two extrapolation scenarios define the only possible prediction range of 
mixture responses according to equation 1. 
The basic version of independent action has been formulated under the simple 
assumption that the susceptibilities of the individuals of an at-risk-population to different 
dissimilarly acting mixture compounds are not correlated with each other (Bliss 1939). 
For a four-component mixture this is can be defined by the equation 
           mix 1 2 3E(c ) 1 1 E(c ) 1 E(c ) 1 E(c ) 1 E(c )         4 . (2) 
Here, E(c1), E(c2), E(c3), and E(c4) denote the fractional effects (x %) caused by the 
individual concentrations c1, c2, c3, and c4 of vinclozolin, finasteride, DEHP and 
prochloraz, respectively, and E(cmix) is the total effect of the mixture concentration 
cmix. The individual effects of mixture compounds E(ci) are estimated from the 
concentration response functions determined for single substances (Table 1 main text). 
Eq. 2 cannot be transformed into an explicit term for an effect mixture dose EDxmix, but 
the value of EDxmix satisfying the equation for a given effect level x has to be computed 
by an iterative procedure. The statistical uncertainty for the predicted mixture effects and 
effect doses was determined by using the bootstrap method (Efron and Tibshirani 1993) 
and expressed as 95 % confidence limits for the predicted mean estimate. Differences 
between predicted and observed effect doses were deemed statistically significant when 
the 95 % confidence belts of the prediction did not overlap with those of the 
experimentally observed mixture effects. 
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Results 
Dose-response analyses with the individual mixture components 
Of all indicators of disrupted sexual development, alterations in retained nipples were the 
most sensitive endpoint, with effects becoming noticeable at the lowest doses. Changes in 
anogenital distance were almost as sensitive, followed by reductions in prostate and 
LABC weights and genital malformations. Finasteride was by far the most potent 
chemical. It exhibited dose-response curves with very shallow gradients for all endpoints. 
Vinclozolin was active in a narrower dose range, with correspondingly steeper dose-
response curves, and the characteristics of prochloraz and DEHP fell between these 
extremes. Information about details of the dosing schedules and the timing of the various 
studies can be found in Table 1. A summary of dose-response descriptors for all tested 
chemicals, based on the pooled outcome of studies conducted before the mixture 
experiment, is given in Supplementary Tables 1a-c; responses seen with individual 
chemicals tested in parallel with the mixture are described in Supplementary Table 2.  
Prediction of mixture effects 
The mixture ratio used in our study was chosen to reflect the NOAELs of each chemical 
alone, judged in relation to the most sensitive indicator of disruption of male sexual 
development, increased nipple retention (NR). These NOAELs, here referred to as NR 
NOAELs, were estimated in our laboratory before the mixture experiment began (3 
mg/kg/day for DEHP, 5 mg/kg/day for vinclozolin, 5 mg/kg/day for prochloraz and 0.01 
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mg/kg/day for finasteride). Our NR NOAELs agree well with the doses that are currently 
used as starting points for establishing tolerable exposures for humans (Supplementary 
Table 3). Mixture doses equal to the sum of NR NOAELs (13.01 mg/kg/day), and 
multiples of 5 (65.05 mg/kg/day) and 10 (130.1 mg/kg/day) were tested experimentally.  
Additive mixture effects 
Figure 2 shows how the experimentally observed responses compared with the additive 
effects of the mixture that were predicted by using dose addition. The effect outcomes of 
the mixture experiment are listed in Supplementary Table 2. Changes in anogenital 
distance, retained nipples, prostate weights and weights of LABC were chosen as the 
endpoints for evaluation. In all cases, the overall effect means measured for all litters 
came close to the predicted response curves. There was considerable overlap between the 
mean responses for individual litters and the anticipated effects. To evaluate the 
relationship between predictions and observations statistically, we used the effect 
variability seen with the single chemicals to estimate statistical confidence limits for the 
predicted (dose additive) effect doses by applying boot-strapping methodology. A 
statistically significant difference between anticipated and observed effect dose could not 
be detected, except for doses that caused changes in anogenital distance at an effect level 
of 60% change relative to controls (Table 3). The mixture effect doses predicted by using 
the alternative concept of independent action did not differ significantly from those 
anticipated by dose addition. For all endpoints, the observed mixture effects were 
stronger than the responses attributable to any one single mixture component. Our data 
suggest that the combined effects of DEHP, vinclozolin, prochloraz and finasteride are 
 22
additive when the evaluation is based on changes in anogenital distance, retained nipples, 
prostate weights and weights of LABC. 
Synergistic effects for genital malformations 
Strikingly, a completely different picture emerged when we evaluated dysgenesis of the 
external genitalia in young male rats at PND 16 and PND 47. Administration of the 
mixture led to severe malformations at PND 16 characterised by enlarged preputial clefts, 
and urethral openings located towards the base of the genital tubercle (not at its top, as 
normally expected), similar to hypospadias in humans. A laterally extending groove 
resembling a vaginal opening was often found at the base of the genital tubercle. The 
number of males affected by these abnormalities at PND 16 was scored and expressed as 
likelihood for severe malformations (Supplementary Table 2, Fig. 3). Milder signs of 
genital dysgenesis, such as small cavities appearing on the inferior side of the genital 
tubercle, minor clefts in the preputial opening or small genital tubercles, were not taken 
into account. At the lowest tested mixture dose, none of the effects classed as severe 
malformations were noted. At the second highest mixture dose, 26% of the animals were 
affected, but at the highest tested mixture dose virtually all animals (94%) showed severe 
malformations. Similar malformation rates for hypospadias, including exposure of the os 
penis and blind vaginal opening became apparent at PND 47. At the doses included in the 
mixture, none of the chemicals alone induced malformations, with the exception of 
vinclozolin at 50 mg/kg/day, where a low frequency was observed (Supplementary Table 
2). 
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Based on the dose-response data for the individual chemicals (pooled data from previous 
studies and tests conducted concurrently with the mixture experiment), we calculated the 
probability for malformations at PND 16 according to dose addition and independent 
action. We found that both these concepts underestimated the observed effects by a 
considerable margin (Fig. 3). Because DEHP and prochloraz on their own were without 
detectable effects at doses between 3 and 30 mg/kg/day, and 5 and 50 mg/kg/day, 
respectively, we based the calculation of combination effects according to dose addition 
on two conjectures: We either assumed that DEHP and prochloraz did not contribute to 
the overall combination effect, or that their individual effects approached 100% as the 
doses increased beyond the tested range. These two assumptions define the extremes of 
the dose addition prediction area shown in Figure 3. The independent action prediction 
yielded a curve that was congruent with the high-dose extreme of the dose addition 
prediction area. Malformations occurred at three-fold lower mixture doses than foreseen 
by both these models (Fig. 3, Table 3). Because of the steepness of the underlying dose-
response curve, this meant that a dose anticipated as being without effect produced 
malformations in 94% of the animals. Evaluated in relation to the low dose margin of the 
dose addition prediction area, the mixture caused malformations at two-fold lower doses. 
The experimentally observed responses clearly exceeded the predictions, suggesting that 
the combined effect of DEHP, vinclozolin, prochloraz and finasteride is synergistic with 
respect to genital malformations. 
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Combination effects at doses around NOAELs 
Next, we tested the idea that mixture effects should not occur when mixed-mode 
chemicals are combined at dose levels close to those that are used as points of departure 
in regulatory toxicology for the estimation of safe human exposures, such as NOAELs. 
DEHP, vinclozolin, prochloraz and finasteride were combined at doses equal to their 
individual NR NOAELs for changes in nipple retention that were estimated in studies 
preceding the mixture experiment. At these doses, none of the individual chemicals on 
their own produced changes in anogenital distance, yet the combination induced a 
statistically significant effect, well predicted by dose addition and independent action. At 
10-fold higher doses, the effects of vinclozolin and finasteride alone (but not of DEHP 
and prochloraz) reached statistical significance. At this point, the combination strongly 
exacerbated the response, with anogenital distances half-way between those expected in 
normal males and normal females (Fig. 4 A). 
With weight changes of the prostate and LABC as the endpoints for assessment, the NR 
NOAEL combination did not produce effects distinguishable from untreated controls. 
When tested in parallel with the mixture, finasteride on its own yielded statistically 
significant responses for nipple retention at its previously estimated NR NOAEL of 0.01 
mg/kg/day. This prevented us from conducting the above analyses in relation to retained 
nipples. 
Combined at their NR NOAELs, the four anti-androgens did not provoke appreciably 
elevated malformation rates, but the 5-fold higher mixture dose induced malformations in 
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around 25% of the males. At this point, none of the single chemicals alone is likely to 
have led to observable malformations (Supplementary Table 2, Fig. 3). Even at the levels 
present in the 10-fold higher mixture dose, three of the single chemicals alone did not 
induce discernable effects, but vinclozolin on its own caused malformations in about 5% 
of the affected males. Yet, when combined at the doses equivalent to 10-fold NR 
NOAELs, malformations in nearly all male offspring were seen (Fig. 4 B). Similar results 
became apparent when malformations were analysed later in the rats lives, at PND 47 
(Fig. 4 C). 
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Discussion 
In relation to certain sensitive hallmarks of disrupted male sexual differentiation, dose 
addition and independent action proved to be equally useful tools for the prediction of 
combination effects of mixed-mode anti-androgens. For alterations in anogenital 
distance, retained nipples and prostate and LABC weight changes, reasonable 
anticipations of mixture effects could be achieved on the basis of dose-response 
descriptors for the individual mixture components. That this occurred despite the 
different mechanistic premises that underlie the two prediction concepts is coincidental. It 
is not explained by toxicological features, but by the mathematical algorithms behind 
each concept (Drescher and Bödeker 1995). Our results hold the promise that predictions 
of combination effects could be obtained in the future without conducting mixture 
experiments, by employing modelling approaches. Considering the high cost and long 
duration of reproductive toxicity studies, this might greatly aid efforts in regulatory 
toxicology. 
All the more remarkable are our observations of synergistic interactions with genital 
malformations such as hypospadias. Because the affected males derived from dams that 
were dosed in the same way as those where additive effects on characteristics of 
disrupted sexual development were found, dosing errors cannot account for the deviations 
from expected additivity. Assessment errors introduced during the scoring of the 
malformations, leading to the detection of false positives, are also not a likely 
explanation, since we disregarded the milder forms of malformations which may be 
 27
difficult to diagnose. The fact that finasteride, when tested concurrently with the mixture, 
proved to be more effective in inducing retained nipples than seen previously also does 
not explain the synergism. There were no changes in the chemicals’ effectiveness of 
causing malformations. As with the other endpoints used in this study, androgens are key 
factors for the normal development of the penis from the genital tubercle. The observed 
malformations, including hypospadias, are indicative of disruption of androgen action. 
This leads to a failure of the folding and fusion that needs to take place during 
development to form normal genitals. Judged from this viewpoint, the mixture would be 
expected to induce additive effects on malformations too. Although we are unable to 
offer a mechanistic explanation for the synergisms, it seems that genital development in 
the rat is also governed by events that differ in important details from those operating 
during the regression of nipple anlagen and the formation of normal AGD. Genital 
tubercle development generally also includes embryonic processes requiring embryonic 
cell movements and apposition of the two advancing tissues  (Gupta and Goldman 1986).  
Recent studies suggest a previously unidentified role for the progesterone receptor, 
possibly interacting with the androgen receptor, in disturbed genital tubercle development  
(Willingham et al. 2006). In utero exposure to natural or synthetic progesterones can 
increase the risk of hypospadias in male mice and intake during pregnancy in humans has 
been associated with increased risks of hypospadias  (Carmichael et al. 2005; Willingham 
et al. 2006). Prochloraz, one of the chemicals in the mixture, was able to induce increased 
testicular progesterone concentrations in male rat foetuses, and this effect occurred at 
lower dose levels than those present in the mixture investigated here (Vinggaard et al. 
2005; Laier et al. 2006; Blystone et al. 2007). Thus, elevated progesterone levels due to 
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prochloraz exposure may have a role in the synergisms with severe hypospadias that we 
observed in our study. Generally, synergisms may  be caused by toxicokinetic 
interactions, where due to interference with uptake or metabolism one or several mixture 
components are present at levels higher than would occur if these chemicals were given 
individually. However, we regard toxicokinetic interactions as an unlikely explanation, 
because dose-additivity was found for all other hallmarks of male sexual disruption, 
including endpoints assessed around or at the same developmental age as the genital 
malformations.  
Our findings echo the observations made by Rider and colleagues (Rider et al. 2008) 
where a mixture of butyl benzyl phthalate, di-n-butyl phthalate, DEHP, vinclozolin, 
procymidone, linuron, and prochloraz induced frequencies of hypospadias that exceeded 
those predicted by dose addition. As in our study, other endpoints that were investigated 
simultaneously revealed dose-additive effects. Rider et al. used historical data for the 
calculation of additivity expectations. Because these data were sometimes based on 
dosing regimens that differed from those used in the mixture experiments, there is a 
degree of uncertainty as to whether the excess malformations in that study represent a 
true synergism. Our evaluations are based on dose-response data for single chemicals and 
mixtures from one large study, and therefore substantiate concerns about the synergistic 
induction of genital malformations by mixed-mode of action anti-androgens. 
The effects seen in the rat are of high relevance to the human and deserve serious 
consideration in ongoing risk assessment efforts. Very recently, changes in anogenital 
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distance (Swan et al. 2005) and suppressions of androgen synthesis have been associated 
with anti-androgen exposure in humans (Main et al. 2006). 
A point that requires careful consideration is whether additive or even synergistic effects 
between antiandrogens are also likely to occur at low, environmentally relevant exposure 
levels. Human intakes of DEHP alone are estimated to be about 1000 times lower than 
used in our study (NRC 2008), and similar low exposures can be expected for the other 
chemicals that we used. It is clear that our developmental rat model would not have 
produced any responses, had we combined all mixture components at such low levels. 
However, human populations are not just exposed to four antiandrogens, but to a larger, 
although poorly defined number of chemicals with a potential to interfere with androgen 
action. Under dose addition, theory predicts that all these chemicals, even at low levels, 
act together to produce combined effects (Kortenkamp et al. 2007). Whether this effect 
will become observable in human populations, depends on the number of chemicals, their 
levels and the sensitivity of humans relative to the rat.  
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Conclusions 
Our findings contradict the widely held view (COT 2002; VKM 2008 ) that chemical 
mixtures exhibiting varied modes of action are without combination effects at levels near 
supposed dose thresholds, used in regulatory toxicology as points of departure for the 
derivation of tolerable human exposures. Were this assumption correct, we should not 
have been able to observe alterations in anogenital distance when all four chemicals were 
combined at their NR NOAELs. Despite the synergism which we detected, the NR 
NOAEL combination did not produce appreciably elevated malformation rates, but this 
may be due to the lower sensitivity of this endpoint. It is likely that a mixture composed 
of a larger number of anti-androgens would have produced malformations at 
correspondingly lower doses, approaching NR NOAELs. Our observations show that the 
use of NOAELs as points of departure in risk assessment may lead to underestimations of 
risk when exposure is to several anti-androgens with common effect outcomes, regardless 
of mechanism. This highlights the deficiencies of the predominant chemical-by-chemical 
approach in risk assessment. It is necessary to supplant current procedures by moves 
towards taking account of mixture effects, and our results underline the importance of 
such a paradigm change. 
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Tables 
Table 1. Studies, groups, doses and number of time-mated animals per group 
Study (No.) Groups and doses No. mated per group 
(pregnant) 
(1) Vinclozolin 
dose-response and 
prochloraz range 
finding 
Control: vehicle-dosed  
Vinclozolin: 5, 10, 20, 40, 80 or 160 mg/kg/day  
Prochloraz; 50 or 150 mg/kg/day 
16 (13) 
8 (6-8) 
8 (6-8) 
(2) Finasteride and 
DEHP, dose-
response 
 
Control: vehicle-dosed 
Finasteride: 0.001, 0.01, 0.1, 1, 10 or 100amg/kg/day  
DEHP: 10, 30, 100, 300, 600 or 900 mg/kg/day  
16 (15) 
8/10 (7-9) 
8(6-8) 
(3) Prochloraz and 
DEHP, dose-
response 
 
Control: vehicle-dosed 
Prochloraz: 5, 10, 25, 50, or 100 mg/kg/day 
DEHP: 3, 10, 30, or 100 mg/kg/day 
16(15) 
8(5-8) 
16/8(6-8/14) 
(4) Mixture study 
of vinclozolin, 
finasteride, DEHP 
and prochloraz, 
Mixture ratio 
5: 0.01:3: 5 
Control: vehicle-dosed 
Mixture: 13.01, 65.05 or 130.10 mg/kg/day 
Vinclozolin: 5b or 50d mg/kg/day 
Finasteride: 0.01b or 0.1d mg/kg/day 
DEHP: 3 b, 15c or 30 d mg/kg/day 
Prochloraz: 5 b, 25 c or 50 d mg/kg/day 
 
16 (13) 
16 (11-16) 
8 (7-8) 
8 (6) 
8 (5-7) 
8 (6-7) 
a This dose of finasteride induced perinatal death and low pup weight and had to be 
decreased to 50 mg/kg bw/day from PND1-3 (block 1) and from GD 18 (block 2), from 
GD 11 (block 3), and in block 4 the dams received 50 mg/kg bw/day during the whole 
dosing period. 50mg/kg bw/day was used for the data analysis b Dose of single chemical 
present in the 13.01 mg/kg bw/day mixture dose. c Dose of the single chemical included 
in the 65.05 mg/kg mixture dose. d Dose of the single chemical included in the 130.10 
mg/kg mixture dose. 
Table 2.  Statistical uncertainty of predicted and observed effect doses for the mixture of 
DEHP, vinclozolin, prochloraz and finasteride. 
 Effect doses for the mixture [mg/kg/day] 
Effect Observed a Predicted by DA b Predicted by IA c 
level Mean 95% CI Mean 95% CI Mean 95% CI 
  Relative AGD index      
90 % 11.8 [4.3;34.7] 12.2 [0.3;53.8] 12.3 [0.2;58.2] 
60 % 77.1 [59.4;99.8] 195.6 [147.2;262.3] 214.3 [179.2;250.6] 
  Number of nipples/areolas     
3 10.6 [6.5;15.3] 8.8 [5.6;13.6] 6.7 [4.1;13.5] 
6 23.3 [17.0;29.4] 25.8 [16.8;35.7] 25.1 [16.8;41.4] 
Organ weights in relation to the controls  
  Ventral Prostate (mg) 
90% 44.7 [13.9;79.3] 44.6 [6.2;65.2] 24.4 [0.1;68.6] 
60% 103.7 [78.9;130.5] 162.1 [128.6;226.5] 148.4 [98.4;200.8] 
  LABCd (mg) 
90% 51.0 [19.3;81.9] 48.1 [3.5;78.3] 25.9 [0.02;93.1] 
60% 118.9 [93.9;152.1] 179.7 [142.8;325.3] 176.2 [109.1;252.8] 
 Likelihood for malformation at PND16 (cleft phallus) 
10% 25.5 [21.0;31.2] 96.5 – 133.1e 140.0 – 140.1 e 
50% 37.5 [32.6;44.6] 149.1 – 226.2 e 226.2 – 226.4 e 
All predicted effect doses statistically significantly different from the observed effect doses are shown in 
bold; 
a Effect doses as calculated from the dose response functions given in Table 2a;b 
b DA – dose addition, predicted effect doses are based on pooled data from studies for vinclozolin, 
prochloraz, finasteride and DEHP and were calculated from the respective dose response functions given in 
Table 2; 
c IA – independent action, predicted effect doses are based on pooled data from studies for vinclozolin, 
prochloraz, finasteride and DEHP and were calculated from the respective dose response functions given in 
Table 2; 
d: LABC – Levator ani/bulbocavernosus muscles;  
e: No pups with malformations were observed for the tested doses of DEHP and prochloraz. For this reason, 
the calculation of expected mixture effect was based on two conjectures: For doses exceeding the tested dose 
range, we assumed that effects were absent, or that they reached maximal response. These two worst-case 
extrapolations define the only possible range of effects and were used to calculate the predicted effect doses 
for the mixture. 
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Legends to Figures 
Figure 1 
Outline of the study design adopted for dose-response analyses of anti-androgens and 
their mixtures. 
Mated dams (orange arrow) were dosed from gestational day (GD) 7 to postnatal day 
(PND) 16 (green bar). Male offspring (brown arrow) were examined for multiple signs of 
disrupted sexual development, including anogenital distance (AGD) on PND 1, retained 
nipples (PND 13), weights of prostate and levator ani/ bulbocavernosus muscles (LABC) 
(PND 16) and malformations of the genital organs (PND 16, 47). 
  
Figure 2 
Prediction and assessment of combination effects of anti-androgens with mixed modes 
of action on hallmarks of male sexual development in the rat. 
Multiple doses of a combination of DEHP, vinclozolin, prochloraz and finasteride with a 
mixture ratio of 3: 5: 5: 0.01 were administered to dams throughout gestation. Their male 
offspring were investigated for A, changes in anogenital index at PND 1, B, weight 
changes of the levator ani/ bulbocavernosus muscles (LABC) at PND 16, normalised in 
relation to body weights and untreated controls, C, number of retained nipples at PND 13 
and D, weight changes of ventral prostates at PND 16, normalised to body weight and 
untreated controls. Black circles are means of individual litters, and red circles the group 
means of all investigated litters, with their standard errors (red error bars). The predicted 
 39
mixture effects (green solid curves) were derived by using dose addition, with their 95% 
confidence belts (broken green lines). Total mixture doses are given.  
 
Figure 3 
Synergistic effects on induction of genital malformations. 
Combinations of DEHP, vinclozolin, prochloraz and finasteride (mixture ratio as in Fig. 2) 
were given to dams. Their male offspring was evaluated for the likelihood of induction of 
genital malformations at PND 16, including enlarged preputial clefts, and urethral openings 
located towards the base of the genital tubercle, similar to hypospadias in humans. Black 
dots are the mean likelihood of these malformations, based on 10-15 litters per group, with 
their 95% confidence intervals. The blue solid line is the best-fit regression model 
(Weibull) with 95% confidence belt (broken blue lines). The green curves marking the 
edges of the green shaded area are the lower and upper estimates of combination effects 
according to dose addition. The grey curve overlaying the upper bound of the dose addition 
prediction area depicts the combined effects predicted by using independent action. Total 
mixture doses are given. 
 
Figure 4 
Combination effects at low doses of DEHP, vinclozolin, prochloraz and finasteride. 
Dams were dosed with 5 mg/kg/d vinclozolin (VZ), 0.01 mg/kg/d finasteride (FIN), 5 
mg/kg/d prochloraz (PZ) and 3 mg/kg/d DEHP. These doses are the NOAELs estimated for 
nipple retention (NR NOAEL). Male offspring were evaluated for A, changes in anogenital 
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distance, B, genital malformations at PND 16, and C, genital malformations at PND 47. 
Grey bars show results in control males and females, red bars are the responses seen after 
administration of each chemical alone. The red bars labelled “mixture” are the observed 
effects of the combination of individual NR NOAELs (left panels), or those seen after 
administration of a 10-fold higher dose (right panels). The green bars are predicted dose 
additive effects (DA), blue bars those anticipated according to independent action (IA). 
Error bars are 95% confidence intervals, stars denote statistically significant effects 
compared to controls.  
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Supplementary Table 1a. Statistical dose-effect descriptors for pooled single and mixture exposures – nipple retention and normalized AGD 
index 
Dose Response Function Effect doses (mg/kg/day) Max. observed 
Substance RM a 1 ˆ 2ˆ  3ˆ  min maxˆ  medium low mean effect 
Nipple retention     ED6 b [CI] ED3 b [CI]  
vinclozolin G.Logit -5.72 4.97 7.80 0 12 42.5 [36.0;45.9] 30.2 [25.9;33.2] 11.8 
finasteride Logit 3.25 2.09 - 0 12 0.028 [0.016;0.047] 0.008 [0.004;0.02] 9.5 
DEHP Logit -4.22 1.32 - 0 12 1598   [612;11680] 234 [127;583] 5.2 
prochloraz BC-logit -2.81 0.20 0.32 0 12 199  [99;714] 60.4 [34.0;93.1] 4.4 
mixture Logit -4.38 3.09 - 0 13 23.3 [17.0;29.4] 10.6 [6.5;15.3] 11.6 
AGD index (normalized to the controls)  ED60 c [CI] ED90 c [CI]  
vinclozolin Weibull -9.97 4.94 - 0 1 76.1 [65.0;86.6] 36.5 [22.1;52.8] 25% 
finasteride Logit -0.99 0.62 - 0 1 8.63 [1.83;94.7] 0.34 [0.19;0.57] 60% 
DEHP Weibull -6.85 1.89 - 0 1 1945  [913; n.d.] 275 [41;1639] 86% 
prochloraz Logit -12.00 4.95 - 0 1 219  [151;6314] 95.4 [39.2;147.7] 80% 
mixture Logit -10.51 1.70 - 0 592 77.1 [59.4;99.8] 11.8 [4.3;34.7] 37% 
a RM – Regression models as defined in  (Scholze et al. 2001); 31 2ˆ ˆ ˆ, ,   – Statistical estimates of model parameters, given for doses expressed as 
mg/kg/day (rounded values); – upper model asymptote; maxˆ min – fixed lower model asymptote; b ED6, ED3 – Effect doses for 6 and 3 nipples, 
calculated from the respective dose response function; c ED60, ED90 – Effect doses for 60 % and 90 % normalized AGD index, calculated from 
the respective dose response function; CI – 95 % confidence intervals for mean effect doses given in mg/kg/day. 
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Supplementary Table 1b. Statistical dose-effect descriptors for pooled single and mixture exposures - organ weights and 
occurrences of malformation from male PND16 rat pups 
 
Dose Response Function Effect doses (mg/kg/day) Max observed  
Substance RM a 1 ˆ 2ˆ  3ˆ  min maxˆ  ED60 b [CI] ED90 b [CI] mean effect 
Ventral Prostate (mg, normalized to the controls) 
vinclozolin logit -7.96 3.94 - 0 0.99 81.1 [66.9;97.4] 27.2 [14.4;47.7] 33% 
finasteride logit -2.02 0.69 - 0 1.00 216.7 [69.3;1965.6] 0.54 [0.02;6.28] 67% 
DEHP G.logit I -9.93 2.44 0.996 0 1.00 2169 [n.d;n.d.] 114.1 [12.7;426.2] 71% 
prochloraz logit -8.58 3.31 - 0 0.99 292 [n.d.;n.d.] 79.2 [4.9;531.8] 80% 
mixture logit -10.18 4.85 - 0 1.00 103.7 [78.9;130.5] 44.7 [13.9;79.3] 48% 
LABCc (mg, normalized to the controls) 
vinclozolin logit -8.32 3.80 - 0 0.99 120.1 [95.4;190.8] 39.4 [16.0;73.6] 47% 
finasteride logit -1.64 0.78 - 0 0.99 38.6 [10.8;651.8] 0.18 [0.01;7.86] 64% 
DEHP logit -3.82 0.59 - 0 1.00 604000 [n.d.;n.d.] 619 [11;13337] 75% 
prochloraz logit -9.55 4.13 - 0 1.00 164 [n.d;n.d.] 60.1 [15.8;113.7] 79% 
mixture logit -9.76 4.53 - 0 1.02 118.9 [93.9;152.1] 51.0 [19.3;81.9] 56% 
Malformationd (likelihood, %) at PND16 ED50 e [CI] ED10 e [CI]  
vinclozolin logit -21.98 11.3 - 0 1 87.7 [78.5;103.2] 56.1 [45.8;74.4] 78% 
finasteride logit -2.27 1.78 - 0 1 18.8 [7.2;62.5] 1.1 [0.3;7.5] 70% 
mixture Weibull -14.68 7.39 - 0 1 37.5 [32.5;44.6] 25.5 [21.0;31.2] 92% 
a RM – Regression models as defined in  (Scholze et al. 2001); 31 2ˆ ˆ ˆ, ,   – Statistical estimates of model parameters, given for doses expressed as 
mg/kg/day (rounded values);  – upper model asymptote; maxˆ min – fixed lower model asymptote; b ED60, ED90 – Effect doses for 60 % and 90 % 
normalized organ weights, calculated from the respective dose response function; CI – 95 % confidence intervals for mean effect doses given in 
mg/kg/day; n.d. – not determined, c Levator ani/bulbocavernosus muscles; d enlarged preputial clefts and hypospadias; e ED10, ED50 – Effect doses for a 
10 % and 50 % likelihood of a malformation occurring, calculated from the respective dose response function.  
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Supplementary Table 1c. Occurrences of genital malformations at PND16 in male rat pups after administration of vinclozolin, finasteride, 
DEHP and prochloraz to pregnant rats from GD7 to PND16. Results from 2-3 independent studies are shown (number of pups and litters 
examined in brackets). 
   Dose (mg/kg/day)      
vinclozolin Controls 5 10 20 24.5 40 50 80 95.9 160 
Study1 0% (40;13) 0% (24;5) 0% (21;6) 0% (32;7) -- 0% (19;7) -- 30.3% (33;8) -- 75% (12;6) 
Study 2 0% (36;13) -- -- -- 0% (37;13) -- -- -- 77.8% (36;11) -- 
Mixture 
studya 0% (31;13) 0% (18;5) -- -- -- -- 4.3% (23;7) -- -- -- 
           
   Dose (mg/kg/day)      
finasteride Controls 0.001 0.01 0.1 1 10 50    
Study 1 0% (46;14) 0% (23;7) 0% (29;7) 5.6% (18;8) 8.7% (23;8) 35.3% (17;8) 69.6% (23;6)    
Mixture study 0% (31;13) -- 0% (17;5) 0% (15;5) -- -- --    
           
   Dose (mg/kg/day)      
DEHP Controls 3 10 15 30 100 300 600 900  
Study1 0% (46;14) -- 0% (28;7) -- 0% (26;6) 0% (23;7) 4.8% (21;6) 0% (23;6) 0% (26;6)  
Mixture study 0% (31;13) 0% (15;4) -- 0% (26;7) 0% (22;6) -- -- -- --  
           
   Dose (mg/kg/day)      
prochloraz Controls 5 10 25 30 50 100 150   
Study1 0% (40;13) -- -- -- -- 0% (29;8) -- 9.5% (21;6)   
Study 2 0% (37;15) 0% (28;7) 0% (27;8) 0% (19;7) -- 0% (19;6) 0% (24;5) --   
Mixture study 0% (31;13) 0% (22;7) -- 0% (14;5) -- 0% (15;6) -- --   
           
a Doses run in parallel with the mixture experiment, study No 4 (see Table 1) 
-- Doses not examined 
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Supplementary Table 2. Summary of the outcome of the mixture experiment, and the responses to the single chemicals tested in parallel 
with the mixture. 
Group 
(dose in 
mg/kg/day) 
# of 
litters 
AGD 
index 
Nipple retention Right 
testis 
(mg) 
Left 
Testis 
(mg) 
Epididy-
mides 
(mg)  
Ventral
Prostate
(mg) 
Seminal
vesicle 
(mg)  
LABCe 
 
(mg)  
Bulbour
Glandsf
(mg)  
Adrenals
 
(mg)  
Kidneys
 
(mg)  
Liver 
 
(mg)  
Thyroid
Gland 
(mg)  
malformation 
(%) 
PND16g    PND47h 
Control 13 11.3±0.2 1.6 [0.9;2.5] 65.9±1.9 66.7±1.6 24.9±0.4 15.1±1.2 18.1±0.8 25.3±1.2 1.6±0.1 10.8±0.6 372±19 949±49 5.0±0.3 0c 0c 
Mix1 (13.01) 16 10.5±0.1b 3.7 [2.6;5.1]a 63.9±1.6 64.7±1.6 23.2±0.7 14.3±0.5 17.2±1.3 24.9±0.9 1.7±0.2 10.5±0.3 348±11 878±26 4.5±0.2 0c 0
0
c 
Mix2 (65.05) 10 9.7±0.3b 10.1 [9.3;10.7]b 65.9±2.2 65.0±2.1 22.0±0.9a 12.2±0.8a 17.8±1.0 18.5±2.6a 1.0±0.1a 10.6±0.3 362±11 942±21 4.7±0.4 25.0 
[13.6;41.5]
21.4 
[7.1;49.4] 
Mix3 (130.1) 12 8.0±0.2b 11.6 [11.1;12.0]b 60.0±2.3 57.2±2.5 21.2±1.0b 6.7±0.7b 12.2±1.8a 13.1±0.8b 0.5±0.2b 10.3±0.4 335±20 870±32 4.4±0.3 92.1 
[78.2;97.4]
100c 
VZ (5) 6 11.1±0.5 2.7 [1.6;4.3] 58.6±1.4 59.5±1.1 21.9±2.1 12.6±0.9 15.7±1.3 21.4±2.4 1.1±0.3 10.5±0.4 356±26 826±49 4.4±0.1 0c c 
VZ (50) 8 10.3±0.3b 8.4 [6.9;9.6]b 63.7±4.4 63.8±3.9 21.9±1.3a 12.9±1.0 16.2±1.6 25.5±3.1 0.5±0.1a 12.0±1.1 373±43 993±95 4.6±0.5 4.3 
[0.6;25.2] 
12.5 
[1.7;53.7] 
0FIN (0.01) 5 10.8±0.2 4.4 [2.8;6.2]a 65.0±2.5 65.7±2.7 24.6±0.6 14.4±0.8 17.0±1.4 24.4±0.5 1.1±0.2 10.2±0.4 362±16 889±35 4.7±0.3 0c c 
FIN (0.1) 6 10.3±0.2b 8.7 [7.5;9.7]b 61.3±2.4 60.4±2.6 22.1±0.9a 15.0±2.0 16.4±1.4 25.6±1.8 0.8±0.3 10.0±0.6 364±23 869±39 4.7±0.5 0c 0
0
0
0
0
0
0
c 
DEHP (3) 5 11.1±0.6 1.8 [0.6;4.7] 61.8±1.1 61.9±1.7 22.8±1.5 13.7±0.9 17.0±1.7 24.0±1.1 1.4±0.3 10.1±0.5 326±7 852±34 5.3±0.3 0c c 
DEHP (15) 7 11.2±0.2 1.7 [0.9;3.0] 63.2±2.2 63.3±2.0 24.0±1.0 15.1±0.8 14.3±1.1 23.8±1.1 1.6±0.1 10.7±0.7 358±22 910±36 5.0±0.2 0c c 
DEHP (30) 7 11.5±0.3 3.1 [2.0;4.6] 68.3±1.9 68.5±1.9 27.0±0.7 17.0±1.0 17.3±1.9 24.5±1.3 1.8±0.2 10.9±0.7 378±13 1005±27 5.0±0.4 0c c 
PZ (5) 7 11.5±0.2 2.9 [1.8;4.5] 65.4±2.9 65.3±2.2 23.6±0.9 15.1±1.4 20.3±1.3 25.2±0.7 1.4±0.2 10.5±0.6 352±17 922±40 4.5±0.2 0c c 
PZ (25) 5 11.5±0.2 3.2 [2.3;4.4] 62.9±0.6 64.7±0.5 23.4±0.6 13.6±0.8 18.0±2.6 25.9±1.2 1.1±0.2 11.3±0.3 346±11 897±29 4.5±0.3 0c c 
PZ (30) 7 11.3±0.4 3.6 [2.2;5.4]a 73.3±4.5 73.5±3.6 26.3±2.2 15.4±1.2 15.1±1.1 23.7±1.9 1.3±0.2 11.9±0.7 377±13 989±53 5.8±0.8 0c c 
Mix1, Mix2, Mix3: combinations of vinclozolin, finasteride, prochloraz and DEHP at the ratio of 5 : 0.01 : 5 : 3. VZ: vinclozolin, FIN: finasteride, PZ: prochloraz. Data 
represent means ± SEM, in the case of nipple retention and hypospadia data are means ± 95%CI 
a, b: Statistically significantly different relative to controls (p < 0.05) and (p < 0.01), respectively. All statistically significant numbers are shown in bold. 
c: Statistical analysis was not possible as all individual responses had the same value. 
e: Levator ani/bulbocavernosus muscles; f: Bulbourethral glands; g: enlarged preputial clefts and hypospadias; h: severe hypospadias including exposure of the os penis and 
blind vaginal opening. 
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Supplementary Table 3. Comparison of NOAELs estimated for nipple retention in the present 
study with those currently used for regulatory purposes in human risk assessment 
 
Compound Our NOAEL 
(NR) mg/kg/day 
Regulatory 
NOAEL 
mg/kg/day 
Comments References 
5  
 
Based on effects on 
testes 
EU RAR 2004 
 
DEHP 3  
Between 1 and 10 Based on effects on 
Leydig cells NTP –CEHR 2005 
4  Study of reproductive 
toxicity 
RAR from 
http://www.inchem.
org 
Vinclozolin 5  
4.9 
 
2. Generation study in 
rats BASF Study 
Prochloraz 5  3.7  Multigenerational 
reproductive toxicity 
in rats 
JMPR 2001 
 
0.10 
 
Based on hypospadias 
 
0.03 Based on nipple 
retention 
Finasteride 0.01  
 
0.003 
Based on AGD 
MERCK Propecia® 
(Finasteride) 
Prescribing 
information 
 
DEHP: 
EU RAR. EU-risk assessment of bis(2-ethylhexyl) phthalate (DEHP). Consolidated final report 
March 2004.  
NTP-CERHR. Expert panel update on the reproductive and developmental toxicity of di(2-
ethylhexyl) phthalate 2005.  
 
Vinclozolin: 
BASF Studies Reproductive Toxicity Testing Two-Generation Reproduction 
RAR from http://www.inchem.org 
 
Prochloraz: 
JMPR (Joint Meeting on Pesticide Residues) 2001 
 
Finasteride: 
Link to prescribing information from the producer MERCK: 
http://www.merck.com/product/usa/pi_circulars/p/proscar.html 
 
 
 
 
